var title_f10_46_10976="Paragard IUD sliding tube back";
var content_f10_46_10976=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F57148&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F57148&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 514px\">",
"   <div class=\"ttl\">",
"    Paragard IUD sliding tube back",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 494px; height: 220px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    With the device stabilized by the rod, the insertion tube is slid back over the rod and slightly out of the uterus to the point where it meets the ring of the plastic rod.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: FEI Women's Health. Copyright &copy;FEI Women's Health.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_46_10976=[""].join("\n");
var outline_f10_46_10976=null;
var title_f10_46_10977="Bamifylline: International drug information";
var content_f10_46_10977=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"10\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Bamifylline: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4324019\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Airest (IT);",
"     </li>",
"     <li>",
"      Bami-med (BE, CH);",
"     </li>",
"     <li>",
"      Bamifix (IT);",
"     </li>",
"     <li>",
"      Briofil (IT);",
"     </li>",
"     <li>",
"      Trentadil (BE, FR, LU)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list synlist drugH1Div drugBrandNames\" id=\"F1977840\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Index Terms",
"    </span>",
"    <ul>",
"     <li>",
"      Bamifylline Hydrochloride",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1977842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiasthmatic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F1977845\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of asthma",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F1977841\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: 600-900 mg/day in 2-3 divided doses, increase to 2800 mg/day in 3 divided doses if needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.M., I.V.: 600 mg/day in 2 doses",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821162\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1977844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet: 300 mg, 600 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10532 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-5D5ABCD1C5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_46_10977=[""].join("\n");
var outline_f10_46_10977=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4324019\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1977840\">",
"      Index Terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1977842\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1977845\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1977841\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821162\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1977844\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10532\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10532|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_46_10978="Open spina bifida in the first trimester";
var content_f10_46_10978=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F66541&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F66541&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 514px\">",
"   <div class=\"ttl\">",
"    Open spina bifida in the first trimester",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 494px; height: 339px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A sagittal view of a fetus with a crown-rump length (CRL) of 6.49 cm consistent with 12",
"    <sup>",
"     6/7",
"    </sup>",
"    weeks. The spine at the area of the arrow shows a bulge consistent with an open spina bifida. This finding was confirmed at the follow-up scan.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ana Monteagudo, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_46_10978=[""].join("\n");
var outline_f10_46_10978=null;
var title_f10_46_10979="Periorbital amyloid purpura";
var content_f10_46_10979=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F51684&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F51684&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Periorbital hemorrhage in a patient with light chain amyloidosis caused by tape used during general anesthesia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 193px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADBAfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5ZPBpOh4op6KTzj5QRk5plDDWna6U8q5kmgiGAQJCV3fQ4xV3REWO48yVD5ZBAaUcKf8AaABJH4CuysbaYW48q7skgPKmOEbTn0JOP0rKU3sjaEE9WZmj+G7yNVudNkR03jAlUMjn0yM4rpdNjk0+aaTULSayOd37mMSwn16cj8qyLu6GmOphmDuG3ExRBfrypxUkPja7V5I0jETynEbMNxGf0qFTcnqdkKbautj0XTNSt5rZ9hSWIjIeIgqwPqPXtUWsX0SRqLcJ5yj5d3AB9MdOfzrzcazql0yWkMUik55RgM9yeBjFQmWfAe81RPKKsDn5S4PUkd/xFbww93qWqSWrZ3Vt4ihm8yK9iAYNlmJBC9h345qb+0tJvLWSZCkUn/PNlAYnnjHXnFeUzaokUe+3JE5fIlkA3FfQ8f8A66qzzebtkZpJy7kYk4/DNbewgZS5b6Hqt1qc8diJzbzhlG/yyoBxjjJJ54FZS38E0yNZwzWYIDskkXyg+2O2eoP4Vy9tHPFqK+evywqMq6ZAyMgkgnnsM11tjeXU2yC9R4pYo8wsOAyHkdM7uc/rQ8PFoST6IL6ZiqSfZFmjOQdq7SR1JGaoyQ6fIqCxne0lYblE6/LIfXHUY6damW0kuZIrpYHLlMtIz48obuSMfp0NWNS0zzcw37+XsGY5IkIbaRxgE8g+h64rN4SNjWNluUfLZVWaVmMoOfNU70bHbI5FWbR7yBBsfz7UklYC2UI7g47elN0S5fTy0V1tO3CsyPgOMdCMdR6n6V1MOm2d45/s6UGAkMI3baw91b+h9K5p4eUdRyVjkrieISBmjEe44dMErj0waSCyjmZ2jZyiHIGOfYgHpXVLoscsu2YkDp0wR/jWfdeHpbad3tJUlweUX5Sw9q5bS6jXLsZQxKAJGkQg4Dg4KmrCzqMqsrhV5wAM/r2qCZWRgJY3QjqOtRK4kIYABlPDAc//AKqTZfKb9tqADpKod3xsaM9x6j3H6it2x1KFMRCRlBzhm4H0PpXFIztITGnXjCnk1atPMwdrYGeh5/Ok2xcqZ2MoS7jkdW2I6gBwxJDDgfga0tM1KGSG3Zl2tISreoYdQfyrk4L54sRt8owADjA57VbsZZIzNuYMrNkkcE+9NSJcLnZXMazGIQgu4ZJRuP8Adbnn6GiczyX8cflboRjcT0z2/CsnTNV86NUiQq5b5gRnB71ryTAxs1w4jQAEsG75/SruSrotPL5KzbXf90BvKjp6D6mrEcE0jRS3LBcDlU+8D/hVJblLiFNjhELbgOm7H9PrVtX3xnJ2uOAVPOKpNPYew4mI3HmGWT5Ox4+pzVzZGEaWCTMzHgPwB7A1lxSxxhzbh3Zjlgx+U/iakiKylmnc7oxhVTO0fX1NUnYGhNSjnmE1neW6ywSJhth+VgR03f4VxfilFlsHure0VLiwKlLgRnem09E9SMn2rsL65uI7ZWtpIzKnKq/Cn1xxxXMHVZptUkuWZ22p5d7FgDYnZ1A+9tzzjIwfane5cbrU27QQxXMc8Z8y4eMbZSflkU85A/Grk9xDeTiK1nZp4XVnjU4RWI43H264rOsrlbGygtNOD3CxoqxO2GKr2Jb096W4u4/Plt5IAkso83dEMZGcZyOM1psTZtgkc91qt099+4T7NHDFcpH8rsWLPj6HA5rQ0iSWIX0Js2UR3jtCT/EGAJI/EtWaZbklWDwmEg7t4yQPYdKsRPINji4OPRyWJX09qTsDiy/NJK81qDtiHnb/AJ+OBnir8sjFMrHvzjH+JrHiuFuI1xC8rIwO/HIOe1abiRATDhnC8KT96s7ikrEcqxvKhLsxU5VB0xjj8utNlhSa5YyuThdibeCuetNNyrSbwFWSL73suKBMqK6KpTI3l2Oc1OhLZDOSSYIwqAD7w5KL24rH1e+it42gsJA19INoZQGIx69uM/hT76VFXyba5kT+OaXGWOe+fU/y6VTs3txaxyRKsMc33Sow/U9PbvU3voFupFNqNxYaVvwtrDDktNJGTwOvlr3br8zdTWLFBcXlx9o1CaRBJH5jQE52IT8gc/xP1OOnscCt6+ee8ZS202MOJIkbgyt2LZ6Ae/U/SqSXbwo0r2TNPK25nBAVeMAlvbpn8qBehQdwsIlv3eSFWKQwRR8Mw6AD1Hqe/J6YrJMc00nmubNHhXEcW4slquQQD6sT8zHvwParFxe3Fwg+xyqEYbTKYyFx/sL6e569TWb8loAz7ppGfewzgHPUue5/kOgqbofK2iprE8UBmSSeaZn++YvmllOPu8fdz0PfHAHWuaF3NLcwq/zXK8ojjZHCQOSFHCgDjJyfQCutkuLSN0RdqspxuSMbUB/hXPSq5uRE263W3Ty33CST5i5+n41oppEODOfvYmSF5brz72QDGZG8qHB9AOSD7de5rJePdIjzZ38gFWEUaKeqonp7nr6V3ty1/eI0cbNJHJy8kgEK+vAzzjtVa20W1ilK3JklckEiJlUf8CPem6ltgVLuckEMyBLC3JRW3NO6ZWP1xvOMnj0+tU2jdZj5NsJrjOC8wyiHscdz6DGPr1r0a7s4plVIoGZV5/d8ZPvI2do/3Rmm2Oj7J0YIkQHIZvmAPsp5J/2m/Kl7S2w/ZpnKaZ4eeFPMvkNzcn5lQnlu/T0z6/lmum07T0urpPttsFsrU73RuELdQrdiQeSMntnniunsNOiVWEJRCw3vLNy7euOPy9Ktmwto7b5DuVeEz0Q+oHr34GaOaTeo1TSM4SGV5ZbW3cLKQqmJQhcepJ5Vf19BVO80tri8H9oSPF5r/LFBncR/d3fe2+oAFb4jlEHlxIwwPld1yT/wEcD8TUlnp4Zj5jyxtjadz7ZJPUnHJ/AihybdkHKlqZE2n2NlHbj7NbxuPu2sbM7+25V/l+tV28MTXoaeS1ghlKHy/MUE5P8AdXkJ9QC3vXbQQWmmSRpbxMYXO5iI9uc9jjr9ayvECy6jCbWx1KUbnzPLbxBAif3Q3JLdgB0709UQ1c4SXw++r6kYVuRNDbkpdXDfLG5A/wBUnc47nj09ae/he1i2LZ2TzErxLK5VEOeiqOT9R+YrvND0Oy02COKzidUjI3SMcnnqBn+dZfiCcs90lvHJKhYBo41IVz6O/Vh0+Revc1UlYVrs8yvNKuPMknhO1GcbTFgCRgTyB3Uc4OTzz2rnBpEsksoQMtuc/vGOdwz2Ppkde/avVW0Q3UytfhlBzuidxlx/d+XhUGMbV69z2p2uJYw2zx3bRsGGWhQAFuONw7KOPvED2oTaRMoI8bl08SOsdpBNv5GSQ249uB0BorrNWlF7GkdsiwoAE2afCzKvXq/Vj9Bj3orVTZg46nAxLvkCllUZ5LHAFdNp+jvFH5kMsTStgYAD9c4APUdKwrKMyTQ+W21weyEk/lnNbMYnSxSQOsSpnMjwBM/jnJqp3eiJgXWurqzlWJUhdzw3ltkA+hJ6H8a0bKK4usRzyCRSeIojsQcdCe9cvHqk7llCJ5R+UgfKoz0yPWr8GvGziRI2GUOC23BbnnA7fX6VvSppas6IzXRmvPb29nA260gkc5TZ9zB9MZyefSsO+MFvJFDGXnuNuZME7V78fSmT6qZJW+z7omkQ7mXJLg+56AetU2mDRtulIT+6vJZh05rpai1oW6yWiZa/tAgbgwEi/djjXb+ZFUJbmZnlJdWdjt3lsnA54zUU7GSIsuxY8jKg/wCc/WoWfMa7SBgkY7/jWMmY1KzlsWopsJtdpHKnIIfg/mKnj1MCQs0Qz3OOMensfesrJB9CO9P2tsDHIVumOdxpKo1sZqpJbHTfboVaOSS+a6SVAGRFKOuOgyf6Vu+H7iK7kWGN/ODkkiTKlT9e/wBK4BUkfKqreav3s4GPpXe+E7hoFtnUyo0jDdLsGIj0yeMbT3zjB710wk5aGkKsmdKs8tnJNM9pJdWygRiNT90DqWH9cVei1W4eLybKDzYopF3PK2w78cN83JHbAps0WpRXis5RkViJZoRgtu5wy9W/M8elWIbSS5vELT4hiBEBjXkDH3c+3tVNJbnRFpq7Mq0Edpqcs+oQfbJLo/ulZCnzc5C4+8eOtdPpcsUF1+5kw2A21QxVB3U9jUN3bRW6QQmaeW3IBTc4JiIbhwR759DWja2l3LGsUkhEK5KoOp9W552nP9OlTKKZvB3Wp1AI1CCBkjVu4Z0CkN3Xj+VSpBb3as8zIzD5SCoUgDGAff39qyrSdYFitgMzED5QCMj1rXSJZtp85UlU7cbRk46j/wDXXBUglITpkeqeGLa7tmLsJfLHAyOc+jDrXB6r4WS3nIiBDYyNy4Ir05Z4Y7TylKEA5EgbafoPWkE1rcwCK5VSm4ktjv8ATrWbpqZnacNTw65imt5/3iMjKcjjIP0pjTKxwsjxzAdwMN+NdF4l1S0tNRuLC5hkg5/d7mGMfXt7ZxXB3GoRo8zMhaDjoCPm56+/86h4WfQ6FGTV2jb+1XCkAnKgZ68Vfsro7FJXa3puznNctBqMZYKuQDhlGRnB7c1o2908O1iSMHhfu4Fc8qbi9SXodbp9zNEjNKQufmIUH8K2raaK+RY2R2ZiDtI4Hof/AK1cfHexsyyAsFzlsnIJrSs7+OS4TfIEXp1xn+lRexO53EEX8UjkkdFXjFJFcBGeOzjEjdHkGdo9ie/0rMtryylSOVJXjXHzBgdw/wB4Vs2rB41ESKI8ZBxgH8KpeQrvqNF09w+6N0ABwWXn8AKtzu0sQFuUjboxUE7h6fWo9sRTyUXoOxwRn6VA/lwqGEjjbjox55pphuRXcMs37owzSRsvKk7gQPX3rIvbYvGttIqRKG3RbmCvG/Yrj+XQ9K6AGdoADkueN/QZrL1Gzhv7fy9VtY2UtnDfeHuD7f8A6q1i76FKT2Oc0aXUIdTuLGeVYE2b4NqlVI3YYH0APQDjDYra0trmZp43ly0HyyNBym70Ge4HUVhzWjaW0tzHHNeWoXY0qkvLCAcj7x+ZfYcj3qLw5rlqmmi2kvbeO5inkR42yj5Lk5wcZznrRtuXvsdO6Issay3DgK3zsFG4+3pTdCuTf2xkdpfO3ukpcf6tgcFQPTGPzzUsThSoknRWdd3ln5yfyp62lmlw97GJUdlCNsY7ZPQsvqPWncd0adoJI0VYZT+7HAI4q4m5TlsyP1ODgVnW15HMxWKUsUyuFAwpqVRICGaXbFn7p9PSobRnLXcsX6Ga2lMKBZSMZ6bqjv5o42hMm5I9wDHbkE/w/hTVmDBwwbHTf6e9V5Lo20aK7+bCOAzc/TNToyLMS/Dyq3l+VhxgZGCcnr+VZ88jyS/IYgiHbAJU4B9fp1xVuTIVysuWJyBgED2FZN7PJDli3mliNoA/Ok3YS7EU1uEmkYySFD8zY53v6k9MewrNuYp7htrsRbn7wTkufQjsP51oPcRlSfMwvXr19vpWXcagXmPlqWVeQFP6gVLaK1C7YqhZ12leu5sD/P0rn3iN3NKtvayycfORnp7k9q0Ql3cXIn3opXld2Tj3A9a1INPvIwVzDDHJyQVyxzznH/6qXK2NNRMGPTIuFlUsx4CgnC/X2rQsdIeEqyQMjD7uU7H610mj2BtZFSPazn/lo7AKO/zVsw6aZIvOugzZPEcZI3H/AD3rVUbkup0OZLFQVWQlm4MjruJx0HSnQ6Zc3Ft5kaQxBWyWMfJJ6knH866r7J9nIzAUiIydpySPTnoP1NQz+dIi28CEAqN0ajaFHuap0basE77GDLpTfaoba3dpsg58peR9STgA9amuNNjtsnbJJgc7mG0H2Pc1siVLC3PlCJpOd8mOeexIrFvr99RuDbySYbGCFbB4Hf2pKm3okUk3r0HvKdyBfJjBbBXOcH34pjxwFt8p3Oj/AHVXav0x1rmdTe8aM5Zo7eE4jaA7CrY5yP4s+ueKzLS6nuIphcXKXAjzGCWZJA/UEDrkccV3Rwia94bsd7Lf20mpCyZ4LRmUOZd2zb9dx4/Wo4tVurDUZdPtrcER7nDttyyj+L1B69PrXnd3Jd6naiO8jllCE7Zpgu5ieuW44zTdH0i8EEpttS2FV3vgZKqfT2PA44rRYeMQUYpanoOj6qNYkZ7yYRK8hHkvKRlR1B6euevSm6xeQ2F7EpMSoxbaFO3OOg+leb6jd3BjD31tJKGm8yQJKdzfRe2fwNYk41E+VdlJWgU4Amcgj/ZAPORQ6CWwuSN9z2CHV/MQI0sUaMMnc33vofSoY75ChFvFNO3J/dxk5PuxwBXm1rrlzJfQx7lhj2jaDn5QD1NdpZ+JtNhRnknj81RhUllwXHU8VjVoST0M2lE0JptTZpI47OCIuMAS/vG+nGBj8ax9RsdSTyomsrfUAfmKvcBYkx03KFA4/GtJdfOpPHHaQWvPO6ScnB9cKMn86l1CzuriMyXb+dEekG0LEfbGefxP4Vyyg09Sea5xF7aa9qVwYrC7itraUbWaJiUx6KSBn8PzorsZLO/ZfNktLNhtG8SzZYKOgU42ge2KKadjFxuzxXS7v7IiC3RxMcjqp689GXjj3qLWNWlvLdbeRVLIckgAfy4q1qiiRCySlIxhQQSecc5B5yefyrDaLdErh03Ftojyd2PX6V28llc5rkfmNtC54HSp7eSASFplJHYEk1BEhd9gxk9ycYrU09LdbORpCGYnb+8X5V75Hqfarp3bBFa4lUxkQs5XPJI2gj+tRkpJHGZZSX5Xbj7gHQ/jUsk3nITI25v4QRkADsKTzi8jfZ08tD0B+bb9Cact9WO12R3MreWkZAAUYB74qF3MsoeTC5wMqoAx06Vch/dbGMWH+8HIyevU5p014yxMIYo0yCjMFBJB/l+FJq+rY3HqyutvuU7WBPXBwMj2zTAQOFUs3VWXgiomJLZPNWbFJZCyp8kbffk2Z2D1z2qU76IlsknuJ7+ZRPcIzs33mwuD6k/56Vq20cSzBn1HzbljtIgb5T659fx61molmxjijZiS7ZlVCWK+46DjsPzq5eaFHaSP596ltgE+W/zuvTapK8bueR271rG61tf5hGVmd9oUxl2gSLKidD6D3ArsJI7mW33W/ls+0DaoA4+g4rw6CeCxnjNlcSysPm86RdqdOVC9TzjnI+lehaD4p3xwmOF1foX64bsNo7dc5/Grc3I7qUlLWJ3WmWjxnCxyJMRkErwD7H8a0rdZbU+Vcb5Sh3QuigunqOOoqhYa5DdxYuHAmQ8Kd2HOM4z647VBceJrWN/KkbcgPygMQV47Gs2pvQvnd7M7zS1t762V4oysyZGNwHJ64qa8BglbdEfs7IC2wjOfQemfSvOIvF9gbjfGZsRMR5sQAVsd1HU/Q10Vx4rt72w3B1IwS8gJwwHQH0NZOnLqhxfvGjcTojEqQIiQcHHI/u+xqnceIFs5548J5DsGQnG5Seo5+n61Sdra9MJeaNoh1KcGRTwDk9we3TvXNeKHtS/2mZWunGAxlJXHTqP0J981pSpdztioS0ZR8YQrqBnvI7WSa3iZi1yjBWVSQDIeuRnIwc8c1x2o3DWOsbLq005rZYgpjhffDMO3KnPv1yPau2ZbVodP82/ae3lkCKkhCLAGOCuOuQe/OQBkVka5Y6dpNxdC5trFoyN6mXmVmBAKrkDJ5yVIB7jI69SjZHPVqcpx93Npa6jFNpsk6wHBMdwBmP23DqPfr61pHU4oLlbeRw0ZwV2HoD7+laujXCPc/wBpQaHplrp/mLAWMLTNGAPmkZC3THJzxnGKyvFVnb3t0+qRXtnb20srQ27R27RidU4LgKCB249awrUOeN+pzqqnoy2zJH88M6GFvm2jkfl61pWN7EFICGRP4lxkEe1cTAs8EZWBWL+ZtDFOGJGf8O3epI9Qigt9rJNFfpKdzZ/dFPZeu7NeTWoOL2NYyW1z2DTHsywkgUoxGSN2SP8AGuijuvn5IlRcFoxkHnvivLvDniDz0RLYq1xyXRQBx9a7myvl8sSzROGHAJIH65rnvbQq1zoYFUyqsLNGoPQk/KKtXszrasjL5qnjK9T+HpVPTrmPUYSs7IjqxUlADjHTmtVI7cDcoIdsKdvOcVS11ROzsxVsHvGViEjUc/M2P0qO5tJrRckwlWbbvdsnPYdOfwq5bJO0f7zyiVb0yQO2ak1LTfOcXMDpDPGu0bmLLIO4Yf1FbRWlybvY5DU7C8W9eGe1kSERlzHa/eZe/wA3THsOfeuZ0u3sLW6i8rTZZrGQM0LiPLo3TY4Pbjjvx34rvo5pXAkZ28sZRowSdhHX6+xrO10yRXAuLWFXDhRIgARnweMdgff8KcpJq5pFvYj+1WsZC/axbpGcOrIdxPfHHWqsSz37rLNIUs2+7Hyksw9W/ur7dT3xW/pE9vKhuUuHEZkYMsmWIPHX0PtV6W0tZcI1vE+M4MbY/E+9S9VdAp8uhQgAYKpjAjRcAAAAe1NliKyJLbMFVT8wBzkYqb7NF5bhZGXB4Qkn8/aqwgmXG7y1jBAGeMnvis2wvcj3LKTI8jYXjjqaroYFabDebv5KEZA46CrEzIAQyBFA6ngn06VnSzxRhupBJH3qQmyVTBbxqJpCo7A96yLy6UtmMAJ29aq3l2A+SCR0wTjP+NYUkpkm3NIAg+8W52e2O9FmyfMtXcsRI3yhGB6f4e9SWdsjOskwCBj8pY8/lVezltRKzLHJKVGN+0AL+dbuj2VoztPMBJIw+WMdPr6mtI0XuJzLFokLyBbS2e4mAJ+9tA96r31/HBdG2Y3D3hUMAiEhcno3PT0xW1c3wgiWSztIog7CONgoDMw7KSepzXm8WpyW8d2Wvrq3nuXcmPauCuTkbjkkHByK9ChQTV2FLXU6rTPEVhEH80QiduBDCfNYYOBls4B7+wHNaGoeILq1gVzbNbz7f3blSwTIzjB6k/r1rzwakDDebTDbMFjSK1VRG+W534/u9+vJxTr7U3t7BWhvd9zuZEiY5bHfnsa63Qi9kKdWCdzt38dpZ2trJNZz3NxIcSNkKhf0XuR7nrUMvxElls5ZrO1ijYkI+X9+h9T7e1ecpa3tyIp7+8trYsvJnb7gxx8vUn6etR29stq0ZO6SJn3O7bk3rzyOCce/8qawsUtTNYinfY9KtdYOpxh57lZGLgKY12oAP97AqtqTX1oFEM0cmnyNh1t8Z9/nx+n5VgWssNk5Fzp8wdm3RJL+72pjJJHOfqOmK0l121k2RR2sSyRqNoB27jnsRnJxTVPl2NJYiL2MrU5hNIt9JJch1L/67lVXttI74HOazxcRG6+1CYIEw2RHyxP8J/un39K19Q1B40cTQjMwbygJRKit/eZT0OPT9a524ubTTtMVPsrsruVa43BmY9+Ow9+tPlY1Wi9zRvLqdoFVZZI0jJ8lI5fNV1B6AH+R59KSx1KSwaJ4I2cs2MxR5K5/h2/071zH9sQwvttFDwMCSJc7jj0IqNNXhu2B8r7PhR80ZJ3uDwTzkdaVuge1g9Dro9XllujIXtLl14CRrgsM9SD39jyKS916zukkS4YCVF4Docj2571y93eLe3ZuJJYY5lG6Ro4+Gx/Gw756cVEr/wBpTrDLMFdx92c7s85+U/59KOW6IlOKZVvvskl3LLbXLKCw4VjkD3GPX09arrKbdo/PkDsDnDJkA9sZp00KQKxgcyDdkMkZUqcfmKovLJGpE8Syc5O4Ybn1PWoSUdWYSqM7PSLxIbgPbq8jNgNvkCkE+nt6V6Ta6ms2nMDCkhTACO3GfcnvXkujslzYKxWaWZWyqqR8o9Oe2OnvWzpeuvpks636ySmZl8sMu046AkfzrOvT5o3RopKSO/uL28lgeKDSbdmA2PJLdBQM9BhQSaKg0G4jmO1YJA5PIhkBGfbNFedysGrM8a8R+Ut21vaPKbRApxLwd5HPH549qyEkRZFLoJUCkbScfqKu6pIsl0Qg6Lt3A9cDFZzHe2eMnrgYxXdN9jiE4I549MCpCxmyXYkjksTRMWkkYhxIFHUDHH0qPjkAA/Wo2AuLNbrYGJow1w0ocStzsUAjbjvkkH8KpjOOhqSPaxYlcDHGD0NOHygsuGAxkE9SfaqtfVgPP/HvmdmOfugGqxY9jwOBSuSCVcHcDjntTSfToKUpX2G3ckhKodzru44Ge/v/AIU+a5llkLl2AIxgcAD0qFe4xknpWlZ2+HHnRGeRWX9wP7vU5I7fTmqhGUtEAzT717dLiKBYlM8flyF0DYGc8cZHTtTyLmVmk2eaztt810OXPqM961rXTkmgZbWRZJwN5jTCL5fXJYnnGRx1NWpdFVx5NuJ5E8vf5oAbdwD0HXB3d+3tXQqMktwsYTR4lKkNKrYkYgDOfb0B5qwJmgaaGWM/aywGd+SG9Mg4HBFTaxJazzLHY2YggztiZV/eSDoSeBnPoelUDp0saqHCAkcZ42nrhge/Sq5JLZAm1sdJZ6l9nadxdtIWTLInzFXx90hjyO2Rz0xmtHR72RrZ1mwLsKXiMnUjvtzxkf3TzXMW0Qicq06r5mJAkkZ3SZAxjH6Cr1mBpt2A9u8vmksVfBUr03L15FWk3qaxqu1mdDbXNtckyP5UUmN6sMhZjxnA7HrkHpiuqsohAkkhaM+YC4ETBwF74UAEAf8A6x3rh4pkEpJOVLBm3D5lB6FvQdPmU+mRXT2t9KY9klr86j/WKMS7gMhk6ZOOoPOBg5qnqrEczTN+KeW3SOOVISCCyOoOJMYypI45HQ/TvVa/sbfVrR7yYSskUwWVkwAgYcq46g88HkcYrIGuNNatBhY4pjyNuUVv7/rsPcDpnvVKxN3FFeiW43xKyw+R1JUqXycHoOzf14rCN7nbSnLlumQ3F99l8q0glVJEUI0uwOGHADdz0IP1WoppFs54J7pTqF06s0jXA3BSBjaST8pBwQ6nHPSmSa3YWjXIt7eJQ/7s47jIyCOo74I9TWRqE73llbQiNtyKyRsx2gp0AC/Qd810aCndvUbYS6lqFxcw2l7csZmCzRxbizg5+UkDsBjn1FdLd6daaTommyfaoZby4RVUXUJItw3XA6blGclQffmsKXU0trC3tLOGaOS2dlVzjDk9pCPQ8jqffiqtlH9qsnmvbi5kcIzI2CwjY5yDxxk9x61N7HPZ31Nq8vNOW7S8hvIC1uRb+TufBUE42YHTPAPpWdrq2E5e7tLsSxiURhnjIkY+oXkFc8ZJzXNT7Lm6fbLLIyN8jbQC3YcfX9K6zSnurXQXs0tFuJpp1uZdwUqQvHzDH3RkgA45J61lL94rNBF66HPJI1tqCvEFiOeNp7+3+FeoaPfrcIPMLLcYwVc+tcd4u0K3hb7VpqxxxpGGkhhfcY+mTtySOfc49qTw/q01tJAlzPmM8Fh1B7HHrXjYmi4Ox2U58y0PZ/DyxxwMVAVmwwbOCpHUY966a1naZCT+7bPVeQa5TRpnCq7LkkKwcdCprasJHfzVlAUlgIypyWz1zWELLQ0eurOhuPOVY5kwsL8jHV//AK3vSTQpNMzqMSFMEZO3b6VE8rrAqSHAVQvHPyjoBTY5P3aLHIxATofT610qwkiSFtsZURiMk5DM2RnsSce1Z1wySLm7IHPKg5yc8EeuakLRo+EJVjyVB4qeW2luIwNyhBnG1cfiaT2KskUYbJF1A3UTPAGXZNCvzCT+65/2h049avMpiiMpLuByUA5JqSFphgpJt2jb90Cmt57BldwPfFQ7WIeojHfbkRocqOpHr2rAms2WNlvp3lG7hJDgJ3wMdK2JGmhwsLo0QG4gjB61zHiTUkhtHE8MjZJyM1lPXUUbp2Kup36229ml3ITwn932+lcnqmqtOQS5iA6ZOOKxL3U57+9McK7ME5JOQg9ves/UPIt/3Khbu5YEhBnNVTpyn0HKSibP2ySc7Y0aQ9cxHO76ntVOK4i8/wCz3LvNITgJGcKCRnlqz4W1M2kW+4iSKSUR+SgK7R6E9vr/ADpqaTqREsNvcoZrk7DDy0kqdsADJHHavVoYNL3pnNKpfRM9D8K6fK80pdraaNH8pVL7grDB5I4Ckd66oarplkZxLd2trFbsfPYSqMYzwvqT0AFeRq/iXSLlHjt3kjQD92iZLKo7rjOAPUfWnf23ca3LLd2lraG7uJAhZAEKS9iFYYxgH6detdapxvoZtdWzr9f8RxTxW0ttdxSXpR0hijK/usMBucHvjOBz2Irzi/muILmOS7XcZGMZaM/dUfw46ZPvzxVhLu7inTUrm0ttqv5SbYw8YboSQ3JIyPm5GRUF3dWs1olsGB8sltpTLcYxhgcZJJPI46c5q+VWGqjhsZ9zI1w4IGJbZCzl2w+EBy2D0AJAx3qvZSXHkNfwTNCqnyUZSBzjnjr/AF54pJorsNdW8hWZ0UHH3yM4PX17d+eK2JYBb2tkZLLyyPmeXHIfvkZ54/l6k01dmE5akejRPCYptVm2QZPKRedIMH+EZwOe2a0I7pprqaW1lKNEViEkg/1g74P5ZzxiqxvxoUDQWrmVJCc7MBn67Nyc7Tk9jyM8VUtLqW3t8+ZFHK+GkiuGZDIT0JGPu5xyTyfam5W0IsXJIbi6nkP9oWjRWuSZPNZegyQpByWx6fhVhRbIbWOVGuIQwbbHKsu5TyTjjb2Hb3qnb3OqLaxyQqq24ILuYB9mBHfcR8zH0Gc1Bc6kJZoDcoFwpXIhEGDklSwHUYz+dSpFpXN2OTSZNQD2MF0XH7uaFCBsbJ5BX8BjtzWdqist44h+zx7Y8PJMrblA4yQe/Xn2FZsVxCI4vIvSSCMeWCrrz9zPAwR29qu/bbiWSGa/vXuIY5DuLtmVSR95geg4A4zRc1jG71KdnZg3cXmJHdRo2RsUqDkd/U9zVO6sGlupWiXEbYIXABPbgD1xwK2pby2e2Xe8mQzlSMbfb5vr3NQ6beFWK3RSCU/MZpF3b2/hBI6fX0pXRSp9SidP+zxhlbLkBXhwPmHs3Y+1ULuGQPJveJ0UbV5zyBwK6eS7a9AU26xxK37xwVwoHQn1/lWfcI1k0BXM7MvmIXYANk4G1fTGBn607IlxMuZpo0WRIpPuKGKZ5P8AnNQRSBzviPQZbzOoP+ye/XpRIzfMqxzRyYIbYe2ecjtTms2S3QIzyAneAeBn6djgdec1lK99Cbs0dDZlnItpAQDjLYDKf7yj0rttKsm1J3WXaXUncHT1AyMdhXL6HEkVxbSFQGlJCrjlG9MjggivRNCXdvnAwCe3GP8AGsK9RxVjSC1uU9Jhs7S7ktLWVVcksY/MK4PptP8ASirmv6Yb3JVS23BIPP4j/wCtRXJo9WdSSlq2eMXsKvbxMqjzAAGC4G09cY9+fyqmUjecKY3SIZJCDcwAHPWtFLSQGRlkKW7AE7x1YHoT+uaq3KF3lK7AS5JIPPP9OOtdfLdHllUoXVQEVSo55wT7nP1qMbNoJLbs8j2+taU8Ukoa4IWR5E5Cqcqc4+YHucZ/Ws10KE8gjOMjoayasMlkYDDRBlBGPw9M96hGMHpSs2cAbto6AnOPpUltCZZdo+Y+go3Y0r6EOCQTQCM5wDWg6nLc8ng5HSnrArxYCxKhfhm65A6Z9K1VFvYpwaKWUJOFJAAHXofWt+ztGby0wShPbghWHzYP4Y5rLjkhRgVUOwPPvV2e/ae3CrlF5G3d054NdFKKjqw2N5oUieK3a5cxnKbQB8sfvn/9dWjqdvcYtoIRNFD8pkI+8Aeq9ML3Pc1xrSvK+5vndU4wcdOn1Nammo5YAxtPKwPyBmXyyOo9yf0rfmVxrU1JtVggb/iXQxWz8qkkn38H+LPY+/6VmQwy3SXMsha4ST7z7l3Fsdy3I9MCtfT9Gu7tIlSCaaZ1LLBEAmACMjcehznpzmtCXS5URI3tLcXa79xm2sX7sqjpuHA75NDuDUUctbOthbvJZOCZlCyGUYKKTwqdTx1Jxjit57d4gkk0ctnJEwl2zKGVyf4lI4OcY5wOx5q+NMtNChMl7Dc27xNgXfllijAn5emMY6g5HHrUk1v9klJ89rqOSVY4A0ajchA5AyRxwcevvSirGbM7VYRFMmHBEkH3YiflB6cHpwTkdDjHHFPXUBZpELt5JlUEJMjbjtAyCvYjv2PHrVe4S1i0yW52sqyTFYZFcnzMHnJ7MOzcAjqKfrsQVpJrK7WVYhEFYgA85wCBnkH86GPcq3OrXFrKIJ4x5GGJix8yj1U8HOeSOvercEsOqTSX08aRpMApMeWXgDhgDwcc59ecVy1vNJMz21wZBBHMC/HETH5Rj0GRjHfAq/pl2baeUiSOONwAwUHBHOG74bPQ++KyvzbGtObidDqllGl1KNMhijgYGXdu3rs78Hkgc+9RGzjuPtcqWu6dyI4Vi2/I3Xds7A4POeKq3SEiCOd/3PRdjbH9wR0PTFWtEtnuNUUQTvFvjyI3yTIo6jI7EZ+mKfM1oWmr6sW00uGd4VvJLm3t1dQYQmWywxuYjoc4AzzitK4Qzm6trVTEJmS3LEAMoGAMjOByMZ/AcmtvToLO6vNU+03pWcx+UmxcC47DIPTnHH41zWtG6Qu00oV44jBOc58wg53bu+cD8aSqJlqDkzlrpE0+8toRN5OAWlljY5Xd05wcHAHA5yajE9zZXc0ME0y288RR3IO4jj5iuevArcsrG9iEWorYm7kkkMlvCq43MAPmGTzjI4x3qp4mlvLvVJdSlsxGVRRKFfau7IB4HG3dkY71lZ81zKWmhLNDDEbaXT4ZoYbgCGYPJu3YAy2eoyc/nxVAqoXcjATKSQc9Mfz/AK1Hqk3lLuAlmiuwNrTKf3eG3fI3GcDjpjmrunJuW4+WP7NtyHzwuRnnjpXPjEmtC6MmmemeCL6afT4lLjzY12EMOAO1d3AzAq0KFjgA4PT3ryv4dzQWsdyjSoXQeuQRjrnpgV6bo063dhFLDIDG6+YpxjcOxryktTtNWaeGGZftErbRknH8Rp0DCeSRPMVI15+vtVSPBDtO4PPyoB2+vvT2mDwIIoiqMcBx90VqnYtLSwlwqAqLeRT6Nu/Spbe9eJQrDgnjng06K2RYsm4TO4Hh8f8A6xTW8reTMCB6pyKOYOZPQnluU3AsHDDlQpyPpTlkkLhzICoBJUCsaK4ieYxQyHyx68EevFXreYO+wuoyNoPqahO5MlZEmqXKLaOxYqDwQTjmvGfG2pS6lqgtLO4VYkHzFTnb9a9B8W6ittbS7ywXBBJGQD7V5PahppJZynlxyncCR1A7/wBaXLzSsR8KuNu5G0bTBLAkBQ8Evyzt/T8Kh0Cw/t2d7lyqXES7zHC22RiBwBnjH06dzVfUdQjlW4tWtpmYLmJymQD3fFJoN45kXTxJbEDCwWryBlVTkthz8ue5U45r18NS5HdnFUqXRNdLLDOyQnUYL27cozRqZYztXop6k57jgVqaVcW9xpd9Pqtxb2ZhO3y3s2aeRwPuxsrLhgcZ6dyfeu9my659hjNu8o2yRQXBMSzqOW8v5iEYgEYyM+lUJ9ctbPWrtLrT91um6MRK3KArgDdkglegY5J49K77mHMdBeX9zZaUsV7rpa/u4hvRWXEVu2OJHU5LMcDAycAnpXJ62NSgv2ju4lgW6IlBRsxyHH3lYcEGlu71NV1CCbba2ERmRT5c+53JXB+Y9sADOCBmrNxC+mC5s7yIzQFS1sxZgB83DIeOcjHTnFTcqF5MknvRd6ccPJbXgIhuUYr5Tx5AVVGMjHJJzg8VWh0W4DvvkwYoslRhgYyOox1+tZNzcSG2WPyt0sZ2A8DK9RlevHPNaGnTG7y80aySpgNvc5UY4245x145HrRdXsa8pJaXEnkP5MADRLv3qSznnr/LrTdR19ZQ0kkcbuiBFVwT3zk+polvktZZY7R344jyB8nqCTzWPqLxXD74bZITuB2JwvTpj8P1qJztohum7XSDS3mnu0twtuskrDLt8uM4wQcjHrmvRdJ0vzdJmvt2k+XAhVQXBnY8DK7jlmx0/hUZwCa8sEnkwOzk+c/AB6Be9I9yZQokKkqAEwSCCOnOOazVZRVjnce53FzfyT6bJ5twIIIWKL5jN5qEemepHYADGSTzWQmlahcbIkhuGVBuCuu7y1xncecAnBwM81U0uS3nDrd3U9lGQVYxx+YHIOfm6Z/x61ehtHuHX99dHcVYeY4wyHjnkdB7H0rRT5kaU6UnsVLOO2MzO0JkiHEgL/ebuAABx/LFaljY/a5EJZlRFLPIqls56AdfxzXR2Ph6WCESSwRzRkj54gQWB/DAI6+4roLDSoYseUyheoQgqVPsf8ip50kd9OmkcTD4f3zj7M0iOzfdcBxx0+X1Ge/rWfqGjz6eqq6Z3kkEt2PYr68Zr1nTtHG2Se5Qgs2MAkDjvUt3YrEiKvlGMHLI6Akj69az9pFs3sk9DxKW3MCbnTegOPNAIyPYGpre5CtbC4yjqfMjz1fsMnsPevVrvSbbayC2jf5iMJ057YrkbvwbE7Tb5BAynK5Ocj0PpVc7WqMpxjJdjHlgtpYdz7mZztEwBBEg+vb2NJbWEcc6lQZ/lLMkWcpjgtjvnvinXGk3enqFLKySIEZsgqxHQgjp+NJJLe20nmTncTx8h2k8Dp/h3p89zndFrYbbReTOdsght94UgHb5mOn0IODXoGhyzFFiEQ+UZ45zxzxXJ+I9JnvYYbi0O5sKxU9gO+PpW7ZrJBbRzJ86qBuPQ/hXJWkpbigbqTtcMMOEQklTRVS1CqdyyKyud4I/hNFcZs0jya7ljSJ1ErIAACA3G3p07mqCQiK4WMsHikChSDjcp7c1t3FsWk2IEUkEEcEioDATfxGR2cLhkBIAYnrx2r0YPQ81rUq36LbJbW8bBnVy5UHHPTAPoRWMYWbcV24Aycn/AB61t67aLDZxNGzyMC28sckDPTNVYh5lnPNPu3swAGOVUDg0KN3qLYzo0GDlh0rXtIEO0LncACBjjr1rNlXdMiA/dAXLdCcfp9KckhTy/mlbjaQcgKw6AeuKasmXF2Lt+Y7VXQofOLEdCNvPTFZvn78Z47DJ/M068lLzFmLMT3b+tVDROo07IJSuWPLyq+WwwcnOOc1PFCWcKhDOBxnv7VRDsABuJA6DtUkUjJ1Jx/OiFSKexBrRNGlmrurNKz7ixGFOP4a3tClhfVhPCBBEqb02yMuxgOTu7E/Nyc1yEs5cgFtzA44HykfStOwv3s4XUiF2JDbZMncO64HX6GuiFRNlpnsPh+S00u38yVIvtsgLMrOZHdWJIYbeePXjPtVPWPEVoWsoZtPjnSN/NXjy97EZw24fdDc4AycfSvLb/wAQXVwAhd4YSNrxxHZvP+0epH1rJkujlWQktgZLdQfrSdaMRadTrtc8Salqd6r+YgaWQIoU/OoyRgn+IZPU/Sm3bmxuIp7uGN44DsSNUCHgEAl1yCefrwPSuPN1I20k/MpBVu4xRJcySb92Mu248d6j6whG3f6k0lvEZIlUvgtgcuAeSDnj06VRmvnnKhf3YyNxUYzj7vT0rPaQt985wKTzHJyWJNRKvdiL0uoSbCgcq+/dvXgtxjJ96r/apGG1SdxwBg88dBVcknrQpKsCOCOQaydWXQZqJqcgPly/LG2FdOQB6nHr9K3zcRQBJba4ffGFwEfdt+XP9e3Toa42RzI5ZvvHrQrMpyrEfSqjXkt9SlLozvJNRuY9TWW5jkAkKgBm25GOxHtWq7TwfYruaJZrZsSMAxVkbJGM9x0NedjUZZJYzOS+OCTwT+NdPZazALeKKYh7b7zxNnAbswA6HGMjoacWpS0OyElKNkaWp6lsljg0qQzzJAytcMflTkklQcfNjj24xWXZs82myuJ7dJJGztaUkInGF2j7xPHHtTNWtLXZHJHlEYqzSk8qCOFK9M+9VoLuHS9OidJkNy7bPNhbEsIzltvbkcc859qu8upz1EkV9ZknmltoL1yHt0KtGCMKSeBgdOAM1uafOos/sq+XlgGJX+IgZ/D0xXNWBe7faxXCBgHfqF5PzHvjmt3RLF47E3cv3JGAjxyQPWuavO8PU1pQ0Ujs/DVvFaQR5wJZgN+xskKexHY+1el2Y8mJdy7EIztxjHp/+qvLdHfykZ9jnDbiw5y3qTXp2i5lg+03bDG0Fe5x615/Wx1X0NCKQ3UX7sMR94luOabLFCygAS+bnJ+bAH4dKfDOriQxKQpHJxyAOtZt/LPIv+ilioBIB+Umpe1zSKbZbeVI0yyhQo54yazb+SYJuSRWb+HA6flUkMc0th5twuJy3ADcgD1xUkBgkRQucZ5OcYqorQ0SsZdtFOkhe4MmWbDEcdfetAyAwJsdt8YxuJySexNTtIYUCBwBnALDNUvLQy7ApUBslWOd341ElZim+bVmF4qlkms5lkxvcBWPpXGS/LHLlc7VA4PDEV1euZQS5LMmfxUH+lZEtutuobuw3EYzn6VpHdM5p3scdo19LBaXslpua8uI2hO4bjtJ5UDsOAcnH41dhkuLi1h+3xD7QkvzTiMbvLYY6dMZyajXRJka6W3YRxCTc4Y/f/iUkDnAya3dGEtzI0lzG6XBVgzMu1SpXAyAOh9hXuRqRSTucXI2Vb3RPMghGnQWUxlwd+C/zcnckgIZSOm0DGeeawbV/t2riWW1VpGJSSFGx9oycNz09OfXmtaSx1R7g28b+RGQCIUdioIB+UZ59eabpt/aQSvLPpzSXEMR3+YAkYyONx6nJHAHU9aPbRewewki3daFpNlYefazRymbICSLveNBkBT/ALRPYfUnpVTWtTR7D7JcLczQxRL5QncKsRI4KADJ68DPrVK98Q3hkEtvYR2riQsdyB9rEY6Hpx2AA4rOuI724xPebjEFJ3Mc5b3P9Kn2qTsa08PJblSaF7zBildnB2sSSePpUceyFwzmZX6EIQAR357Zq/C827zPJcpkb2jGDnHTNJNpc80rbY2+b5uT0zUucWrxN1QdyKTypLDc5xJIx2qfmIA9WPue1VorbbcKDh13c4OQRWjaaJK8pSQugA67c5rpLTRv3xVYjDGQASM88/8A66m8ZayNI0HHc5yTw3O9wipbsY5CCHPUA8/yq3YaJFFNdxX0D/u42EbIg+9ngkEf/Xrtbe0nW+aaMgwHOBIxyQeMD6YFdNYKI8ytCWfBdi2Dlj0OD29vXmpdSK2G6UY9DgvD/hu5dQ1xKrWzjcCExnn+IEdP8K7mHSraMxu0Ss5OS5fIwBgc4zitQOssJAtS5Lggl8jjpT/t087eYbZ4ygwylgwOBwMf41HtmySlY2TQTho1KDaQERt5x6nJFLdLIrbYXIbaN+9MAZ7A96nnmlgK7/LhSVf4oM5Pc4zzz7ClkV1sjH9oE0TD7wg6D6E/hxUuRa7kUTyqrN8gbuAd2MjuKfFdeYCSNhPALgEHjrzVKaV0tvmkCEKRvAGD7HjINZN1qFzNnZFEnAbcXB3DHb61N7Gi1L0erC9vWEDqoQYOQRn/ABqcTIiOJFTDtjOBWPFJcPEglKxBUAJ25UewA5P1NI1w8kYECxAxgt83GR/X8K0tzbETiuhqXVtbTYgaBWLrym3qtcnr/g8iINpjyhFbd5MjbgPcf4VffUp4biORYR5pG0nf0H9BWlDetdRKyY+oPFKzS1MmpQ1RlaSLm2CF23MEKMoGB+A9CKUK5LNGuduN8aLj8f5VZidhclFPzKclj0Oex9qSQMb0S2v7tjlXj6DdWMlc53vckUyQyF7eOJlwCwPQ0VPJi4K4G0N0J5YnvkUViaJnmc28lmi3fO2Rzz170jSLuMrrteMD+X/1quX1vJaOAADublj0yfbtWJrs7pb/ACM4ZjsyDwcd/r6mvSi1y6HA3qEe68uBEIkbaTKQ3Tb7fiahEd29ooBb93lpCD3Y4Cn24rOtLpoZMjcWPDfNjNa0GrQPC0MyrDvO5ty8P3H05q4tNaibuygjLLaRxSgb2bfn161BMnluoXapU4zzwR3qacoR8wQRycqQchW9vao7m4EoPmgI7Y3KADn39jUSlFFqJBdqyFC0iOzDJ287ecYPv3/GqtWWTKjBBHY96h2N83ynC9TjpWDldkyi0Mpc0oXIJOB9aQcc8UhCUZxyDzS8cU/zW/hCr9BQCt1EVGd8Lkk0MhVmU4464NBkfP32/OkYMFUnODyDmlqP3bD44iysT2xz2+tJJEyYyRzTSpABPU9B61r6FokmppPKSyxQ+i53H0oVx6PSxkbG9Pemmu3m8IOQFsg8vUmXGEUdhz1/CrGn+AJJWQyTFHA5U/3vY1PPbRm/1Wb1RwFFepnwFp1umZkuZGDAHDjqfb0rK1Twto1vBJKt2wwxJCHLIPcHj9auPvbA8HUSucFSVbntlSVliLMA2AW4rc0rQRd2zXMi7QuMR/3v64qlFt2MlRk3Y5+2t3uZhHEQWxnPoKntolW5AklG1SMtyQv4d66Cz8NXF45lhj8mEZJcdAP6n2FVtbsFhQXEB/cjEYQj5m2j5m+n+e9VKk7XsaKl7N3kaDWoSxnuZA0sYkTypZAQrjeQcHpjGOv4dKyb8RMfJs4oFyuyWSPlRhj0Yk7iRjLcU+O9vbvTvsRm8223qixk9wDgge2Tj611Vjo0FnYmS7jX7QygwLjknrkqe3v+FVzp/I3VFVPeb0Odt7e2EkNnGJxO3ygADDsSOPoBkn14Fdt5KW1t9mi4CADKnoMdB71qabosVtAmqX0YEqIQowMqT1x9T+VUIdqNLeyEfIDwem7H9K4as+aVx/kS6VbywW0e5z9nZirKpzhgehHrivRoLAvZ77w4U7ThSVGOwrg/DlrFbuj7QjsfNnIz17ZPfFdvc3vl2xMUzOzDhT0IPqKyUb7nRCDbVi1PM7SeShMcbAAKowCBTfsDFCxKu3UhumB2qDSBJNslcFR2BOSTWq0bR2rZBeNOozyTTaRs/ddkRWcRtkjP33fILN0A9sVALOJTNGN2WIdTtyMmrgcq0YSHEZXkNwenpV4SRSL8rh1IOcHmkrSJbe5glVkeQSI8SZAAk5J+lE6JGC3Eitxvx938K02WGZTmTJ5xkflVG5G0L84cKeeaT7iepx+pbnluBwyqhwOeR3/Q1jxRRPDt+Z2iymSe3Y102uIsNtMi4MhPyuvIU9+a5ssLSYAqWQRgc/3f68/zpXRlNdRmmtBDeutwXjVju3gcc8fN7e9dNHBCwg2qZJGXK5bAXv26jFchOtzNA0kGBcQncm4feU9QR6GrHhzXpr3TZIJJbe3liba2VMZHoNx4J/WumD9pA5+Rp3NTVrA/JPGoafGUdex/vfQVy+oLcy2TbEEgRszADHJPGP8AGtCHW5LORLmdgJGdoFkZ/ukcjPbBB71Bp12upan58ewc48pV2nGPr2PYV0QpySKc7bmekyBnF3PJb3TnIPBBJ6nNamnzW8yvZ+Zbx27D7iNvJPrn681z3itIF1HbKgIx95Gyff6VjWt1FB5iIq7N3DsSrqPqP5Ypyi9kbQ1Wp6bcWtgojutOjFtc20eybym3rKQc5Ydx71KI7WWM3sB3F2xMgGQr9/oPavLn1XdcIIZpEjPXzHx29ff0q5o+pXbXAlhQuXTDIsuw4z3x3+tc75loaR5dr6no4ht/LX90MOwdWj5ZR349K3ZrS1e1bbCzqp+Vnb5vxA7149Nretwl1tgzbWO4oucZ9TUmnan4j1KYxRTiI4+4flOOhIzUOckgla9rnrtvcaVCjRyugZSUywxjPcZp1xqdjBGIpsNGm4+dDyQQM4P+FeaXvhHVXiE02pbzuXjnoSOfwqh4t8KXel6XdXp1OeYo5Ypk8jO3J560oOU9DnqzhHXc9U0/xNZwW/mSGPeqsDlhuwO4Hrimw+MdOtYJ7cLHKWO5HIwxBIAVieOxOK+cMTyNuLOzNyWLHJphaVD99x75NWoyWzMHWju4s+k9W8TaTeIXS68uVNyW23DHI4YZ9O4rQXxDYsbe3nm8i22D96qhy8gJ3bsew/Kvl9bq4TAWeQYJYYboT1NWodZvoiCJt2CD8wznHrVe+NV6drO59Jale2VzYXEqSia583G6HiMr2P5c/hVGXStOuLvZDJGrFA0hzhd2MkfWvCrDxVqFpD5SyNswFIB4IHatnTvGTqfKk5WUKrE9cqMKc/TipblfVGkZxfwyPQ722MFs9wsh8sNt6859cViar5trIGVHeNRuIjPJHqPSmWXiq0vWk+1YQoGUhu3bd9anfUrbUEIilUq4CK33fm/wNLneyZ0RnZ6nO22oGS4MVypEMhxuJwV/HvW5o94Ir2SKGZWCDtyPyrPeCS2ke0hDNtHmKHI27jjnPc/yxTIzKJi7ocqAC4HXHTApxc47m03Ga0OruAkkxmjbHdvQ1WjuvLmPmMJI92w8/kRVXTsraBfNJySQG6jPrStEoOF+UMAc/wCBq73PNmrOx0EcA81JbYF0dcspP6iiq+j3Atv3km7DcKeoFFZNpBqefeL7gw2+xlKs55YHJGDXNXcomtsGRWJYYIORkDp+VXfF0xlvN2cqVIOenX/GqmkiM2soBzMV4XHT0xXfH3dDi6lGKPKuzhgygbQo61WJDZPfNdnpOgCazSWXqxyTz9z1rP1XS4YGMNtEfO+8xJ+6B/KspzS0ubqg3sc+ZPmRgqDAAwBnp3pjHLEjP41OI1Wcq6kouc+5qUWTcLsbfgcY6+9ZcyRKpSeiKZYs2R1PYU9WcqUDEL95ueDW09gLe4ET+X5m35tvOz246t/+qls9NdZApjCyE8hx04/mKXOjaOGk+pjJbyyqWVchRuOTjAzipoHEVvcxtbI8kqhFkbrHzklR6nGM1tXFqJLkhUyhwoHZq2tO0SLP72FXA6KR0J6Ck5u9jdYHrc8/YFTg9aUFABwS2eR2xXosvh6FmYJbgA4UNjIHrUth4chWNpBDsbcFRSuSfc+mf0q07i/s+W/Meank/Kp+nWtHTNIur25jjELIsnSRxhV56n1r2DT9PtIlMYt42dR83y9anbR5g63SoUhBI80jhCOucc0nNW01FHBWfvM4Vfh3Mq20txdqLeVA2FGG9P59K7zwpoMFlYPDapHJG+D+8Xd+Wehq+PD0jIov7iSJk27oymWJJ64Psf1rstFGno1vJAPLjiKrO8wyjMfvBRwcAYOOeeaIty8jo9lTpxvHVmRZ6LJEhYDdEflYnhV79elWpbOOKORwsLhAWZlkX5VVS7MSTwAo/PAp3jLxDaaNavbacqym4tipgdWZxtI3OQOBk49Omea8tefVZLqbUNW3sluziNWtCwLt9wOB17sA3GF79K2hSV7BHmkuZ6E/iPWbie5hFrgQSJtVijKqk+oIzn61y1zBHd3TW4uBCj4EckxK7u+eeink55qbVdQuTZWsMLM/mxrhyPmmPQsD1xnj8KXSNKjka1RzHcvPKyyRwvlkRFzgHtnP4YrZRSdkbOo3G2xW0Pw9NrE1yIYgUiOGupATGuQSoyOAWxx/TFXYLSFFXEknnKqSMqcYj3YYnuSSQAo65qxZagNAa+jIdLaZWYQkg5wNo9s4JAPvVKOITxs9veRSXgUwRrGPujOVJYjJJHHB4x+FWrIwkpJ6G1BrMy2j2S6f5KrIxdwcp1LBNwzxgduTjBzXCapepLePHJM0iJv2ZJClm5yB6Zx9cVsXFzqc9tEZ2hjRlLF0cLvy2SWA/iyOuM8VgXlrOki3UsbTWu8Bd+QPXbRUfu6HLOMk9ifQWSPULZzG0xDj90oyznuM+ma9j0fRpURr7VmElw3AwOF9FX2A4rzvwJp8jXSXoUblfYgYcE/4V6tc3Drbjccn1B4H4V51aprZG9mkkYfiW58myIJbzDyq/wB0npxXLTTSzyQ2Q2shOG44Hr9TV3XNSidZQ0b+YhBAI7f/AFz/AEpug2SWweeU5kbBwByK5W23oUlbQ6S22xW8CsQAvIxxvPv61twW5u/vDchwTtbg1zJujK6QRKzpnaSBnnvW/ZCe2bJmVbdiNsbdm9qtO+iOiN0jorNPsjguxOSDtP8ACOwq/LLtQ9OTkD0HesiKY7jgkNjluvX3rR3RSIACScAEkgCps+gmtbsbd3kFqoknOSRgDuagt5RIoe3dhE4J8vHGf8aku4IX8qJgXB5yD09OamihTzA0aM3lqNwbrmocW2NtJaDVcKFDkEnkkVUuNiqJH5Zn27V6MKuXKo3MfAGcr/npUckcbxINqnaOQaNSWzF16KKGN8KPLYEgenoa5XUAs1rHIgJUKFIB7d/8a6nVwLiPZ82xDtKgc/hWFFYrNbXHzNAiFhyOGH0q0jNrTUoLarc20UlvKySKoAIPOQenv9KoXujTt5lxasQ5OXjMeeB3x3A9Km0+RsSRuVmhb58/Q9R74rodKgfypYmlM2HOxz97bjofcetEZuD0J1SuedwWPnX93Y3Msk6yjzfmyvz5wfzAH6elMt0aC7uUvpJFueSJeTjA4XaBk5Fdhr1n5TC42b3VuuOx6muR1a/+2agHt9sdypEg2gEuQvb1zzwK9WhNyiTOPNqX5LItOs88iXdqMoJVlGVPGMgdh0P/ANasfWNCW3n82AtJEQW3beoPQY7H3rUV4544UZxJAUwrQkZAAyVAB54IOD71bm1ORmImdbqG0GYIZEw56F2bHI4Prx17Vu4i1POZIcMw+6uMgDnmovNMUe4NwD+IrvPGkNkBBdPHs8yIsmyPPm7jgMx6ZHP4j3rmfOsRdQyJEEsxIB5UpDFVA6n/AGic+3SsnBNESly6og0m6mW6QxuFl5bOSD9K9J8PXGna0RaXyRveooYCMkY/Hsa4S40u9ljtNRk8mWC4YvEiuC2MnCtt6HGOOtXvD+p6pYzM1nHIwA5RQHbHpz2z1zWbw+jNYYhSjaR6gIL61C+Rm7hHRJSN4Hs3Q/jWX4llj1fSbu38t7eSSJl2SDBz1z6dqu+H/GtjqH2W3uG8m4lwkm4Yjjc8AF8ADJ9fzrf1fQ53tBut9kcrMqyowcHaeeR29+h7Vyqm6bJklPRnzIjuVCsANpweMHPTFNaBmU4OTnlc16vrnw8t7uRpLNntZmOdwOUc+pB/pXKXfg3XrWVkfT1mSLCebG20AE8Eg85os0/dMXDS0jjmkf7OsLBdisXB285Pv1xxUVXL8TRSNBcx+XKGOd64P/6qrfKCc8g9MGtE+5ytJPQaBkH2oxU4CeU+AQTgAkVLptlNqF1Ha24+Zjgseij1ouLlLWlaTe6izyaeofYASoyBk9uf881WMstrLhwVKsCMdiDXo1pc2GiWclhaMrIpPmzY+9049eT3rjdZVbu6eSFSxbkgL39qylOLdjsp0aijdaD7LX3SRlllJVm3bz95fpXW2Gr2t1buwb52O3J4x6GvOHtJRgMpQg7cEU6B5YWXaA7LjbkE7QOelHKujD2s/tI9REyyW8vlumchjJnG329+KklKs1uEwwXJJzwe9eYJdyQ/ZlaRhs3BkJyOCSOD9f0rc0FLvUb9XvnkeEBQBkgDvx6cijYhPnZ6RYzKYAzsNzctmiq4idYjn5XU8/Lziis/U05TyzxA4MygAldzA+nXipfClkl7qOW3bYxuGOATXVXPhyG95MfygksQau6TpaWt0Y4dixLGRlRlif8APFdarXWhyuFmWFRorVUjGQoAwenHfNYWo6e5EpY7ZHbczc5bnv612MEalYxtwzHbgmo72y8uMl8HjIGc7q5ajszupM4Ww0pDCSFHnMARu6YzkGrraKZJhIJGRNpVjjt14+pzxXRoYUCh0J7LsGSc9quRpG0bxEFZCuFB4Ur6/wD1qyV2bapnm88G2YjAXB4Of61fidmtLiRwC68fN13n09a6OXR4WbzI1XCdAOanGkwMAwwMYLcccVexo5RMKwtUa6hzIHYRjac9q3NNkQPMrDiLDSewPAP40h0y3CRvID5jnI2jB9hUNzpdxb3MdxDGrGM8RseWwc4//XVNu2hakmbG9SzKDyWXpx8vPU/hWzbPbqE8+THl/Puzk5wRxntXKyTTxzNcKEukjY4G7BcY7D2/pV6O3kjYfMiPcJu+Zd+70BHvSjVHbQ6bTGSDUF1U2/lRKxbyVB2SquBkHk7s5JJpkHiBl0m4092Qo5VnyvzvgkjJPTGc/L171m6bpl20bRpI6gklmIwP/wBVM1HRIVUTy3G65jX5AQcYz29/Y1pFtrQi0G7M6CbWIpJHM0imWdUxIsQ35U8YIOAWHUt1p9jcRiznguYbS7V1YxGZSyw7uTgkcn0J6YI6VykUe+Tz42i2sBlQPlQjjJzzz6etdLBDDGqm+ussy7mXO0nHbB7ngda05KiegpQSM8lpJpzCGmjBWNYg2C6jop6lsD8qgOsmw02aaNFtwzlAgYszn+8YxjcwwRk9OK6B54IFSLTrcT5KvI+BGI27ZZh93PGaxbjRit19vCtNM/z4jOcEdeT+vTOK3iuXfcejXvI841rTrltSja4khkaaRAZQu1FdxkK3HGB/I1qePNB/sfTdLuJriGS5lcxM0ahAiqOOg5HPU89a0NXNvrxkM8otUMsck0hYKAoR8N6E5Fcrrd/eag7m+MrzKimMMw+XHOTkZAwCccHp1rdpJXIne66DbqzNvA6GdZjA6HcV3BB3GD169BVG/tFttRuoo1DKkYb5BkKSAT9ME/hWrLPc6hPbsXiWe8CxIFGxccDcw+mTk/WquqxWlraJHZSeeWcmWYcDcCQFweenJPI5FKSi9SeuhTuZBcWqSeYoYuIxHGMMR3JHrWtPZyXjWdmmTEp3Sc5wcd/U4qpoJja6jhnYMELOoA6v6578cAV3Wk6c0aO6oPOcluT2J6D8a5K9e2iG1Z3Zf0exWBUAC4QbQOxPc/Sotev3jjZAo3fxHt9KvS+dp9qm9wc8bV/lXP6pIzzrEjgyvycpkbj1P4DpXBJ3epCRm6bam9uGmc8hsnjt2H9a0py6/wDLRfmXlgOh/wAirENsLe3UxkZ24IAxx6j34rNubjy7n7PLBsYen8XfNUloOOrNrQEigjMzn525A6j8q6ODbPcHzY2G5dyn+VYOlkI0RRSxbkkjvWobxbMBpZANvBz9aImm7NqKORRlIgSBgHrirEyvLGu1cL3JHWsj/hIrOAou/YH5DAcmr8bRzRErIwT72G4xWiSb0LimtWSxjaG81zhuBmr+nTdUGRt4Pfiq8Nh5yeYHXYf4AOTVyyjhDOu9lkRc5HQ0pIJyVipc7/OAQ8bsktx+ZqGeV45pRhWbPJ9asTkvvVz8pGARwaxnDwyb97GPbjbnrz1+tZcliFqixdbTakx8MfmwTzWbBB5yXKno0eMZ+6e+KdLPIyKCQqK+eOuP/r1FBdkQuF6M27IHrQZNMxbmwNnbAxblEajaCOhFaWlyrhmVmAc8A/wn0zVq/k/tCziGMOOVP07H3rDec2V6cr5lu+Ede4PbH+NSC10Z0eqWsVxbBHJ+ZNp2nBGRXjmu6Y2j3wjV1kjKh1kYbgcHOMetewQ3MckTRbiqFtyDOQcfzxWD4ksIry18pVTZJyDjGSD1/TtXTh6riy4RurM8/ku0nsoR/qSTiJdvytJnlgB0AHHPUcelbd5cpbaQzQSFrjdv3TEeYz44f16dMcYGDWBJY3Gl6jbb48lGaRCB1/H04rTnuHfTJl8+QhxukRCoIUnO3OM9zwOv4V66alG5ztOErdCne6lJ9jjjv4kZFXfGyrglTyAfbdWSwlW1+0Sw2k0Jn2m2wdyk8/gDmty5BvdDt2kILxp5CJkFnTvk+g4x35rnoYjGdpdmhLquQDyByM+h9B3rP4WTNc2g6KYwhnlItz5glAVA0ZdM7RtHTgt9a0JGS5kup5sm0RcyyxZG4joVU888E56cmqdn5bW1xBcXX2MscEuoIdSecYGcdOPyq/HFLfaPMZtTtmhVtsjCUecRxj5cbnGABkHj061alfRHM4OLM821vIkjWV8bhcb5Ec+WZOhwAepH4n0FdZ4Y1bXrK4t7ayCSRFMSJcEqY1wcIWzwCOh6HNc9YaWBfebBa27yQFZPJa53b8dQx4Az1/Cmatd3t6sc8ttNFc27GPzYmYbUHO0A8AAVk4K12tTWLklY9g8M+KtK1qyT+05oop5G/dqvEuOOFUfeHXrV3WLWQW8v2UucEI24ZKt2yQSM4IOOvWvEYb/YZNSt5U092OHjgxgtjhgvVffGR9Kv23irWSFdGtiwmBWVjlkOP7ueVA46dzWFSnc1i+p6NNpUV9aJBdos7kAZdAzD2rnb3wTobPu8koMkMELKQaxj45kRMJZvJey8PcO+CTnvx09Bjiul0jXTql3Il3LBPc7F34JO58dR68YBPrWMm0tCuVSbujPk8AaJ5CyRee2RnBlzWjaeFtGt4FjitjnaSxDnn3NWxq9r9omto5YzBGwy+4DknH+R7GpJtSgt7OWZeRllQgffGcDA75PFSqt9yowjF6Ix59O0uyhaQwxfKQGyc4NRxR2d/aym3VERVwQq4IIq3d39pDBcrclBGhwygZbPHyj/AGh1rlLUXVyfP8/7PbiTcsMeMtgnk+3tWXtGnpsbuV0Z+oaf5HmByQB+8y3UYPWq1s0chaTyyodWAO3g5HJrWvI5Lm9YzbpYc5YcAk9cYHbt6VBNZSxQXEkw/fTbRGoHzD5ux6YA6/hioV2ZyV9znJLYHU4UGWR3VQxGP8817P4d0uOG0RgituGMsOT2rlk0eNdUtXSJiEZd4I6Z9K9PsYBHDhIwQBx6fhW0XdamDjbYzZrQmH5s5AyGHHHoaK1pogEOQOvr+lFIDl5Y44ogAuyQtxnqcetZt1IElAjGGICZB5ArdmKA5VS7D24NYupgBg2QRu+hpwdjNxuNhSQKCTnBJDHrmmmUKodg24jpngH1p8xbywEGdoztz1qNpMpHFIoMR4fsR6USavqdFLzHWs6lhIYxwDsx69zVmOTzHfyohuByVbjAxyB/9alZUwCGTA59SfpWdbX6Rah5Up2uTlV9T2rSMEzZLm1RbggdJxsCs8nHPT/PvU7t5KPHPEc4xnORj61MoLfOgLBhyM9+/wCFR3RYAmJgWxnjgD2+lZTjroF+ZkbTRW8kgRmKEAYbGcYz1pqajAzDdh1VRGCPQf8A665u6lvULSPFEign0JIrT0dbSby2hWNM8MqjLHPp6HPrW0YKCubezSV2bcNlDOBsREzzu7j3961LWwtoWB5aTjoP50trEAuHjZCOM9Rj3rTRxC+Qiv2z0/GudpXOdyfQVopkAHyxpyAx9u+Kp3GlyXcqxzQvO6EFmR+HA5wB6f8A166JXnKK0mTGxwC+DuP0psMEiRGQSndu+6orVVOXYUZNamBqOm2iWXlx2qqS29ySRg+oA6Ae9Y17pcN7DKBAQd+1EwSAvrknA55r0KWORg0aLnP385/T0p0NsXPzogPGCeeT/P1xW8a5pCtyLU5fw1oKoszOpWIYGHBzJ07HoP8APeutezjW1YSxJtkwuACAPbjtU0dqIA5idsqMNgAflUN5cAMhkkdWRc4zwv4VDk73ZjUqOpK55d4w0wxXNvHZ7o0luAgigGfkXq2D16964G++zzanLawq8Fmlw2/zCTJJg4GSec4/LJr0XxfE99f232eSYRW6ujeSuSwPzEj6n6cV5+8DQJ5l0kkkVtGVWNJANshO5gDjsSCT+FdkNYmurSv0G2dyg1CWaWzR4ndUESkDakfJH5Ae3WoLiWC8lkmeMpPIxZRHgKuT0A6fhTLaOXyblpGP2l3Nv5Y6s3Vjk9B6gVo6Zp4M7O6LKMbVDdQ2OSfwqak1GN2XTa1Zb8PW0RZp1iULgom7kjnk/XNd/prPFbrNIiqy+2cccfjisDSrZbXL7WZgOUI4Uf57VeuLmUltsihVXOfXPYe9eROo5O5nN8xRv9SNxdsmMrn1wQfQfzJp+n2jN+9bYCSemeB9T/KobfTJQ8knUsew6H/9Vach8uaLdwoxgfwk9yazRDa6FfUYDHCQ7nzWG4ey1y6PIX3ANtV8KSMqPU/WtrxJcgYQvgngHP8AM96q2LBzEqBkiVQoDc7jW0RwuaOn2suzEbOrHn05qLxKyWS+TiSW6wCwUZwT2FdHbtGiRwthVxukc+vpVDXLCK81WG8gd1VVAYA9QO9OSbRrG9zjFllSDzNxaRflVWPJY9h7V23h+XUZlia/8o/LtUAchR/Oof8AhHra4uz5ImkR2DKSNqrXW2dl5EKOEVnT5FbPX2oowd7l3LluuyKNvtAwTwPQe9OkmKkSoRv5GVOBioXidgAFILdMClRGjIhkG4EcMvUfWtJvUVuol1N5sG9QFXI5Xms6GUFxnDbGwR/9atKaNREzKMYPFYl5GIZzKpBSXHOMYasZak6FXUZVhkZ48GNsLjuCTgVlzXUlrEbcgM4/dseuCTxxVvVIpHsgwILhxnPHNZsU3nXQ82Mea2FY5696FroZGxpXmFBC8ZGGOOOp6VBqkCwLcGVM7sYY8E8egq/pYSOSVSMb2Dge/ermqQQ3ZiQAFjxu9u9Jqy0FJ6mLpaAFlkw0q/NGB1X39/Sq9zC51iKGRJGgmB3P0KZ9D7VPer5NxNJaxPI0G1ZVY46jt+FaCTGcQliBt+UZ/Spu1sVCdinqGiR3Filvz5YTaGByQB3z6157NYXegaj5M0iPbzEJ5h6Njscd8cgmvXN4iAjkXh/untWdrOnR3cDLJGrqcZIHANb4fEOnKz2E9dzy+e6jtoHVFDwyFoA0TAFiPb1+YHnj0PFRafc7Vms5FiLyKFKyAKrYAII9Cf8AJ5qfXNCk0248q93IkzFlbbwx6DHpkVnW8JtxJLsEiQtt3qMhc4w3PUdsdjXrpqSujPlsjOuMo9xb3lsEnXIiRwUMfPb6dgeKqpbFiBBPBLKSUUbuVI59MEH1rsbyASNm8tPMEcTJP5Z8w44+YEcgjIOTnPfFZ91pg+wRt5WEicCSaEEF8jg5xjOOfpkVKp9TOUW9jGtbSaRvMT7pIBYsBj6YFIVvbmOSIJJcbevz4C8+p98cVrafBNJIyWdySqpumErbWYjt93k+npVhPtMm2VRaLEzFHaUKFducgH+LAI9xVqndEN9DAhhgNunEkdwAWIcgRk9gc1ILV5LWJ3uAxPEQUBue4I/hP1q3KPIvJcICyMA0QUBUzj34+vOKSEyRCWDzo1jmb59pJBweMd//AK1L2aNKcXIfaaKtw2+eWbLjOQM+2Cfr3pLe2u9CHnRzBGYFQytu4/Cus0L5bSUSGN5SgWIpgqDnqT6Y9Ky9d093ut0xgeNvu+U+Tj1+lZuCbtY3jSfNoO8L2YlgkmdmXYBtb5Rubvx1/HrW1DpV1d5lkBdOPmBIEYPTA9OvuayI7dLG2QLcCSRjtZyMFOcjAHrx+tXm8R3UEUSnaI2bYxZD19feuOeH7GnJPdCahpTwsEV2ATocAEDuB6Va0m3tlhCCCNAo5Jbr+dXLaC5vm87f5iYxgdAKvwQW0bIbhg+wZIPGKwdJxehnJvZmVNp0LvvjgbzM4GAea3bTTVCqDlmX1GaktZjJI6oQsfqP6Vr2oWTIcFDxknqaXI09TNkUVmshQMGKg7lXHHua0RF5QLq/y9QM0OqIivGQD1zVZZd+Y+oU4+lVewJElzKGiyRwcke1FVLp8RvtPrRU7kszAjW0LbVY55A64rEuIriadmML7RxwOB7VtPNvkLlhsXnLdKcpimHmfmMYFUu5cY6XMC1iumAYqqQjIA6sasRW6llBYO6jnIwAK0ZoV2fu92Ac+wqoDIX/AHSEepIwKUrFJDLq3M4XY5CqScLwG+tYGp6Uzt5luWE4bOOv1zXTwxkqu9gSTjgUs0KLtEmcE8A+v4VUKjSsaQm46GZpt0zAROTx8pJ9RWsgQwMxBMmOT6f/AFqrCKNHI2AHtg4rVjeBFJkbYcYxjJapU7sUl1RWtrW2nuSs8SOgGSQuMH0zWrY6TbxL8kaBV/vDH61WsWWQusChe5ZupqxJFcA8sueMg81bbtZkq70NCF0K+U0Q64Dc5A9qtQmAMoRd0gPyAjOPrWZA0jwYV9x65YdPp6VcspFjQfaG3SNyzDkn2qbDcbGnATGwD7SWGC3OVH17VZfy2cFCVlPUgfyrNi1JIgqx9epb+gpLrWYLdJDGuH4JdjwT60Ecrb2NRXVAUJOMYJz1NLJewwDIKKOmRyc/TvmsBrt2h80yMN3OwDOR3IqaDy5k895tsYGQEjyPzq0tC+RLVmhLqyxBgFO4jcTnv2/CsC91CNJo2vY2laVx8hfG70FXWmjQOiAfN8zMxzs7gZrmLl4by8EkwJcNiNevGetJ3LpqN9S3q8jJDdec580MSEiXdtGM5H6flXlt9evOzvFF5huHVpEblfLXcUT2Hy7iO+K9XWzZNKu5Wj2KVJXcxX5ScDkdic8e1eY6rbny5iInTbJtijThQpG3Iz1+UH15rqpzVhqKkmkZcFr9o8tomklnZS7NKmMljncPYeveuz0+0SBkl+fzCBkdDj0x+tZWlWj2qW8TlpWZt2Af9WnXaT2ycVvtIsUskkq/u1AXk479q5MTiFL3VsQ/dXKiaZ1hkiEjnyw3/fbfSrFvaTTq8uxUt+AuevHr6UgSG5nidAJEALbj3xV0yyG3VAN24k4HTJ7/AErkXczb7Ecu2EAoxO3B2p/L8azry4E92HcNhRjgjGPb0rU1QiG32sG6ZZh/SudupytrHJI+HLbQehAHf6VUVdiuZmo4lvBhlkAGVOOa1rZY0it93zMOVFYdvumuhKQdxY5PY/4V0sNm7CHDAAD5jnk1vFGtNdWWnV5ZdpfAPOB39K2LGxY7g5/dlRl+4PtVK0QQzI7KpUjBOeQK2LKQl9rNlcZUZ7U7dze7tZGlbQxxW4gjRvm5yasWunCSRZVmJC9MjAz3qD7bFavvCHH3ck5zU80rkiS2kbPULj7ppqWlibNFm/gICbmYyZ3ZT7v41VZmZGEgy46VUupb5E2B43d+uSQCP8alaUwQDzVfcRgY7VLl2K5NNyCV8gg8Hbwe/wCNZz5LEHDLnKg/yq5DcxmSSKYHzlwR6GsmeCeK6M8ZGxzjGfu/SocrszlG25U1OUQwbeMEncPQ1iMrJOQe4G3jpWvrVu5t2ZnBYruHvWJFfpezuNpSdUI29uO9K5k12Oi06QeSJmILMM8HODirckzybHSMgZHyZwRnnOKzNH2tbysWG0bd+Bz/APqrXtyuAQ4OB0J5P4VLuTcW6h85TINiuem5c4YdMj19KytXa7TSC2mrGlxG6jew4x3yPWti4hjS0WNQcPk7s9PSsW6aaeNxbt5Vwr5CbciQdM+/qKiTsJGxDK81pa5ChyA7HGQB3x71bDhto5Xa3OO/+NZcdww2xyL1ABK9wBVvT1mdneQqMt8gA4A9/U0lLUu2hT8S6K2oWEiXY8xgSUO35V9Ca8mX7Ro880d2myOaNoXcLuDZ578Y6V7zHIhcRclsEMMdPeuV8R6DBdK6OzNuUhQP4c9/auyhXcH5Ewd9Gec6fMG8v7NPNZ3kLoXRXA3AD7y564Pb0OKu6xFO4jEa2a3EqGR7eLKupych1PQ5+YY9fwrL1m3msrhynlo6sEMYTa23bglc/wCcnNUGu2UsSrTxBxgyE+ZH+Ocj6jjNeqppocoWZe0WcCSRbmArL0Vgccn15/I1auYkhldG84OflJZvmLEZzj1P5HNUU84N5kN2biFwSUlHzFTjIPqPUZHSprXYIXCncm35juIEZ78djnt0qoshwuQXNvFJtWN1ZFB3uYSBlhwpPXikvYWgt4/P2CX5TIquWLeh9uBWmtr5vmXFrLMxlIDJFIME+hAPQdad/YmpiSKC4tSbXBYYwNobv19fWrlZoqmuV7mfp7zELtyH6jGRhRz+Nb1jp8twySyyAOynLSDaeOmD3/z0rRtdCvjhfLt1YgLG2VJjA/Hj6da6+y0kPZ+VKCSRhhjhvWuapJROp1Ukee21t56S5HyucMiA/KfY1bj0yW9uEhjQIkeAcsM/iK7WfS/LiYJbHC8oV5BNQ2cEqShkiJwMfOuP1rnlVG6l1dBpumG2tYokchVGC3f/APVTrm1iePcF3dt1WGuXVwXjkX3C8H2quzEzMql1DDOCOPxrn5m3c45J3KE13bWgEW5A2egPb2q1pmprcKPL645J+tZmraP9rbdGcNnlwO/9KdpelvZsJC7NGB90cEn3PpWjinG9yko28zpHdpAGJIAPpjNRmYR8HIJBzVNbp/M8t2Cd+lQXd/5L7pUBTpuHIrCWhNixLcZJ4AK5/Giuau5715iLTlGzk9xRSXmZyjqdGLaN4AsuSmcqD3/KpPLDMEcKqKOhHWoY5CNqsW3Y/i5wPWrsLJktyG6dOv8AhQmbDGSNkAUkN0x0AH9KhmXKbQAzcbucVadnVs7Qh6En0pnlGQEoQSeh9PxqWy0jNUFmzGmFPcf54pZUKLlc7T0yc89+a0BEWTyyfl79smntZAlNwLYH3T60my9DIYpsD7gr559velZI12yMhA6mrs1mRJuRRvA4AwcUgdIiwLGXeeCFzg1UFqDWg6CRHLBIsMnXBPNX1jlkUIgHmFcgetS2aIEUbB5jjazY6j61agtxFhOT1JbkGrnZO4tClHBIxMbsqtggrjBX/GnvYqYz+9lkLDGU6Y9BWoLRGGEG44z1zj3zUkVokFuDHIQ553BNo+lSpdyXLsYsejsAHYmIOcHe2T064FRXWkr85kY4HAwSBXVy2hkhGZGdwARtOcD3759qzpNOCOCyysgOSCeAfeqv2RKm77nOLaMZEjUtG44L5LEj0HtVyaOeOMqVIT72A2eO2ccCt9dNmEXmqFihAyAmBkdjnNZl5elS0aqCGPQCnKdhuo3sYXlF2bfvEbHgA459asaVY7J3eNRhv3aFhk+5/AUTF5iY4mVcnAJHQVsW0BjhMO5/NUEFQOi9WJrJVLsmUmQ6jtFhLDC6yOcHbuzsxwB6eprl9ajigWKeVTIScBT/ABHptz71r6rqUVjEJliklLyBIkjTJdsYGfSqOoyST3qCdMCID7q8bsdPyz+dZyqPoON0Ylvb/ZoWM3yzSHezDgD0A9gKdqFubuFYQ6gDlicZK069cXssaR5ULgqO59BUungSq07rs3MYxuGOlZPXQH3JbOMRZEahY12oueTj2qW6nuYbi1htUQxOGEkjDlAOnHv6U61jMcgfG5nbdnnGPWmXjbpExlmIyPl25wepzVrYzb1GalOhs97SAqwKbn7Y7kVyN1ffa5o2mXzlBAZQSoIHUZ7Ve1y8ULsGAhY9B0x2/HrWVZIUUuyfxAHj7wrogtBI27GERqJAqrEw6ddvPH1rZsZ0G9sFAfvMev0rFYvc24WNiiLjGB3rVtFcJGrKS4OGPrV2NoLQ0Qkk7jaoVOpyO1admqtAfJhIVflJJ+99Kfp8sk0QbaAPujHNa+n2qvIY2Aynzdafka8zRDaxkumVXIwdp6H2rXgw0xURLGG7KatJGgCnCgnv0qxFaF1CxKm4c7ietCi7GbqdzI1K2ULls5U521U3yblj4OOmR2roZgwQJ5Q2Hgkjv7VktbzEOGRWC8gg9aXs+xUJ3WpkXkK7kd4zuOd2O4qrfxxSQmKMs0Y5XtWndI6qpVSsh4PeoGjdZQpwGxg5FZ8vKxt3Ry+po8tsUHYZDZ6e1c5LA1vdgj5Wfpj3Fdze2uBP5YOQMn8a5bxCjxWS3KAb4zkH1FKyepk5dBmiXioiFQVVz5b57HNdTEu258xSmRgNgen+c1x2hl5rQSOP3hl3DHT3FdfZkssLHA34Ofoai3QiTsN1YSz2RWyIWYYznoeeeKDsRgLcKJ0wFOOAKndIlVw525XIVjwCT2qBgwYiIBgvc8kgdR9ahiTvoLLGXt98WDMhwuOvuf8A61XrYmNIY0EjS4JyF6HPr2GKqxxlI42jbALHcfXIqa1nd3jIi2gqc+oFQ9GXurGhbgMHL8SYGSuOnrUs0KywcqWYDGT+h96z1KSOJBJhN3y1djmHlYJ+6Rzj9fpVqQcpxOq6Oz3Dm4GxSSM7SSuOm4/nzXKXXhK5F4giZiGR5Y9hA57AV6tes9zERFGRkH5iOn19qp6fpiw7LiMZQYKRuSwUD+H6da7aeIaVjdyvHU8it4NQsnl02RFSRx5hSZSCuO+fp1qo7SW5Ylilw/zNCy8N6Nnv/hXf+KrU3VxbSFnMsBOH34YJ0IHt6Vz1tAkErW9wGmtWkIyy5YkDpz6ZrthU5lcSp3VzMiaW32RT2Ihilw3mxp82DjkMOv0rtPDtjPt8yOUSpvOFdfvD2OetTaHpkUNvcxu5e1YgquCBj0APfpXQ29itsVEcbGE/wr/AfbFRUquKsxSatZD4vLBDXKNHIBt3A8eozitCO7tVTCldxGTg55qIRwmPaFjLDq+Dj9aGgKupVSy55CjBz7VyObl1M9COXUIocNLIFz/snDfSoTdI87vH5mSMYAPGe9WLiPfCVK7mXnGOlUoF8vaQSCucj8aGrrcaa6GhGhcp5iht3cVS1K23EPHwUOdrDg1eE7Yyq7gBn0wfSq5kkZyykHPt0/CkmSk27lKW3RV48wNjIVGyD/jTJ3lt4gB8yk8gjDCr237O7mQ5B5C4706ZI51DBWUbR3zQmimkZEhnddzWz+V13iq9xPBAqpIPlY49cZretIzHv8sud3AJ6U660uK7RWZV8xTncRyPpSehLtfUwLW3jtiskedmcHCk49896K6GG3l5wuVxg5OKKCbLqYH/ADGYv+ubfyFaUv8Ax7/8C/rRRUMsa/35KNL+430oopM06F9PvfjTz/rz/vGiip6iMy7+5L/vCn2X/Hvb/wDAv50UVpAvobejf6tfof5U656D6UUVEzPqalt9+L/eFWD9xf8Aeb/0KiimtiHuEP8Ax/zf74qK7/48F/3X/lRRV9CHuTXn/HhP/uL/ACFcbJ/r2/3m/wDQaKKmqOBFpn+sX6rW+v8Ax8av/wBezf1oorJFTMSP/j2m+grJ/wCW0n/XQ/8AoIoorMEZdt/x/R/WP+VWbj7sH4f+hGiipWw5F23+83/XOs6//wCPs/8AXH+lFFbRMmcrrn/Ho/8AvCrsn/HrH/u/4UUVshFy06x/Wta1/wCPn8BRRWkdzaJ1eg/8ex/H+daNr/yEX/3DRRT6s17mhP8Aeiq7af6v8RRRSW5jLY0h/wAg0fSsc/61PrRRWxnEp33+vb6VXv8A/Wt/uiiisJ7myMiX/j6uP9yub8R/8gZv9xqKKzj1M3uYnhn/AI8of+uzfyrqLb/kHRfU0UVPUmRYvf8AWJ/vL/KktP8Aj3f/AK7P/Siis+pSJrT/AJB6/U0tt/qk+tFFZyGtyWz/AOPe6/3hUsHSP/e/woooRqX5Puz/APXL+tV7f/kEP/vD+dFFbwEzmvEX/HrL/wBc/wCtYg/49F+lFFdlLY6Y/CbJ+9pH+6f611UX/Ht/wGiipnuctQh1T/UR/SjT/wDj2P8Au0UVzx+ITCD/AFsf/A/5VlN/x+t/vj+dFFaLYUdzV/v/AOe9Rx/8fI/CiimtiiPV/wDWyfWo7f8A1KUUVmiuhcX/AFT1O3V/oKKKuRkyS0/49x/u0UUVKMmf/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This image shows palpebral and periorbital purpura in a patient with amyloidosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Weingarten TN, Hall BA, Richardson BF, et al. Periorbital ecchymoses during general anesthesia in a patient with primary amyloidosis: a harbinger for bleeding? Anesth Analg 2007; 105:1561. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_46_10979=[""].join("\n");
var outline_f10_46_10979=null;
var title_f10_46_10980="Penicillium marneffei papule";
var content_f10_46_10980=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F56450&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F56450&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Penicillium marneffei infection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple erythematous, umbilicated papules were present on the skin of this patient with Penicillium marneffei infection.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_46_10980=[""].join("\n");
var outline_f10_46_10980=null;
var title_f10_46_10981="Insulin injection sites";
var content_f10_46_10981=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F78710&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F78710&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 518px\">",
"   <div class=\"ttl\">",
"    Diabetic injection sites",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 498px; height: 607px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The shaded areas may be used for insulin injections. Injection sites should be rotated. Insulin is absorbed more rapidly when injected into the abdomen, as compared to the arms or legs.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_46_10981=[""].join("\n");
var outline_f10_46_10981=null;
var title_f10_46_10982="Developmental milestones 4 through 8 yrs A";
var content_f10_46_10982=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F60900&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F60900&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 630px\">",
"   <div class=\"ttl\">",
"    Developmental milestones: 4 years, 0 months through 7 to 8 years",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 610px; height: 715px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     &copy; 2007 Chris Johnson, MD, AAP Council on Children with Disabilities. Adapted with permission and contributions from: Frances Page Glascoe, PhD and Nicholas Robertshaw, authors of PEDS:Developmental Milestones; Franklin Trimm, MD, Vice Chair of Pediatrics, USA/APA Education Committee; the Center for Disease Control \"Act Early\" Initiative; the National Institute for Literacy/Reach Out and Read; and the Inventory of Early Development by Albert Brigance published by Curriculum Associates, Inc. Permission is granted to reproduce these pages on the condition that they are only used as guide to average development and not as a substitute for standardized validated screening for developmental-behavioral problems.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_46_10982=[""].join("\n");
var outline_f10_46_10982=null;
var title_f10_46_10983="Phentermine and topiramate: Drug information";
var content_f10_46_10983=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Phentermine and topiramate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?25/17/25877?source=see_link\">",
"    see \"Phentermine and topiramate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F15057041\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Qsymia&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F14634241\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anorexiant;",
"     </li>",
"     <li>",
"      Anticonvulsant, Miscellaneous;",
"     </li>",
"     <li>",
"      Sympathomimetic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F15059968\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     <b>",
"      Weight management:",
"     </b>",
"     Oral: Initial: Phentermine 3.75 mg/topiramate 23 mg once daily for 14 days. Increase dose to phentermine 7.5 mg/topiramate 46 mg once daily for 12 weeks then evaluate weight loss. If 3% of baseline body weight has not been lost, discontinue use or increase dose to phentermine 11.25 mg/topiramate 69 mg once daily for 14 days, and then to phentermine 15 mg/topiramate 92 mg once daily. Evaluate weight loss after 12 weeks on phentermine 15 mg/topiramate 92 mg; if 5% of baseline body weight has not been lost at dose of phentermine 15 mg/topiramate 92 mg gradually discontinue therapy (eg, 1 dose every other day for at least 1 week).",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F15059969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15059970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Renal function should be estimated using the Cockcroft-Gault formula with actual body weight.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Mild impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;50 mL/minute): No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Moderate-to-severe impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute): Maximum dose: Phentermine 7.5 mg/topiramate 46 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Dialysis: Use is not recommended (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15059971\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Mild impairment (Child-Pugh class A): No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Moderate impairment (Child-Pugh class B): Maximum dose: Phentermine 7.5 mg/topiramate 46 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Severe impairment (Child-Pugh class C): Use is not recommended (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F15893978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, extended release, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Qsymia&trade;: 3.75/23: Phentermine 3.75 mg [immediate release] and topiramate 23 mg [extended release] [contains tartrazine]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Qsymia&trade;: 7.5/46: Phentermine 7.5 mg [immediate release] and topiramate 46 mg [extended release] [contains tartrazine]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Qsymia&trade;: 11.25/69: Phentermine 11.25 mg [immediate release] and topiramate 69 mg [extended release] [contains tartrazine]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Qsymia&trade;: 15/92: Phentermine 15 mg [immediate release] and topiramate 92 mg [extended release] [contains tartrazine]",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F15070498\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     C-IV",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F14634227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM312590.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM312590.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F15059973\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer in the morning without regard to meals; avoid late evening administration (potential for insomnia).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F14634231\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Chronic weight management, as an adjunct to a reduced-calorie diet and increased physical activity, in patients with either an initial body mass index (BMI) of &ge;30 kg/m",
"     <sup>",
"      2",
"     </sup>",
"     <b>",
"      or",
"     </b>",
"     an initial BMI of &ge;27 kg/m",
"     <sup>",
"      2",
"     </sup>",
"     and at least one weight-related comorbid condition (eg, hypertension, dyslipidemia, type 2 diabetes)",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F15059447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As reported with combination product (also see individual agents):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache (10% to 11%), insomnia (6% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Serum bicarbonate decreased (6% to 13%; marked reductions [to &lt;17 mEq/L] &le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Xerostomia (7% to 19%), constipation (8% to 16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Paresthesia (4% to 20%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Upper respiratory tract infection (12% to 16%), nasopharyngitis (9% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Palpitations (1% to 2%), chest discomfort (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Dizziness (3% to 9%), anxiety (3% to 8%), depression (3% to 8%), fatigue (4% to 6%), attention disturbance (2% to 4%), irritability (2% to 4%), hypoesthesia (1% to 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Alopecia (2% to 4%), rash (2% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Hypokalemia (&le;3%), dysmenorrhea (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Abnormal taste (1% to 9%), nausea (4% to 7%), diarrhea (5% to 6%), dyspepsia (2% to 3%), gastroenteritis (1% to 3%), GERD (1% to 3%), appetite decreased (2%), oral paresthesia (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Genitourinary: Urinary tract infection (3% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Back pain (5% to 7%), muscle spasm (3%), musculoskeletal pain (2% to 3%), neck pain (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ocular: Blurred vision (4% to 6%), dry eyes (1% to 3%), eye pain (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Renal: Creatinine increased (2% to 8%), kidney stones (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Sinusitis (7% to 8%), bronchitis (4% to 7%), cough (5%), pharyngolaryngeal pain (3%), sinus congestion (3%), nasal congestion (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Influenza (4% to 8%), thirst (2%)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F15057047\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity or idiosyncrasy to phentermine or other sympathomimetic amines or any component of the formulation; hyperthyroidism; glaucoma; use during or within 14 days following MAO inhibitor therapy; pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F15057048\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Cardiovascular effects: Can increase resting heart rate; monitor closely when starting or increasing dosage, and in patients with cardiac or cerebrovascular disease. Reduce dose or discontinue use with a sustained increase in resting heart rate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; CNS effects: Cognitive dysfunction and psychiatric disturbances (mood disorders including anxiety, depression or insomnia) may occur with use; incidence of cognitive events (including attention or memory difficulties) may be related to rapid titration and higher doses; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Risk may be increased in patients with a history of depression; dose reduction or discontinuation may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Glaucoma: Topiramate has been associated with acute myopia and secondary angle-closure glaucoma in adults and children, typically within 1 month of initiation but may occur at any time; discontinue in patients with acute onset of decreased visual acuity or ocular pain.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hyperthermia: Topiramate may be associated (rarely) with severe oligohidrosis and hyperthermia; use caution and monitor closely during strenuous exercise, during exposure to high environmental temperature, or in patients receiving other carbonic anhydrase inhibitors and drugs with anticholinergic activity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypokalemia: Can cause hypokalemia; use caution with concurrent use of hydrochlorothiazide or furosemide as risk of hypokalemia may be increased; monitor potassium closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypotension: In hypertensive patients, weight loss in conjunction with antihypertensive therapy may increase the risk of hypotension; monitor blood pressure and adjust antihypertensive treatment as necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Metabolic acidosis (hyperchloremic, nonanion gap): May decrease serum bicarbonate concentrations, due to inhibition of carbonic anhydrase and increased renal bicarbonate loss. Risk may be increased in patients with conditions that predispose to acidosis (eg, diarrhea, ketogenic diet, renal disease, severe respiratory disorders, status epilepticus, surgery) or concurrent treatment with other carbonic anhydrase inhibitors. Monitor serum electrolytes and bicarbonate prior to and during treatment.  Reduce dose or discontinue use if persistent metabolic acidosis develops.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal calculus: Use is associated with kidney stone formation. Topiramate exhibits weak carbonic anhydrase inhibitory properties and may increase the risk of kidney stones.  The risk of stones may be increased in patients on a ketogenic diet or concurrent treatment with other carbonic anhydrase inhibitors; risk of stones may be reduced by increasing fluid intake.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal effects: May increase serum creatinine; peak increases from baseline were observed after 4-8 weeks of treatment. Monitor serum creatinine prior to and during treatment. For persistent elevations, dose reduction or discontinuation may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Suicidal ideation: Pooled analysis of trials involving various antiepileptics (regardless of indication) showed an increased risk of suicidal thoughts/behavior (incidence rate: 0.43% treated patients compared to 0.24% of patients receiving placebo); risk observed as early as 1 week after  initiation and continued through duration of trials (most trials &le;24 weeks). Avoid use in patients with history of suicide attempts or current suicidal ideation. Monitor all patients for notable changes in behavior and discontinue use in patients who experience suicidal thoughts or new onset or worsening depression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Diabetes: Use with caution in patients with type 2 diabetes mellitus; antidiabetic agent requirements (eg, insulin or oral hypoglycemic agents) may be decreased with weight loss, anorexigens and concomitant dietary restrictions. Monitor blood glucose levels prior to and during treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; dosage adjustment may be required. Avoid use in patients with severe hepatic impairment (Child-Pugh class C).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Sedatives: Avoid use with other sedative drugs or ethanol; CNS effects may be potentiated",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Abuse potential: Phentermine is pharmacologically related to the amphetamines, which have a high abuse potential; prolonged use may lead to dependency. Prescriptions should be written for the smallest quantity consistent with good patient care to minimize the possibility of overdose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Withdrawal: Anticonvulsants (including topiramate) should not be discontinued abruptly because of the possibility of increasing seizure frequency. Therapy should be withdrawn gradually to minimize the potential of increased seizure frequency, unless safety concerns require a more rapid withdrawal. Tapering doses over at least 1 week (1 dose every other day) is recommended.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F14878056\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F14878054\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the adverse/toxic effect of Phentermine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alkalinizing Agents: May decrease the excretion of Amphetamines.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists: Carbonic Anhydrase Inhibitors may decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: May decrease the serum concentration of Amphetamines. This effect is likely due to an enhanced excretion of amphetamines in the urine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Carbonic Anhydrase Inhibitors may decrease the excretion of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): Amphetamines may enhance the analgesic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the excretion of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergic Agents: May enhance the adverse/toxic effect of Topiramate. Specifically, the risk of oligohidrosis and hyperthermia may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticonvulsants (Barbiturate): Carbonic Anhydrase Inhibitors may enhance the adverse/toxic effect of Anticonvulsants (Barbiturate). Specifically, osteomalacia and rickets.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticonvulsants (Hydantoin): Carbonic Anhydrase Inhibitors may enhance the adverse/toxic effect of Anticonvulsants (Hydantoin). Specifically, osteomalacia and rickets.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihistamines: Amphetamines may diminish the sedative effect of Antihistamines.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May diminish the stimulatory effect of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Weakly to Moderately Effective) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May decrease the serum concentration of Topiramate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May enhance the adverse/toxic effect of other Carbonic Anhydrase Inhibitors. The development of acid-base disorders with concurrent use of ophthalmic and oral carbonic anhydrase inhibitors has been reported. Management: Avoid concurrent use of different carbonic anhydrase inhibitors if possible.  Monitor patients closely for the occurrence of kidney stones and with regards to severity of metabolic acidosis.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May decrease the excretion of Amphetamines.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): Topiramate may decrease the serum concentration of Contraceptives (Estrogens). Contraceptive failure is possible.  Management: Risk appears greatest for higher topiramate doses (200 mg/day or greater).  Some have recommended using at least 50 mcg/day of ethinyl estradiol, but the effectiveness of this is unclear.  Consider a nonhormonal form of contraception.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): Topiramate may decrease the serum concentration of Contraceptives (Progestins).  Management: Caution patients that this combination may be associated with reduced contraceptive effectiveness.  Consider adding an additional (non-hormonal) contraceptive method.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: May enhance the adverse/toxic effect of Topiramate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethosuximide: Amphetamines may diminish the therapeutic effect of Ethosuximide. Amphetamines may decrease the serum concentration of Ethosuximide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Flecainide: Carbonic Anhydrase Inhibitors may increase the serum concentration of Flecainide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of Topiramate. Topiramate may increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal Acidifying Agents: May decrease the serum concentration of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ioflupane I 123: Amphetamines may diminish the diagnostic effect of Ioflupane I 123.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May diminish the therapeutic effect of Anticonvulsants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May diminish the therapeutic effect of Anticonvulsants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: May diminish the stimulatory effect of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Topiramate may increase the serum concentration of Lithium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May enhance the hypokalemic effect of Topiramate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypertensive effect of Amphetamines.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mefloquine: May diminish the therapeutic effect of Anticonvulsants. Mefloquine may decrease the serum concentration of Anticonvulsants. Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of convulsions.  Monitor anticonvulsant concentrations and treatment response closely with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Memantine: Carbonic Anhydrase Inhibitors may decrease the excretion of Memantine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MetFORMIN: Carbonic Anhydrase Inhibitors may enhance the adverse/toxic effect of MetFORMIN. Specifically, the risk of developing lactic acidosis may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methenamine: Carbonic Anhydrase Inhibitors may diminish the therapeutic effect of Methenamine.  Management: Consider avoiding this combination. Monitor for decreased therapeutic effects of methenamine if used concomitant with a carbonic anhydrase inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methenamine: May decrease the serum concentration of Amphetamines. This effect is likely due to an enhanced excretion of amphetamines in the urine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PHENobarbital: Amphetamines may decrease the serum concentration of PHENobarbital.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of Topiramate. Topiramate may increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Amphetamines may decrease the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Primidone: Carbonic Anhydrase Inhibitors may enhance the adverse/toxic effect of Primidone. Specifically, osteomalacia and rickets. Carbonic Anhydrase Inhibitors may decrease the serum concentration of Primidone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May increase the serum concentration of Amphetamines. Specifically, data indicate that Proton Pump Inhibitors may increase the rate at which Amphetamines are absorbed.  Total exposure to Amphetamines is not significantly changed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Carbonic Anhydrase Inhibitors may decrease the excretion of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the adverse/toxic effect of Carbonic Anhydrase Inhibitors. Salicylate toxicity might be enhanced by this same combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May enhance the hypokalemic effect of Topiramate. Thiazide Diuretics may increase the serum concentration of Topiramate. Management: Monitor for increased topiramate levels/adverse effects (e.g., hypokalemia) with initiation/dose increase of a thiazide diuretic. Closely monitor serum potassium concentrations with concomitant therapy. Topiramate dose reductions may be necessary.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May enhance the stimulatory effect of Amphetamines. Tricyclic Antidepressants may also potentiate the cardiovascular effects of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: Topiramate may enhance the adverse/toxic effect of Valproic Acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F15057042\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F15057043\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Based on human data, topiramate may cause fetal harm if used during pregnancy. Use of this combination product is contraindicated in pregnant women. Females of reproductive potential should have a negative pregnancy test prior to and monthly during therapy. Effective contraception should be used during treatment. If irregular bleeding or spotting occurs while using hormonal contraceptives during pregnancy, patients should be instructed to continue the contraceptive (contraceptive failure is not expected) and notify their health care provider if symptoms become troubling.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     The risks of using appetite suppressing drugs in pregnant women are not known. Weight loss therapy is generally not recommended for pregnant women (NHLBI, 1998). Obese women should participate in weight reduction programs prior to attempting pregnancy (ACOG, 2005). Refer to individual monographs for additional information.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Healthcare providers are encouraged to enroll women exposed to Qsymia&trade; during pregnancy in the Qsymia&trade; Pregnancy Surveillance Program (888-998-4887).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F15057044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excreted in breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F15057046\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topiramate and amphetamines are excreted in breast milk. Due to the potential for adverse effects, the manufacturer recommends to discontinue therapy or discontinue nursing. Weight loss therapy is generally not recommended for lactating women (NHLBI, 1998). Refer to individual monographs for additional information.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F15059972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take with or without food in the morning; avoid taking in the late evening. Most effective when combined with a low calorie diet, increased physical activity and behavior modification counseling.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16570444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsule, 24-hour",
"     </b>",
"     (Qsymia Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3.75-23 mg (30): $144.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.5-46 mg (30): $162.74",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     11.25-69 mg (30): $195.29",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15-92 mg (30): $220.68",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F15059975\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Weight; resting heart rate; serum bicarbonate, potassium, glucose, and serum creatinine (at baseline and periodically during treatment); blood pressure; suicidality or mood disorders; symptoms of secondary angle closure glaucoma; symptoms of acute acidosis and complications of long-term acidosis (eg, nephrolithiasis)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F15059962\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phentermine: A sympathomimetic amine with pharmacologic properties similar to amphetamines. The mechanism of action in reducing appetite appears to be secondary to CNS effects, including stimulation of the hypothalamus to release norepinephrine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Topiramate: Effect on weight management may be due to its effects on appetite suppression and satiety enhancement and based on a combination of potential mechanisms: blocks neuronal voltage-dependent sodium channels, enhances GABA(A) activity, antagonizes AMPA/kainite glutamate receptors, and weakly inhibits carbonic anhydrase.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F15059964\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American College of Obstetricians and Gynecologists, \"ACOG Committee Opinion Number 315, September 2005. Obesity in Pregnancy,\"",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2005, 106(3):671-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/46/10983/abstract-text/16135613/pubmed\" id=\"16135613\" target=\"_blank\">",
"        16135613",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Heart, Lung, and Blood Institute Obesity Education Initiative, &ldquo;Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. The Evidence Report,&rdquo;",
"      <i>",
"       NIH Publication",
"      </i>",
"      No. 98-4083. Bethesda, MD: U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Heart, Lung, and Blood Institute, 1998. Available at",
"      <a href=\"file://www.nhlbi.nih.gov/guidelines/obesity/ob_gdlns.pdf\" target=\"_blank\">",
"       file://www.nhlbi.nih.gov/guidelines/obesity/ob_gdlns.pdf",
"      </a>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 85870 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-1E1E8CC54B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_46_10983=[""].join("\n");
var outline_f10_46_10983=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15057041\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14634241\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15059968\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15059969\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15059970\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15059971\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15893978\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15070498\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14634227\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15059973\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14634231\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15059447\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15057047\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15057048\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14878056\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14878054\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15057042\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15057043\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15057044\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15057046\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15059972\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16570444\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15059975\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15059962\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15059964\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/85870\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/85870|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?25/17/25877?source=related_link\">",
"      Phentermine and topiramate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_46_10984="Overview of tremor";
var content_f10_46_10984=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of tremor",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/46/10984/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/46/10984/contributors\">",
"     Daniel Tarsy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/46/10984/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/46/10984/contributors\">",
"     Howard I Hurtig, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/46/10984/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/46/10984/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/46/10984/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tremor is defined as a rhythmic and oscillatory movement of a body part with a relatively constant frequency and variable amplitude. It is caused by either alternating or synchronous contractions of antagonistic muscles. Tremor is the most common of all movement disorders, occurring from time to time in most normal individuals in the form of exaggerated physiologic tremor [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10984/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will cover the classification, clinical features, diagnostic evaluation, and treatment of tremor. The treatment of essential tremor (ET) is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/17/19737?source=see_link\">",
"     \"Pharmacologic treatment of essential tremor\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/4/28741?source=see_link\">",
"     \"Surgical treatment of essential tremor\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tremors may be broadly classified into static and action tremors (",
"    <a class=\"graphic graphic_table graphicRef68810 \" href=\"UTD.htm?29/60/30667\">",
"     table 1",
"    </a>",
"    ). Static tremors may be further divided into those occurring at rest (resting tremor) and those occurring with the head and limbs held in a fixed posture (postural tremor) (",
"    <a class=\"graphic graphic_table graphicRef72091 \" href=\"UTD.htm?32/18/33067\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef77497 \" href=\"UTD.htm?37/42/38571\">",
"     table 3",
"    </a>",
"    ). Action tremors remain unchanged during the course of a voluntary movement, while intention tremors increase during the course of goal-directed movement. The term kinetic tremor has been used to designate action and intention tremor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RESTING TREMOR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parkinson disease (PD) and other parkinsonian syndromes are the most common causes of resting tremor. This tremor is evident with the affected body part supported and completely at rest and temporarily dampens or disappears during voluntary activity. Resting tremors usually fluctuate in amplitude and may appear and disappear depending upon the degree of patient repose, whether the patient feels he or she is under observation, and other unknown factors.",
"   </p>",
"   <p>",
"    Resting tremor is typically less disabling than postural, action, or intention tremors because of its absence during voluntary activity. However, the tremor may quickly reappear as soon as the body part assumes a new resting posture and may therefore interfere with the use of eating utensils, handwriting, typing, and other purposeful postures or movements. In such cases, resting tremor is more of a handicap or disability than pure resting tremor, which is of greater cosmetic concern.",
"   </p>",
"   <p>",
"    In the examination, resting tremor is usually activated while carrying out repetitive movements of the opposite limb or during walking.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Idiopathic Parkinson disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The resting tremor in PD typically appears first in one hand. It later may or may not spread to involve the ipsilateral leg",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the contralateral upper limb. Leg or foot tremor is more commonly due to PD than to essential tremor ET. The face, lips, and jaw may be involved but, unlike ET or cerebellar disease, PD only occasionally produces tremor of the entire head. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/13/14554?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical manifestations of Parkinson disease\", section on 'Tremor'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When the tremor is limited to distal muscles of the hand it may produce a characteristic \"pill-rolling\" tremor, with a frequency of 4 to 6 Hz. With increasing severity, the tremor may become more continuous, larger in amplitude, and more proximal in distribution, but the frequency remains constant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Tremor-dominant Parkinson disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;A low amplitude resting tremor of the hand or jaw, unaccompanied by other manifestations of parkinsonism, sometimes occurs as an isolated finding and may not progress to more generalized PD. However, tremor is such a common first sign of PD that it just as often leads the way to progressive and more disabling symptoms such as generalized bradykinesia, gait disturbance, and postural instability.",
"   </p>",
"   <p>",
"    Patients can go years into their disease with tremor as the only or the most prominent sign of their illness. When this happens, this is referred to as tremor-dominant PD, although it is most reliably applied in retrospect when the relatively benign course has already been charted.",
"   </p>",
"   <p>",
"    Other disorders associated with resting tremor include Wilson's disease, non-Wilsonian hepatocerebral degeneration, and midbrain injury due to stroke, trauma, or demyelinating disease. Resting tremor may also occur as a \"spillover\" phenomenon in a variety of disorders in which very severe postural-action tremors predominate, such as Wilson's disease, severe forms of ET [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10984/abstract/2\">",
"     2",
"    </a>",
"    ], and other cerebellar or extrapyramidal syndromes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17610950\">",
"    <span class=\"h2\">",
"     SWEDDs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term SWEDDs (Scans Without Evidence of Dopaminergic Deficit) has been used designate patients with relatively isolated upper extremity resting and postural tremor resembling early PD who failed to evolve over time into more generalized PD [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10984/abstract/3\">",
"     3",
"    </a>",
"    ]. Unlike patients with PD, these individuals lacked evidence for nigrostriatal dopamine deficiency on dopamine transporter imaging (DaTSCAN). Patients with SWEDDs sometimes exhibit reduced arm swing and mild focal dystonia on the affected side, and may have jaw or head tremor or facial hypomimia, but no signs of parkinsonian akinesia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10984/abstract/3\">",
"     3",
"    </a>",
"    ]. They are therefore to be distinguished from individuals with tremor-dominant PD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Rubral tremor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rubral tremor, sometimes called Holmes tremor, occurs with midbrain injury and is probably due to combined lesions of the superior cerebellar peduncle, substantia nigra, and red nucleus that interrupt the outflow pathway from the cerebellum to the motor thalamus. This tremor is present at rest but tends to have a slower frequency (3 to 5 Hz) than typical Parkinson tremor (5 to 7 Hz). It also persists unchanged or increases with postural changes or goal-directed activity. It may produce a combination of rest, postural, action, and intention (kinetic) tremors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     POSTURAL AND ACTION TREMORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postural and action tremors comprise the largest group of tremors. They are elicited during examination under two circumstances: with the arms suspended against gravity in a fixed posture; and during the course of goal-directed activity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Physiologic tremor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal individuals have a very low amplitude, high frequency physiologic tremor of approximately 10 to 12 Hz that is not visible under ordinary circumstances. Many factors can enhance the tremor to the point of detection, most often by increasing sympathetic activity [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10984/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Common drugs that increase adrenergic activity include beta-adrenergic agonists such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/55/12151?source=see_link\">",
"       terbutaline",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/31/23029?source=see_link\">",
"       isoproterenol",
"      </a>",
"      , epinephrine, amphetamines, selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants, levodopa, nicotine, and xanthines such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"       theophylline",
"      </a>",
"      and caffeine.",
"     </li>",
"     <li>",
"      Anxiety, excitement, fright, muscle fatigue, hypoglycemia, alcohol and opioid withdrawal, thyrotoxicosis, fever, and pheochromocytoma also enhance adrenergic activity. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/22/30057?source=see_link&amp;anchor=H8#H8\">",
"       \"Neurologic manifestations of hyperthyroidism and Graves' disease\", section on 'Tremor'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Miscellaneous drugs and toxins that increase physiological tremor by other uncertain means include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      , antidepressants, corticosteroids, sodium",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"       valproate",
"      </a>",
"      , bromides, mercury, lead, and arsenic.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Enhancement of physiologic tremor is the most common cause of postural and action tremors. Thus, a medical rather than primary neurologic cause for postural-action tremor should be considered in most cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Essential tremor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Essential tremor (ET) is the most common neurologic disorder that causes postural or action tremor, with an estimated prevalence worldwide of up to 5 percent of the population [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10984/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. The incidence of ET increases with age, although it often affects young individuals, especially when it is familial.",
"   </p>",
"   <p>",
"    ET is referred to as familial tremor when there is a family history (approximately 50 percent of cases have an autosomal dominant pattern of inheritance) and benign essential tremor when it is sporadic. The use of \"benign\" as a modifier for ET has historically been employed to distinguish it from Parkinson disease (PD); it is best omitted, since the tremor can be severe and disabling [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10984/abstract/7\">",
"     7",
"    </a>",
"    ]. While prospective data are limited, ET may be associated with an increased risk for developing Parkinson disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10984/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ET appears to be genetically complex [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10984/abstract/9\">",
"     9",
"    </a>",
"    ]. While no causal genetic mutations have been confirmed, the importance of genetics in ET is suggested by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dominantly inherited ET has been tentatively linked to genetic loci on chromosomes 2p, 3q13, and 6p23 [",
"      <a class=\"abstract\" href=\"UTD.htm?10/46/10984/abstract/10-13\">",
"       10-13",
"      </a>",
"      ]. Other families with ET are not linked to any of these loci [",
"      <a class=\"abstract\" href=\"UTD.htm?10/46/10984/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      First-degree relatives of patients with ET have an increased risk of developing the disorder, particularly when the proband develops ET at an early age [",
"      <a class=\"abstract\" href=\"UTD.htm?10/46/10984/abstract/15\">",
"       15",
"      </a>",
"      ]. The lack of 100 percent concordance among monozygotic twins suggests that environmental factors are involved in the pathogenesis of the disease [",
"      <a class=\"abstract\" href=\"UTD.htm?10/46/10984/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Genome-wide association studies in Icelandic and European subjects with ET have identified sequence variations in the LINGO1 gene [",
"      <a class=\"abstract\" href=\"UTD.htm?10/46/10984/abstract/17-19\">",
"       17-19",
"      </a>",
"      ], which appears to play a role in oligodendrocyte differentiation and axonal myelination. Findings from another genome-wide association study of European subjects suggest that ET is associated with polymorphisms in the glial glutamate transporter gene (SLC1A2) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/46/10984/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Accumulating evidence suggests that the neuropathology of ET is localized in the brainstem (locus ceruleus) and cerebellum [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10984/abstract/21\">",
"     21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One of the largest published studies analyzed postmortem findings from 33 patients with ET compared with 21 controls [",
"      <a class=\"abstract\" href=\"UTD.htm?10/46/10984/abstract/22\">",
"       22",
"      </a>",
"      ]. Brainstem Lewy bodies were found in eight (24 percent) ET cases; in the remaining 25 (76 percent) ET cases with no Lewy bodies, degenerative changes in the cerebellum (Purkinje cell loss and axonal swelling) were significantly more frequent than in controls.",
"     </li>",
"     <li>",
"      In another case-control study, depletion of pigmented neurons in the locus ceruleus and cerebellar gliosis were significantly more common in 21 subjects with ET than in 21 controls [",
"      <a class=\"abstract\" href=\"UTD.htm?10/46/10984/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A study using diffusion tensor MRI has shown changes consistent with neurodegeneration in the dentate nucleus and superior cerebellar peduncle of patients with familial ET [",
"      <a class=\"abstract\" href=\"UTD.htm?10/46/10984/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast, a neuropathology study that compared findings from seven patients with ET, six patients with PD and two normal control brains found a similar age related reduction in Purkinje cell numbers in all three groups and no evidence of Lewy body pathology [",
"      <a class=\"abstract\" href=\"UTD.htm?10/46/10984/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The significance of these findings is currently uncertain, and further age controlled neuropathologic and neuroradiologic information is needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Clinical features of ET",
"    </span>",
"    &nbsp;&mdash;&nbsp;ET is a heterogenous disorder with considerable variability in the character of the tremor, the circumstances in which it is exacerbated, and its association with other neurological deficits [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10984/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. It varies from a low amplitude, high frequency postural tremor of the hands to a much larger amplitude, postural and action tremor that is activated by particular postures and actions. ET most often affects the hands and arms and can be asymmetric. It can also affect the head, voice, chin, trunk, and legs.",
"   </p>",
"   <p>",
"    The diagnostic criteria for ET are shown in the Table (",
"    <a class=\"graphic graphic_table graphicRef62078 \" href=\"UTD.htm?6/5/6235\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10984/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ET becomes immediately apparent in the arms when they are held outstretched; it typically increases at the very end of goal-directed movements such as drinking from a glass or finger-to-nose testing. Cerebellar outflow tremor should be considered when the tremor oscillations increase steadily before arriving at the target rather than at the termination of goal-directed activity, although a distinction between the two is often difficult.",
"   </p>",
"   <p>",
"    Tremor in the legs is unusual in ET. Head tremor may be vertical (\"yes-yes\") or horizontal (\"no-no\") and is usually associated with hand or voice tremor. Head tremor rarely occurs in isolation in ET [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10984/abstract/29\">",
"     29",
"    </a>",
"    ]. When it does, the possibility of cervical dystonia with dystonic head tremor should be considered.",
"   </p>",
"   <p>",
"    By definition, tremor should be the only neurologic manifestation of ET. However, in some severe cases, mild gait disorder and cerebellar signs may be present. In addition, preliminary studies suggest that very mild cognitive deficits with reduced performance on tests of memory and frontal executive function may be more common in patients with ET than age-matched controls [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10984/abstract/30-32\">",
"     30-32",
"    </a>",
"    ], and that ET may be associated with an increased risk of dementia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10984/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some patients with ET develop enhanced physiologic tremor due to anxiety or other adrenergic mechanisms, thereby aggravating the underlying tremor. ET is typically relieved by small amounts of alcohol but, in contrast with physiologic tremor, is not usually aggravated by caffeine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Differential diagnosis of ET",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is a common mistake to refer to any postural or action tremor as &ldquo;essential tremor&rdquo; since there is a broad differential diagnosis for tremors of this type. The most common differential diagnosis is with parkinsonian tremor (",
"    <a class=\"graphic graphic_table graphicRef60694 \" href=\"UTD.htm?36/56/37771\">",
"     table 5",
"    </a>",
"    ). Differentiation from classical resting tremor should be straightforward; however, some patients with PD also have a postural-action tremor indistinguishable from ET [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10984/abstract/35\">",
"     35",
"    </a>",
"    ]. In fact, it is not unusual for patients with PD to present with a postural tremor shortly before they display other signs of PD. Likewise, patients with severe ET may have a rest component to their tremor. The presence of subtle bradykinesia or micrographia in early cases of parkinsonian postural tremor helps make the diagnosis, although these signs may not appear until later. Conversely, elderly patients with ET may have mild bradykinesia and limb rigidity as a nonspecific accompaniment of aging.",
"   </p>",
"   <p>",
"    Head tremor is more likely to be a manifestation of ET, whereas tremor of the jaw or lips is more typically parkinsonian. Head tremor is also common in cervical dystonia (spasmodic torticollis) where it may be due either to a coincidence of the two disorders or to a manifestation of dystonic muscle spasm.",
"   </p>",
"   <p>",
"    Ataxia, dysmetria, proximal distribution of the tremor, or gait disorder usually suggests a cerebellar disorder rather than ET. However, mild cerebellar signs are present in some severe familial tremors (",
"    <a class=\"graphic graphic_table graphicRef54735 \" href=\"UTD.htm?15/48/16139\">",
"     table 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10984/abstract/36\">",
"     36",
"    </a>",
"    ]. Voice tremor rarely occurs in isolation; when it does, it is important to differentiate it from spasmodic dysphonia. Essential voice tremor produces a quavering voice best identified by asking the patient to hold a steady note such as &ldquo;ahhhh&rdquo; or &ldquo;eeeee&rdquo; unaccompanied by the hoarseness, straining, and voice breaks characteristic of spasmodic dysphonia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Primary writing tremor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many action tremors are particularly severe during the act of writing. Tremor that occurs exclusively while writing, and not during other voluntary motor activities, is referred to as primary writing tremor [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10984/abstract/37\">",
"     37",
"    </a>",
"    ]. This tremor is limited to the hand and causes relatively large amplitude supination-pronation movements at a frequency of 5 to 6 Hz. The low frequency and large amplitude of the tremor, its frequent occurrence in writer's cramp or writer's dystonia, its relative resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    , and its occasional response to anticholinergic drugs suggest a closer relationship to dystonia than to ET.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Orthostatic tremor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Orthostatic tremor is limited to the legs and trunk, and occurs exclusively while standing [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10984/abstract/38-41\">",
"     38-41",
"    </a>",
"    ]. Both high and low frequency orthostatic tremors have been described; their relationship to ET is uncertain. In cases of high frequency tremor, movements of the legs may be so low in amplitude that they initially escape clinical detection. Orthostatic tremor is uniquely, but not always, responsive to treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/45/26328?source=see_link\">",
"     clonazepam",
"    </a>",
"    (see",
"    <a class=\"local\" href=\"#H22\">",
"     'Treatment'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Cerebellar tremors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cerebellar tremors can be postural, action, or intention (kinetic). In severe cases, they can spill over to also occur at rest. Tremor frequency is typically low (3 to 4 Hz) and can be associated with ataxia and dysmetria.",
"   </p>",
"   <p>",
"    Rubral tremor is caused by disturbances of cerebellothalamic projections (see",
"    <a class=\"local\" href=\"#H6\">",
"     'Rubral tremor'",
"    </a>",
"    above); it is usually present at rest and increases during postural fixation and voluntary activity. Titubation of the head and neck (\"to and fro\" movements) may be associated with cerebellar tremor; it is distinguished from essential head tremor by the presence of other cerebellar findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     NEUROPATHIC TREMOR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tremor is sometimes associated with large fiber peripheral neuropathy. This association is most commonly observed in hereditary neuropathies, during the recovery phase of some cases of Guillain-Barr&eacute; syndrome, and in chronic inflammatory demyelinating polyneuropathy (CIDP). Muscle weakness and loss of proprioceptive or muscle spindle inputs may account for the tremor. The frequency and amplitude of neuropathic tremor may vary greatly when associated with a proprioceptive deficit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     INTENTION TREMOR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intention tremor, also called kinetic tremor, is due to disturbances anywhere along the path of the cerebellar outflow projection system from the dentate nucleus of the cerebellum to the motor division (ventral lateral nucleus) of the thalamus. The most common causes are multiple sclerosis, midbrain trauma, and stroke. Heredodegenerative diseases of the cerebellum, severe forms of essential tremor (ET), Wilson's disease, hepatocerebral degeneration, and mercury poisoning may also produce this tremor.",
"   </p>",
"   <p>",
"    The tremor typically increases in severity as the hand moves closer to its target, in contrast to postural and action tremors, which either remain constant throughout the range of motion or abruptly increase at terminal fixation. Intention tremors are usually very large in amplitude due to involvement of proximal muscles and are sometimes difficult to distinguish from severe cerebellar ataxia. The frequent association with ataxia, dysmetria, titubation, and other cerebellar signs serves to identify the cerebellar origin of intention tremor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     PSYCHOGENIC TREMOR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Useful criteria for the diagnosis of psychogenic tremor have been established [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10984/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. These are typically complex resting, postural, and action tremors with abrupt onset, a static course, changeable features, functional disability out of proportion to tremor magnitude, and resistance to treatment. Any body part may be involved, but, remarkably, the fingers are often spared with much of the upper limb tremor occurring at the wrist [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10984/abstract/43\">",
"     43",
"    </a>",
"    ]. Other features of psychogenic movement disorders are also often present, such as inconsistent display of symptoms and clinical features that are incongruous with known tremors.",
"   </p>",
"   <p>",
"    Examination usually shows variable tremor frequency or tremor entrainment (ie, shift of tremor frequency to the speed of contralateral finger tapping), especially with distraction maneuvers such as repetitive tapping tasks with an uninvolved opposite hand or foot.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic approach to patients with tremor involves the history, physical examination, and selected laboratory studies. Action tremor is most common and, of these, essential tremor (ET) and enhanced physiologic tremor are the most frequent diagnoses [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10984/abstract/44\">",
"     44",
"    </a>",
"    ]. Patients with tremor due to other disorders such as hyperthyroidism, Parkinson disease (PD), dystonia, Wilson disease, or drug-induced tremors frequently have additional signs or symptoms that help point to the diagnosis, although this is not always the case. The criteria for ET and methods for distinguishing it from other tremors are shown in the tables (",
"    <a class=\"graphic graphic_table graphicRef68810 \" href=\"UTD.htm?29/60/30667\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef72091 \" href=\"UTD.htm?32/18/33067\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef77497 \" href=\"UTD.htm?37/42/38571\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history concerning the onset of tremor is usually straightforward, since it is a highly visible symptom that is readily evident to the patient and family members. Examination of previous handwriting samples may be useful in determining the precise time of onset. Precipitating, aggravating, or relieving factors such as caffeine, alcohol, medications, exercise, fatigue, or stress should be elicited; a complete list of all medications should be reviewed to exclude the possibility of enhanced physiologic tremor (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Physiologic tremor'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    Family history in ET reflects an autosomal dominant pattern of inheritance in approximately half of all patients. Parkinsonian tremor is usually sporadic, but a family history of PD is present in approximately 15 percent of cases; the disease affects first-degree relatives (parents, siblings or offspring) in about half of the familial cases. Autosomal PD affecting three or more generations is rare.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examination begins with observations of the tremor during the interview. Many patients with tremor are more symptomatic during the early part of the examination because of stress than after they become acclimated to the doctor-patient encounter. Patients should be observed sitting, lying down (with the affected body part fully supported), and walking. Horizontal or vertical head tremor is usually associated with tremor elsewhere. Isolated head tremor should raise the possibility of cervical dystonia or midline cerebellar syndromes. Localized face, jaw, and lip tremors are more commonly a manifestation of parkinsonism. Essential voice tremor is readily audible and may be further enhanced by having the patient hold a prolonged note.",
"   </p>",
"   <p>",
"    Tremor in the arm is observed with the affected limb fully supported at rest, with the limb elevated against gravity, and during goal-directed movements. Most resting tremors cease with changes in limb posture but may reappear following repositioning to another fixed posture, referred to as re-emergent tremor. Parkinsonian tremor, by contrast with ET, is usually activated by repetitive movements of the opposite hand, during walking, and during mental distraction such as reciting the months of the year backwards.",
"   </p>",
"   <p>",
"    Postural and action tremors are best elicited with the arms held outstretched; with the shoulders abducted, elbows flexed, and index fingers held an inch apart in front of the face; during finger-to-nose maneuvers; and while drinking or pouring from a paper cup. Writing and drawing may demonstrate the large, tremulous, angulated loops of ET or the micrographia of parkinsonism.",
"   </p>",
"   <p>",
"    Tremor of the leg should be assessed with the limb at rest, during heel-to-shin testing, and while standing and walking. Leg tremor is more commonly due to parkinsonism than ET.",
"   </p>",
"   <p>",
"    The gait is almost always normal in patients with ET, while it is characteristically narrow-based and shuffling in PD, and is wide-based and ataxic in cerebellar disorders. The gait may have histrionic qualities in patients with psychogenic tremor.",
"   </p>",
"   <p>",
"    Tremor frequency should be estimated at rest and during postural and action maneuvers. Enhanced physiologic tremor is high in frequency (10 to 12 Hz), ET can be either low or high in frequency, and parkinsonian rest tremor is usually low in frequency (4 to 6 Hz). Orthostatic tremor is 15 to 20 Hz. Psychogenic tremors tend to vary in frequency as well as amplitude from moment to moment and either become more irregular or subside entirely when the patient is asked to carry out a complex, repetitive motor task with the contralateral limb. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Psychogenic tremor'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The routine laboratory evaluation of tremor should include tests of thyroid function, diagnostic studies to exclude Wilson's disease, and screening for heavy metal poisoning such as mercury or arsenic, if an environmental cause is suspected. Wilson disease should be suspected in anyone under age 40 who has tremor or other involuntary movement or posture [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10984/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14088?source=see_link\">",
"     \"Tests used in the diagnosis of Wilson disease\"",
"    </a>",
"    .) Hypoglycemia and pheochromocytoma may need to be ruled out in patients with enhanced physiologic tremor.",
"   </p>",
"   <p>",
"    Brain imaging can be useful in patients suspected clinically of having a structural cause for tremor, such as Wilson disease, brain trauma, stroke, or mass lesion, but is otherwise usually not indicated.",
"   </p>",
"   <p>",
"    Quantitative computerized analysis of tremor is available in some tertiary care facilities, but its ability to reliably distinguish between tremor types has not been established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of tremor depends upon the underlying cause.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Enhanced physiologic tremor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enhanced physiologic tremor is best managed by reduction or removal of the responsible offending medication or toxin; diagnosis and treatment of possible associated endocrine disorders; and dealing with stress, anxiety, or fatigue (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Physiologic tremor'",
"    </a>",
"    above). Single doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    taken in anticipation of social situations that are likely to exacerbate tremor, as with tremor associated with public speaking, are useful in some patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Rest tremor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of rest tremors, such as those associated with Parkinson disease (PD) or other parkinsonian disorders, is accomplished by treatment of the underlying disorder and usually consists of anticholinergic drugs or other antiparkinson agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/46/13031?source=see_link\">",
"     amantadine",
"    </a>",
"    , dopamine agonists, levodopa, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/2/10279?source=see_link\">",
"     zonisamide",
"    </a>",
"    . This topic is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/63/32762?source=see_link\">",
"     \"Pharmacologic treatment of Parkinson disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Cerebellar tremor",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no useful pharmacotherapy for cerebellar tremor. The rare patient with severe intention tremor and little or no ataxia, such as sometimes occurs in multiple sclerosis, may be helped by deep brain stimulation of the ventral intermediate nucleus of the thalamus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/4/28741?source=see_link\">",
"     \"Surgical treatment of essential tremor\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Orthostatic tremor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Orthostatic tremor is limited to the legs and trunk and occurs exclusively while standing. Clinical experience suggests that orthostatic tremor is uniquely, but not always, responsive to treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/45/26328?source=see_link\">",
"     clonazepam",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10984/abstract/39\">",
"     39",
"    </a>",
"    ], although little data are available and no controlled trials exist. There is anecdotal evidence suggesting that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    is effective.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Essential tremor",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     Propranolol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/14/30952?source=see_link\">",
"     primidone",
"    </a>",
"    are the most effective and well-studied medications for the treatment of essential tremor (ET). The medical treatment of ET is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/17/19737?source=see_link\">",
"     \"Pharmacologic treatment of essential tremor\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Both deep brain stimulation and unilateral thalamotomy are effective for the treatment of medically refractory ET. This topic is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/4/28741?source=see_link\">",
"     \"Surgical treatment of essential tremor\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?13/14/13538?source=see_link\">",
"       \"Patient information: Tremor (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/6/34913?source=see_link\">",
"       \"Patient information: Tremor (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10984/abstract/1\">",
"      Jankovic J, Fahn S. Physiologic and pathologic tremors. Diagnosis, mechanism, and management. Ann Intern Med 1980; 93:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10984/abstract/2\">",
"      Cohen O, Pullman S, Jurewicz E, et al. Rest tremor in patients with essential tremor: prevalence, clinical correlates, and electrophysiologic characteristics. Arch Neurol 2003; 60:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10984/abstract/3\">",
"      Schneider SA, Edwards MJ, Mir P, et al. Patients with adult-onset dystonic tremor resembling parkinsonian tremor have scans without evidence of dopaminergic deficit (SWEDDs). Mov Disord 2007; 22:2210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10984/abstract/4\">",
"      Louis ED, Ottman R, Hauser WA. How common is the most common adult movement disorder? estimates of the prevalence of essential tremor throughout the world. Mov Disord 1998; 13:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10984/abstract/5\">",
"      Dogu O, Sevim S, Camdeviren H, et al. Prevalence of essential tremor: door-to-door neurologic exams in Mersin Province, Turkey. Neurology 2003; 61:1804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10984/abstract/6\">",
"      Benito-Le&oacute;n J, Bermejo-Pareja F, Morales JM, et al. Prevalence of essential tremor in three elderly populations of central Spain. Mov Disord 2003; 18:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10984/abstract/7\">",
"      Busenbark KL, Nash J, Nash S, et al. Is essential tremor benign? Neurology 1991; 41:1982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10984/abstract/8\">",
"      Benito-Le&oacute;n J, Louis ED, Bermejo-Pareja F, Neurological Disorders in Central Spain Study Group. Risk of incident Parkinson's disease and parkinsonism in essential tremor: a population based study. J Neurol Neurosurg Psychiatry 2009; 80:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10984/abstract/9\">",
"      Jasinska-Myga B, Wider C. Genetics of essential tremor. Parkinsonism Relat Disord 2012; 18 Suppl 1:S138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10984/abstract/10\">",
"      Gulcher JR, J&oacute;nsson P, Kong A, et al. Mapping of a familial essential tremor gene, FET1, to chromosome 3q13. Nat Genet 1997; 17:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10984/abstract/11\">",
"      Higgins JJ, Loveless JM, Jankovic J, Patel PI. Evidence that a gene for essential tremor maps to chromosome 2p in four families. Mov Disord 1998; 13:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10984/abstract/12\">",
"      Higgins JJ, Pho LT, Nee LE. A gene (ETM) for essential tremor maps to chromosome 2p22-p25. Mov Disord 1997; 12:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10984/abstract/13\">",
"      Shatunov A, Sambuughin N, Jankovic J, et al. Genomewide scans in North American families reveal genetic linkage of essential tremor to a region on chromosome 6p23. Brain 2006; 129:2318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10984/abstract/14\">",
"      Kovach MJ, Ruiz J, Kimonis K, et al. Genetic heterogeneity in autosomal dominant essential tremor. Genet Med 2001; 3:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10984/abstract/15\">",
"      Louis ED, Ford B, Frucht S, et al. Risk of tremor and impairment from tremor in relatives of patients with essential tremor: a community-based family study. Ann Neurol 2001; 49:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10984/abstract/16\">",
"      Tanner CM, Goldman SM, Lyons KE, et al. Essential tremor in twins: an assessment of genetic vs environmental determinants of etiology. Neurology 2001; 57:1389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10984/abstract/17\">",
"      Stefansson H, Steinberg S, Petursson H, et al. Variant in the sequence of the LINGO1 gene confers risk of essential tremor. Nat Genet 2009; 41:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10984/abstract/18\">",
"      Thier S, Lorenz D, Nothnagel M, et al. LINGO1 polymorphisms are associated with essential tremor in Europeans. Mov Disord 2010; 25:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10984/abstract/19\">",
"      Jim&eacute;nez-Jim&eacute;nez FJ, Garc&iacute;a-Mart&iacute;n E, Lorenzo-Betancor O, et al. LINGO1 and risk for essential tremor: results of a meta-analysis of rs9652490 and rs11856808. J Neurol Sci 2012; 317:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10984/abstract/20\">",
"      Thier S, Lorenz D, Nothnagel M, et al. Polymorphisms in the glial glutamate transporter SLC1A2 are associated with essential tremor. Neurology 2012; 79:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10984/abstract/21\">",
"      Louis ED. Essential tremor: evolving clinicopathological concepts in an era of intensive post-mortem enquiry. Lancet Neurol 2010; 9:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10984/abstract/22\">",
"      Louis ED, Faust PL, Vonsattel JP, et al. Neuropathological changes in essential tremor: 33 cases compared with 21 controls. Brain 2007; 130:3297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10984/abstract/23\">",
"      Shill HA, Adler CH, Sabbagh MN, et al. Pathologic findings in prospectively ascertained essential tremor subjects. Neurology 2008; 70:1452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10984/abstract/24\">",
"      Nicoletti G, Manners D, Novellino F, et al. Diffusion tensor MRI changes in cerebellar structures of patients with familial essential tremor. Neurology 2010; 74:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10984/abstract/25\">",
"      Rajput AH, Robinson CA, Rajput ML, Rajput A. Cerebellar Purkinje cell loss is not pathognomonic of essential tremor. Parkinsonism Relat Disord 2011; 17:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10984/abstract/26\">",
"      Jankovic J. Essential tremor: a heterogenous disorder. Mov Disord 2002; 17:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10984/abstract/27\">",
"      Louis ED. Essential tremors: a family of neurodegenerative disorders? Arch Neurol 2009; 66:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10984/abstract/28\">",
"      Findley LJ, Koller WC. Essential tremor: a review. Neurology 1987; 37:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10984/abstract/29\">",
"      Louis ED, Dogu O. Isolated head tremor: part of the clinical spectrum of essential tremor? Data from population-based and clinic-based case samples. Mov Disord 2009; 24:2281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10984/abstract/30\">",
"      Lombardi WJ, Woolston DJ, Roberts JW, Gross RE. Cognitive deficits in patients with essential tremor. Neurology 2001; 57:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10984/abstract/31\">",
"      Gasparini M, Bonifati V, Fabrizio E, et al. Frontal lobe dysfunction in essential tremor: a preliminary study. J Neurol 2001; 248:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10984/abstract/32\">",
"      Benito-Le&oacute;n J, Louis ED, Bermejo-Pareja F, Neurological Disorders in Central Spain (NEDICES) Study Group. Population-based case-control study of cognitive function in essential tremor. Neurology 2006; 66:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10984/abstract/33\">",
"      Benito-Le&oacute;n J, Louis ED, Bermejo-Pareja F, Neurological Disorders in Central Spain Study Group. Elderly-onset essential tremor is associated with dementia. Neurology 2006; 66:1500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10984/abstract/34\">",
"      Thawani SP, Schupf N, Louis ED. Essential tremor is associated with dementia: prospective population-based study in New York. Neurology 2009; 73:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10984/abstract/35\">",
"      Pahwa R, Koller WC. Is there a relationship between Parkinson's disease and essential tremor? Clin Neuropharmacol 1993; 16:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10984/abstract/36\">",
"      Stolze H, Petersen G, Raethjen J, et al. The gait disorder of advanced essential tremor. Brain 2001; 124:2278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10984/abstract/37\">",
"      Bain PG, Findley LJ, Britton TC, et al. Primary writing tremor. Brain 1995; 118 ( Pt 6):1461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10984/abstract/38\">",
"      Papa SM, Gershanik OS. Orthostatic tremor: an essential tremor variant? Mov Disord 1988; 3:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10984/abstract/39\">",
"      Heilman KM. Orthostatic tremor. Arch Neurol 1984; 41:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10984/abstract/40\">",
"      Gerschlager W, M&uuml;nchau A, Katzenschlager R, et al. Natural history and syndromic associations of orthostatic tremor: a review of 41 patients. Mov Disord 2004; 19:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10984/abstract/41\">",
"      Mestre TA, Lang AE, Lang AE, et al. Associated movement disorders in orthostatic tremor. J Neurol Neurosurg Psychiatry 2012; 83:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10984/abstract/42\">",
"      Koller W, Lang A, Vetere-Overfield B, et al. Psychogenic tremors. Neurology 1989; 39:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10984/abstract/43\">",
"      Deuschl G, K&ouml;ster B, L&uuml;cking CH, Scheidt C. Diagnostic and pathophysiological aspects of psychogenic tremors. Mov Disord 1998; 13:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10984/abstract/44\">",
"      Louis ED. Clinical practice. Essential tremor. N Engl J Med 2001; 345:887.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4895 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-197.136.42.3-BB0417C59D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_46_10984=[""].join("\n");
var outline_f10_46_10984=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RESTING TREMOR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Idiopathic Parkinson disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Tremor-dominant Parkinson disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17610950\">",
"      SWEDDs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Rubral tremor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      POSTURAL AND ACTION TREMORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Physiologic tremor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Essential tremor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Clinical features of ET",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Differential diagnosis of ET",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Primary writing tremor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Orthostatic tremor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Cerebellar tremors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      NEUROPATHIC TREMOR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      INTENTION TREMOR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PSYCHOGENIC TREMOR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Enhanced physiologic tremor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Rest tremor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Cerebellar tremor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Orthostatic tremor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Essential tremor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/4895\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/4895|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/60/30667\" title=\"table 1\">",
"      Common tremors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/18/33067\" title=\"table 2\">",
"      Classification of tremor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/42/38571\" title=\"table 3\">",
"      Differential DX tremor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/5/6235\" title=\"table 4\">",
"      Criteria for essential tremor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/56/37771\" title=\"table 5\">",
"      Parkinson vs essential tremor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/48/16139\" title=\"table 6\">",
"      Signs of nonessential tremor",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/13/14554?source=related_link\">",
"      Clinical manifestations of Parkinson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/22/30057?source=related_link\">",
"      Neurologic manifestations of hyperthyroidism and Graves' disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/6/34913?source=related_link\">",
"      Patient information: Tremor (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?13/14/13538?source=related_link\">",
"      Patient information: Tremor (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/63/32762?source=related_link\">",
"      Pharmacologic treatment of Parkinson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/17/19737?source=related_link\">",
"      Pharmacologic treatment of essential tremor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/4/28741?source=related_link\">",
"      Surgical treatment of essential tremor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14088?source=related_link\">",
"      Tests used in the diagnosis of Wilson disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_46_10985="Chapter 2D: Regulation of GFR and renal plasma flow";
var content_f10_46_10985=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chapter 2D: Regulation of GFR and renal plasma flow",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/46/10985/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/46/10985/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/46/10985/contributors\">",
"     Theodore W Post, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/46/10985/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/46/10985/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/46/10985/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/46/10985/contributors\">",
"     Theodore W Post, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/46/10985/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 1, 2004.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regulation of renal hemodynamics is primarily achieved via changes in arteriolar resistance, which can affect both RPF and GFR (by altering Pgc and RPF). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/20/36163?source=see_link\">",
"     \"Chapter 2C: Determinants of GFR\"",
"    </a>",
"    .) In normal subjects, for example, changes in posture or diet can produce alterations in renal perfusion pressure. In this setting, two closely related intrarenal phenomena, autoregulation and tubuloglomerular feedback, interact to maintain the GFR and RPF at a relatively constant level [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/1\">",
"     1",
"    </a>",
"    ]. In comparison, pathophysiologic states, such as volume depletion, can lead to activation of systemic neurohumoral factors that can override these intrarenal effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     AUTOREGULATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since Pgc is an important determinant of GFR, it might be expected that small variations in arterial pressure could induce large changes in GFR. However, the GFR and RPF remain roughly constant over a wide range of arterial pressures (",
"    <a class=\"graphic graphic_figure graphicRef57043 \" href=\"UTD.htm?32/29/33245\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. This phenomenon, which is also present in other capillaries [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/4\">",
"     4",
"    </a>",
"    ], is intrinsic to the kidney, occurring in denervated, perfused kidneys, and has been termed autoregulation.",
"   </p>",
"   <p>",
"    Since the GFR and RPF are maintained in parallel, autoregulation must be mediated in part by changes in afferent arteriolar resistance (",
"    <a class=\"graphic graphic_figure graphicRef63192 \" href=\"UTD.htm?13/28/13773\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/1,5\">",
"     1,5",
"    </a>",
"    ]. As systemic pressure rises, for example, an increase in afferent arteriolar tone prevents the elevation in pressure from being transmitted to the glomerulus, allowing Pgc and GFR to remain unchanged [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/5\">",
"     5",
"    </a>",
"    ]. The enhanced arteriolar resistance also increases total renal vascular resistance and, from Eq. 2-3, this increase in vascular tone balances the rise in pressure and minimizes any change in RPF.",
"   </p>",
"   <p>",
"    Conversely, as blood pressure decreases, afferent arteriolar dilation will initially protect both GFR and RPF. However, the ability to maintain renal hemodynamics becomes impaired at mean arterial pressures below 70 mmHg. In this setting, GFR and RPF fall in proportion to the drop in blood pressure and the GFR ceases when the systemic pressure reaches 40 to 50 mmHg.",
"   </p>",
"   <p>",
"    The mechanism by which autoregulation is mediated is incompletely understood. The simplest hypothesis is that myogenic stretch receptors in the wall of the afferent arteriole are of primary importance, similar to the role of the precapillary sphincter in the muscle capillary [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/4\">",
"     4",
"    </a>",
"    ]. An elevation in renal perfusion pressure, for example, will increase the degree of stretch, which will then promote arteriolar constriction [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/5\">",
"     5",
"    </a>",
"    ]; this effect is mediated in part by increased cell entry of calcium [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efferent arterioles, in comparison, have different characteristics: they do not seem to respond directly to changes in stretch and therefore do not contribute directly to the myogenic response. Why this occurs in not clear, but the apparent absence of voltage-gated Ca2+ channels in the efferent arterioles may play a contributory role [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, autoregulation of GFR is mediated by more than myogenic responses, as both angiotensin II (when the renal perfusion pressure is reduced) and tubuloglomerular feedback (especially when renal perfusion pressure is increased; see below) can play an important role [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/3,8\">",
"     3,8",
"    </a>",
"    ]. Others regulators of renal vascular resistance, such as the vasodilator nitric oxide (endothelium-dependent relaxing factor), do not appear to participate in autoregulation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As illustrated in the following figure (",
"    <a class=\"graphic graphic_figure graphicRef57043 \" href=\"UTD.htm?32/29/33245\">",
"     figure 1",
"    </a>",
"    ), for example, the administration of an angiotensin II antagonist results in the dissociation of the autoregulation of RPF and GFR [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/3\">",
"     3",
"    </a>",
"    ]. As described above, the renin-angiotensin system is activated as renal perfusion pressure is lowered, resulting in both local and systemic generation of angiotensin II [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/10\">",
"     10",
"    </a>",
"    ]. The preferential increase in efferent arteriolar resistance induced by angiotensin II contributes to autoregulation of GFR by preventing any fall in Pgc; consequently, infusion of an angiotensin II antagonist or an angiotensin converting enzyme inhibitor leads to less effective maintenance of the GFR. This angiotensin II-dependence is most prominent when the renal perfusion pressure is substantially reduced. Autoregulation of GFR with the initial decrease in renal artery pressure is primarily mediated by TGF and the stretch receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Clinical implications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with bilateral renal artery stenosis, due most often to atherosclerotic lesions, have an elevated pressure proximal to the stenosis but a normal or reduced pressure distal to the stenosis. As a result, the administration of antihypertensive therapy to lower the systemic blood pressure is likely to diminish the distal renal artery pressure (which includes that perfusing the glomeruli) to a level that is below normal. In this setting, autoregulation plays an important role in maintaining Pgc and GFR, a response that can be partially impaired by diminishing the production of angiotensin II with an angiotensin converting enzyme inhibitor. Up to one-half of such patients given a converting enzyme inhibitor will have a usually mild decline in GFR, although severe (and reversible) renal failure can occur [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Diuretic-induced volume depletion appears to be an important risk factor for this problem, since it makes maintenance of the GFR even more angiotensin II-dependent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/3,13\">",
"     3,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A similar decline in GFR can occur in the affected kidney in unilateral renal artery stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/14\">",
"     14",
"    </a>",
"    ], a change that can lead to eventual ischemic atrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/15\">",
"     15",
"    </a>",
"    ]. This is not easy to detect clinically, however, since the presence of the contralateral nonstenotic kidney prevents the development of acute renal failure (as would be evidenced by a rise in the plasma creatinine concentration; see below).",
"   </p>",
"   <p>",
"    Other medications are less likely to produce this problem, since they do not interfere with autoregulation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/11,16\">",
"     11,16",
"    </a>",
"    ]. However, the ability of autoregulation to protect the GFR is impaired if the perfusion pressure is markedly reduced (",
"    <a class=\"graphic graphic_figure graphicRef57043 \" href=\"UTD.htm?32/29/33245\">",
"     figure 1",
"    </a>",
"    ). Thus, any antihypertensive agent can produce acute renal failure when there are severe and bilateral renovascular lesions (or a marked unilateral lesion in a solitary kidney) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of acute renal failure after angiotensin converting enzyme inhibition is not limited to renovascular disease, but can occur in any condition in which renal perfusion pressure is reduced. As an example, angiotensin converting enzyme inhibitors are standard therapy in heart failure, leading to increases in cardiac output, patient survival, and renal blood flow, as well as an improvement in functional status. Despite all of these beneficial changes, the GFR falls in about one-third of cases, presumably due to a reduction in Pgc induced by efferent arteriolar dilation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. This is most likely to occur in patients with a diastolic pressure below 70 mmHg who are being treated with high doses of diuretics.",
"   </p>",
"   <p>",
"    Although the autoregulatory changes in arterial and arteriolar resistance are reversed when the renal perfusion pressure is elevated, angiotensin II levels are low in the basal state and it is unlikely that any further reduction is responsible for the maintenance of GFR. There is, however, substantial evidence for the role of tubuloglomerular feedback in this setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Tubuloglomerular feedback",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tubuloglomerular feedback (TGF) refers to the alterations in GFR that can be induced by changes in tubular flow rate (",
"    <a class=\"graphic graphic_figure graphicRef73046 \" href=\"UTD.htm?6/63/7165\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. This phenomenon is mediated by the specialized cells in the macula densa segment at the end of the cortical thick ascending limb of the loop of Henle; these cells sense changes in the delivery and subsequent reabsorption of chloride [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. The importance of chloride is, as described previously, probably related to the chloride dependence of the Na+-K+-2Cl- carrier in the luminal membrane that promotes the entry of these ions into the cell [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/49/36630?source=see_link\">",
"     \"Chapter 4A: Cell model for loop of Henle transport\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    TGF plays an important role in autoregulation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/8,25\">",
"     8,25",
"    </a>",
"    ]. An elevation in renal perfusion pressure can activate TGF via an initial rise in GFR; the ensuing increase in macula densa chloride delivery will then initiate a response that returns both GFR and macula densa flow toward normal (",
"    <a class=\"graphic graphic_figure graphicRef73046 \" href=\"UTD.htm?6/63/7165\">",
"     figure 3",
"    </a>",
"    ). This effect is mediated primarily by afferent arteriolar constriction, thereby decreasing the intraglomerular hydraulic pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/5,26\">",
"     5,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If, on the other hand, the Na+-K+-2Cl- cotransporter in a single nephron is inhibited by a loop diuretic (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    ), there is a marked impairment in autoregulation as renal perfusion pressure is increased [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/26\">",
"     26",
"    </a>",
"    ]. That part of the autoregulatory response that persists has been thought to reflect myogenic, stretch-induced vasoconstriction [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/6,26\">",
"     6,26",
"    </a>",
"    ]. There is, however, an alternate possibility: cooperativity among adjacent nephrons supplied by a common arterial branch [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/27\">",
"     27",
"    </a>",
"    ]. The afferent vasoconstriction occurring in one nephron may be transmitted back up the artery and lead to vasoconstriction in adjacent nephrons. Thus, the in vivo effect of increasing distal Cl- delivery in all nephrons will lead to a greater degree of afferent vasoconstriction in a single nephron than is induced by the macula densa in that nephron.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Mediators",
"    </span>",
"    &nbsp;&mdash;&nbsp;The factors that mediate TGF are incompletely understood [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/21\">",
"     21",
"    </a>",
"    ]. The afferent site of constriction seen with increased distal flow involves the cells of the juxtaglomerular apparatus that are responsible for renin secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/5\">",
"     5",
"    </a>",
"    ]. Although this observation suggests an important role for angiotensin II in tubuloglomerular feedback, this hormone appears to play a permissive role, perhaps by sensitizing the afferent arteriole to the true mediator [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/28\">",
"     28",
"    </a>",
"    ]. This action of angiotensin II appears to be relatively specific, since other vasopressors such as norepinephrine and ADH do not have a similar effect [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The sensitizing action on TGF is essential if angiotensin II is to contribute to maintenance of the effective circulating volume by decreasing Na+ excretion (see above) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/30\">",
"     30",
"    </a>",
"    ]. The angiotensin II-mediated increase in proximal reabsorption will diminish distal flow which should, via a decrease in the TGF signal, raise the GFR to return distal delivery to the baseline level. This response is minimized by the associated increase in sensitivity of the afferent arteriole to the mediator of TGF, thereby permitting the desired reduction in Na+ excretion [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite its modulating effect, angiotensin II is not the primary mediator of TGF since changes in renin release do not correlate with TGF. As an example, increasing distal NaCl delivery will activate TGF at the same time that macula densa-mediated renin release is diminished.",
"   </p>",
"   <p>",
"    Some evidence suggests that changes in arteriolar resistance associated with TGF are at least in part mediated by alterations in the local release of adenosine [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/31\">",
"     31",
"    </a>",
"    ], which can induce the observed constriction of the afferent arteriole [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/32\">",
"     32",
"    </a>",
"    ]. The TGF response to increased NaCl delivery is largely inhibited by blockade of the adenosine receptor",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    adenosine formation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    How adenosine secretion might be regulated in this setting is unknown. One possibility is that raising the GFR will increase sequentially the filtered Na+ load, tubular sodium reabsorption, and the utilization of ATP, which results in the generation of adenosine [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/31,35,36\">",
"     31,35,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The adenosine hypothesis can also explain how the macula densa can concurrently perform two functions: regulating TGF and renin secretion. The increase in adenosine release with volume expansion can both activate TGF [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/33\">",
"     33",
"    </a>",
"    ] and inhibit renin release [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/31,37\">",
"     31,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another vasoconstrictor that may participate in TGF is thromboxane. Thromboxane production is increased when TGF is activated, the administration of a thromboxane mimetic increases the sensitivity of TGF, and the TGF response is blunted by a thromboxane antagonist [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/38\">",
"     38",
"    </a>",
"    ]. ATP itself is also a constrictor of the afferent arteriole that may contribute to TGF [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vasodilator responses in TGF occur when macula densa flow is reduced. This may be mediated in part by reduced availability of the above vasoconstrictors [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An additional significant regulator of TGF is nitric oxide (NO). NO, a molecular gas synthesized by cells in the macula densa, blunts the TGF response to increased sodium chloride delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/41\">",
"     41",
"    </a>",
"    ]. NO release from the macula densa is increased in this setting, thereby countering the afferent arteriole constriction elicited in the TGF response. Thus, changes in macula densa NO production may underlie the resetting of TGF that occurs when salt intake is varied; the response is appropriately blunted with a high salt diet, as maintenance of glomerular filtration promotes excretion of the excess salt [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An alternative hypothesis suggests that changes in interstitial Cl- concentration or osmolality constitute the signal for alterations in arteriolar resistance. The interstitial region bordered by the early distal tubule (including the macula densa) and the glomerular arterioles (",
"    <a class=\"graphic graphic_figure graphicRef69949 \" href=\"UTD.htm?31/9/31889\">",
"     figure 4",
"    </a>",
"    ) is poorly perfused; as a result, solutes transported into this area from the luminal fluid are slowly removed, because they must diffuse over a relatively long distance before they can enter the peritubular capillaries.",
"   </p>",
"   <p>",
"    Direct measurements in this region have demonstrated that, as distal flow rate and therefore macula densa Cl- reabsorption are progressively increased, there is a rise in the local interstitial Cl- concentration from about 150",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    (similar to plasma) to over 600",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/43\">",
"     43",
"    </a>",
"    ]. This increase in solute concentration or in osmolality may then directly increase afferent arteriolar tone [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/44\">",
"     44",
"    </a>",
"    ]. In comparison, the interstitial Cl- concentration remains relatively constant in areas that are further away from the juxtaglomerular region [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/43\">",
"     43",
"    </a>",
"    ]. These sites are better perfused, and reabsorbed NaCl is rapidly removed by the peritubular capillaries.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Functions",
"    </span>",
"    &nbsp;&mdash;&nbsp;A major function of autoregulation and TGF is to prevent excessive salt and water losses . To understand this concept, it is important to appreciate the differences in function between the proximal and distal segments of the nephron. The bulk of the filtrate (about 90 percent) is reabsorbed in the proximal tubule and loop of Henle, with the final qualitative changes in urinary excretion (such as hydrogen and potassium secretion and maximum sodium and water reabsorption) being made in the distal nephron, particularly in the collecting tubules. The collecting tubules, however, have a relatively limited total reabsorptive capacity. Thus, the ability of the macula densa to decrease the GFR when distal delivery is enhanced prevents distal reabsorptive capacity from being overwhelmed, which could lead to potentially life-threatening losses of sodium and water. Viewed in this light, it may be that it is macula densa flow itself, not the GFR, that is being maintained by autoregulation and TGF [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A possible clinical example of TGF is the fall in GFR seen in acute tubular necrosis, the most common form of acute renal failure developing in the hospital. In this disorder, proximal and loop sodium reabsorption are impaired by ischemic or toxic tubular damage. Thus, the reduction in GFR (which is not easily explained by any histologic abnormality) may in part represent an appropriate TGF response to maintain sodium balance [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/19,46\">",
"     19,46",
"    </a>",
"    ]. Similarly, TGF also mediates the reduction in GFR that occurs when proximal reabsorption is partially impaired by the administration of the carbonic anhydrase inhibitor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"     acetazolamide",
"    </a>",
"    , a proximally acting diuretic that can be useful in patients with edema and metabolic alkalosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/14/14568?source=see_link\">",
"     \"Treatment of metabolic alkalosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On the other hand, glucosuria seems to",
"    <strong>",
"     impair",
"    </strong>",
"    TGF, by an unknown mechanism that is in part mediated by the increase in tubular fluid glucose concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/19\">",
"     19",
"    </a>",
"    ]. This may play an important role in the marked fluid losses typically seen in diabetic ketoacidosis or nonketotic hyperglycemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/55/4986?source=see_link\">",
"     \"Clinical features and diagnosis of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults\"",
"    </a>",
"    .) The osmotic diuresis induced by glucose reduces sodium and water transport in the proximal tubule and loop of Henle [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/48\">",
"     48",
"    </a>",
"    ]. If TGF were normally active, the ensuing increase in delivery to the macula densa would diminish the GFR, thereby minimizing the degree of fluid loss.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     NEUROHUMORAL INFLUENCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The intrarenal effects of autoregulation and TGF are likely to be most important in the day-to-day regulation of renal hemodynamics in normal subjects. Autoregulation also may help to maintain the GFR in patients with hypertension or with selective renal ischemia, as with bilateral renal artery stenosis. In fact, many of the experimental studies of autoregulation have been performed by using a suprarenal aortic clamp to selectively alter renal perfusion pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/3,8\">",
"     3,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients, however, renal artery pressure is most often reduced because of effective circulating volume depletion (as with true volume depletion, heart failure, or cirrhosis). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/45/7893?source=see_link\">",
"     \"Chapter 8A: Effective circulating volume and the steady state\"",
"    </a>",
"    .) In these disorders, there is marked stimulation of the vasoconstrictor sympathetic nervous and renin-angiotensin systems [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. As described previously, angiotensin II increases the resistance in the efferent and to a lesser degree the afferent arteriole [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. In comparison, norepinephrine (either circulating or released from the renal sympathetic nerves) directly increases afferent tone and indirectly, via stimulation of the release of renin and angiotensin II, enhances efferent resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/51,53\">",
"     51,53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, a reduction in systemic perfusion pressure is associated with renal neurohumorally-mediated vasoconstriction rather than autoregulation and TGF-induced vasodilatation. The effect of these changes varies with the degree of neurohumoral activation. A relatively mild increase in renal sympathetic tone may produce no change in baseline renal perfusion, but may be sufficient to impair autoregulation (and therefore maintenance of GFR) as renal perfusion pressure is reduced [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/54\">",
"     54",
"    </a>",
"    ]. In comparison, patients with advanced heart failure or severe volume depletion have more marked increments in norepinephrine and angiotensin II. In this setting, RPF is reduced at rest with a lesser fall or no change in GFR, since efferent constriction increases the Pgc [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/51,53\">",
"     51,53",
"    </a>",
"    ]. This is a very effective adaptation because it preferentially shunts perfusion to the critical coronary and cerebral circulations, while maintaining GFR and therefore excretory capacity.",
"   </p>",
"   <p>",
"    Renal vasodilator prostaglandins play an important role in modifying these vasoconstrictive effects. Both angiotensin II and norepinephrine stimulate glomerular prostaglandin production [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. The ensuing attenuation in the degree of arteriolar constriction prevents excessive renal ischemia, which might otherwise be induced by the high local concentration of vasoconstrictors [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. To a lesser degree, increased secretion of vasodilator kinins by the kidney also may act to preserve renal perfusion in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Clinical implications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical importance of these protective vasodilator responses has been amply demonstrated in humans by the administration of nonsteroidal antiinflammatory drugs, which inhibit prostaglandin synthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/60\">",
"     60",
"    </a>",
"    ]. These agents, which are widely used in the treatment of arthritis and other disorders, have little effect on renal function when given to normovolemic subjects in whom the baseline level of renal prostaglandin production is relatively low.",
"   </p>",
"   <p>",
"    The nonsteroidal antiinflammatory drugs can, however, produce an acute decline in GFR and renal plasma flow when given to patients with high angiotensin II and norepinephrine levels. This most often occurs with effective circulating volume depletion due, for example, to heart failure or cirrhosis. In these conditions, prostaglandin synthesis is appropriately enhanced and administration of a nonsteroidal antiinflammatory drug can lead to unopposed action of the vasoconstrictors and acute renal failure (",
"    <a class=\"graphic graphic_figure graphicRef78038 \" href=\"UTD.htm?10/25/10653\">",
"     figure 5",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. Studies in animals indicate that both afferent and efferent resistance are increased in this setting; the ensuing reduction in renal perfusion leads to a fall in GFR which, as mentioned above, is flow-dependent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The decrease in renal perfusion seen with effective volume depletion is also typically associated with a marked alteration in the distribution of intrarenal blood flow. Under normal circumstances, approximately 80 percent of renal blood flow goes to the outer cortex (where most of the glomeruli are located), 10 to 15 percent to the inner cortex (the site of the juxtamedullary nephrons) (",
"    <a class=\"graphic graphic_figure graphicRef55088 \" href=\"UTD.htm?22/60/23503\">",
"     figure 6",
"    </a>",
"    ), and the remaining 5 to 10 percent to the medulla. With hypovolemia, however, there is a marked reduction in outer cortical flow, with a preferential increase in perfusion to the inner cortex [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/61-64\">",
"     61-64",
"    </a>",
"    ]. The mechanism by which these changes occur is unknown; angiotensin II, catecholamines, and prostaglandins have all been implicated but their role is unproven [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The physiologic significance of this intrarenal shunting of renal blood flow is also uncertain. It has been postulated that increasing inner cortical flow might promote Na+ retention in hypovolemic states because the juxtamedullary nephrons with their long loops of Henle have a greater reabsorptive surface than those in the outer cortex. However, redistribution of blood flow is not necessarily associated with redistribution of glomerular filtration, making this hypothesis less likely [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Volume expansion",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to these hormonal changes with volume depletion, volume expansion (as with a high-sodium diet) tends to be associated with increased renal perfusion and perhaps a mild rise in GFR [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/66\">",
"     66",
"    </a>",
"    ]. Reduced secretion of angiotensin II and norepinephrine and enhanced release of dopamine and atrial natriuretic peptide all may contribute to this response. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6744?source=see_link\">",
"     \"Chapter 8C: Regulation of renal Na+ excretion\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dopamine dilates both the afferent and efferent arterioles [",
"      <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/1\">",
"       1",
"      </a>",
"      ], thereby raising renal blood flow while producing a lesser increment or no change in GFR.",
"     </li>",
"     <li>",
"      Atrial natriuretic peptide, on the other hand, appears to produce the unusual combination of afferent dilation and efferent constriction, both of which will raise Pgc and therefore the GFR; there is a lesser alteration in RPF since total renal vascular resistance is relatively unchanged [",
"      <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/67\">",
"       67",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These hormonal alterations also facilitate excretion of the excess sodium: the release of those agents that enhance sodium reabsorption (angiotensin II, aldosterone, and norepinephrine) is diminished whereas that of atrial natriuretic peptide and dopamine is enhanced.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Endothelin and nitric oxide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endothelin, released locally from endothelial cells, is another potent renal vasoconstrictor that affects both afferent and efferent glomerular arterioles, leading to reductions in renal blood flow and GFR [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/68-70\">",
"     68-70",
"    </a>",
"    ]. As with the other renal vasoconstrictors, the degree of ischemia is minimized by endothelin-induced release of prostacyclin [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although endothelin is probably not an important regulator of renal hemodynamics in normal subjects, it may play a role in the reduction in GFR seen in postischemic acute renal failure. In this setting, endothelial injury may lead to the release of endothelin and subsequent renal vasoconstriction [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/72\">",
"     72",
"    </a>",
"    ]. A similar mechanism may contribute to the decrease in renal perfusion induced by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/73,74\">",
"     73,74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another vasoactive factor released from the endothelial cells (in addition to prostacyclin and endothelin) is nitric oxide. Nitric oxide appears to released tonically in the renal circulation, thereby lowering renal vascular resistance (in contrast to the vasoconstrictive effect of endothelin) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/68,75,76\">",
"     68,75,76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Glomerular hemodynamics and progressive renal failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arteriolar resistance and renal hemodynamics also may play an important role in patients with underlying chronic renal disease. A large body of experimental and clinical evidence suggests that intraglomerular hypertension is partially responsible for the progression of many disorders to end-stage renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/77,78\">",
"     77,78",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/19/26938?source=see_link\">",
"     \"Secondary factors and progression of chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    According to this theory, the loss of nephrons (due to almost any renal disease) leads to a compensatory rise in filtration in the remaining more normal nephrons. This is an appropriate response in the short-term, as it tends to maintain the total GFR. It is driven by afferent arteriolar dilatation which leads to a rise in both Pgc and plasma flow. The elevation in intraglomerular pressure, however, appears to be maladaptive in the long-term, since it tends to lead to progressive glomerular damage. Similar findings are seen in diabetic nephropathy, except that the renal vasodilatation is a primary event, induced in some way by hyperglycemia or insulin deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/79,80\">",
"     79,80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These observations are of potentially great clinical importance, since treatment at can be aimed at reversing the hemodynamic adaptations. Both dietary protein restriction and antihypertensive therapy, perhaps preferentially with an angiotensin converting enzyme inhibitor, can lower the intraglomerular pressure and diminish the degree of glomerular injury in experimental models of renal disease. Several clinical trials in chronic renal disease in humans suggest that administration of an angiotensin converting enzyme inhibitor can slow the rate of loss of GFR, particularly in diabetic nephropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/81-84\">",
"     81-84",
"    </a>",
"    ]. The efficacy of dietary protein restriction remains controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/85-87\">",
"     85-87",
"    </a>",
"    ] with evidence of benefit being best in patients with diabetic nephropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The apparent preferential benefit of angiotensin converting enzyme inhibition compared to other antihypertensive drugs is thought to be related to reversal of angiotensin II-induced constriction of the efferent arteriole. Decreasing vascular resistance at this site will directly lower the intraglomerular pressure, independent of the reduction in the systemic blood pressure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The GFR is normally maintained within relatively narrow limits to prevent inappropriate fluctuations in solute and water excretion. Regulation of the GFR is primarily achieved by alterations in arteriolar tone which influence both the hydraulic pressure in the glomerular capillary and renal blood flow. In normal subjects, the GFR is maintained by autoregulation, a phenomenon which is mediated by at least three factors: stretch receptors in the afferent arteriole, angiotensin II, and tubuloglomerular feedback [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10985/abstract/8\">",
"     8",
"    </a>",
"    ]. These responses, however, can be overridden by neurohumoral vasoconstriction in hypovolemic states, in an attempt to maximize coronary and cerebral perfusion.",
"   </p>",
"   <p>",
"    This text is continued elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/55/21368?source=see_link\">",
"     \"Chapter 2E: Clinical evaluation of the renal circulation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    (From Rose, BD, Post, TW, Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York, 2001.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/1\">",
"      Steinhausen M, Endlich K, Wiegman DL. Glomerular blood flow. Kidney Int 1990; 38:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/2\">",
"      Navar LG. Renal autoregulation: perspectives from whole kidney and single nephron studies. Am J Physiol 1978; 234:F357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/3\">",
"      Hall JE, Guyton AC, Jackson TE, et al. Control of glomerular filtration rate by renin-angiotensin system. Am J Physiol 1977; 233:F366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/4\">",
"      Johnson PC. Autoregulation of blood flow. Circ Res 1986; 59:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/5\">",
"      Casellas D, Moore LC. Autoregulation and tubuloglomerular feedback in juxtamedullary glomerular arterioles. Am J Physiol 1990; 258:F660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/6\">",
"      Harder DR, Gilbert R, Lombard JH. Vascular muscle cell depolarization and activation in renal arteries on elevation of transmural pressure. Am J Physiol 1987; 253:F778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/7\">",
"      Carmines PK, Fowler BC, Bell PD. Segmentally distinct effects of depolarization on intracellular [Ca2+] in renal arterioles. Am J Physiol 1993; 265:F677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/8\">",
"      Schnermann J, Briggs JP, Weber PC. Tubuloglomerular feedback, prostaglandins, and angiotensin in the autoregulation of glomerular filtration rate. Kidney Int 1984; 25:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/9\">",
"      Beierwaltes WH, Sigmon DH, Carretero OA. Endothelium modulates renal blood flow but not autoregulation. Am J Physiol 1992; 262:F943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/10\">",
"      Kastner PR, Hall JE, Guyton AC. Control of glomerular filtration rate: role of intrarenally formed angiotensin II. Am J Physiol 1984; 246:F897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/11\">",
"      Hricik DE, Dunn MJ. Angiotensin-converting enzyme inhibitor-induced renal failure: causes, consequences, and diagnostic uses. J Am Soc Nephrol 1990; 1:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/12\">",
"      Jackson B, Matthews PG, McGrath BP, Johnston CI. Angiotensin converting enzyme inhibition in renovascular hypertension: frequency of reversible renal failure. Lancet 1984; 1:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/13\">",
"      Hricik DE. Captopril-induced renal insufficiency and the role of sodium balance. Ann Intern Med 1985; 103:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/14\">",
"      Wenting GJ, Tan-Tjiong HL, Derkx FH, et al. Splint renal function after captopril in unilateral renal artery stenosis. Br Med J (Clin Res Ed) 1984; 288:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/15\">",
"      Michel JB, Dussaule JC, Choudat L, et al. Effects of antihypertensive treatment in one-clip, two kidney hypertension in rats. Kidney Int 1986; 29:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/16\">",
"      Textor SC, Novick AC, Tarazi RC, et al. Critical perfusion pressure for renal function in patients with bilateral atherosclerotic renal vascular disease. Ann Intern Med 1985; 102:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/17\">",
"      Packer M, Lee WH, Medina N, et al. Functional renal insufficiency during long-term therapy with captopril and enalapril in severe chronic heart failure. Ann Intern Med 1987; 106:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/18\">",
"      Ljungman S, Kjekshus J, Swedberg K. Renal function in severe congestive heart failure during treatment with enalapril (the Cooperative North Scandinavian Enalapril Survival Study [CONSENSUS] trial. Am J Cardiol 1992; 70:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/19\">",
"      Blantz RC, Pelayo JC. A functional role for the tubuloglomerular feedback mechanism. Kidney Int 1984; 25:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/20\">",
"      Briggs JP, Schnermann J. The tubuloglomerular feedback mechanism: Functional and biochemical aspects. Ann Rev Physiol 1987; 49:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/21\">",
"      Schnermann J, Traynor T, Yang T, et al. Tubuloglomerular feedback: new concepts and developments. Kidney Int Suppl 1998; 67:S40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/22\">",
"      Lorenz JN, Weihprecht H, Schnermann J, et al. Renin release from isolated juxtaglomerular apparatus depends on macula densa chloride transport. Am J Physiol 1991; 260:F486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/23\">",
"      Lapointe JY, Bell PD, Cardinal J. Direct evidence for apical Na+:2Cl-:K+ cotransport in macula densa cells. Am J Physiol 1990; 258:F1466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/24\">",
"      Schlatter E, Salomonsson M, Persson AE, Greger R. Macula densa cells sense luminal NaCl concentration via furosemide sensitive Na+2Cl-K+ cotransport. Pflugers Arch 1989; 414:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/25\">",
"      Moore LC. Tubuloglomerular feedback and SNGFR autoregulation in the rat. Am J Physiol 1984; 247:F267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/26\">",
"      Moore LC, Casellas D. Tubuloglomerular feedback dependence of autoregulation in rat juxtamedullary afferent arterioles. Kidney Int 1990; 37:1402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/27\">",
"      K&auml;llskog O, Marsh DJ. TGF-initiated vascular interactions between adjacent nephrons in the rat kidney. Am J Physiol 1990; 259:F60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/28\">",
"      Schnermann J, Briggs JP. Restoration of tubuloglomerular feedback in volume-expanded rats by angiotensin II. Am J Physiol 1990; 259:F565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/29\">",
"      Schnermann J, Briggs JP. Effect of angiotensin and other pressor agents on tubuloglomerular feedback responses. Kidney Int 1990; 38 (suppl 30):S-77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/30\">",
"      Navar LG, Saccomani G, Mitchell KD. Synergistic intrarenal actions of angiotensin on tubular reabsorption and renal hemodynamics. Am J Hypertens 1991; 4:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/31\">",
"      Spielman WS, Arend LJ. Adenosine receptors and signaling in the kidney. Hypertension 1991; 17:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/32\">",
"      Weihprecht H, Lorenz JN, Briggs JP, Schnermann J. Vasomotor effects of purinergic agonists in isolated rabbit afferent arterioles. Am J Physiol 1992; 263:F1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/33\">",
"      Schnermann J, Weihprecht H, Briggs JP. Inhibition of tubuloglomerular feedback during adenosine1 receptor blockade. Am J Physiol 1990; 258:F553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/34\">",
"      Thomson S, Bao D, Deng A, Vallon V. Adenosine formed by 5'-nucleotidase mediates tubuloglomerular feedback. J Clin Invest 2000; 106:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/35\">",
"      Jackson EK, Dubey RK. Role of the extracellular cAMP-adenosine pathway in renal physiology. Am J Physiol Renal Physiol 2001; 281:F597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/36\">",
"      Kriz W. Adenosine and ATP: traffic regulators in the kidney. J Clin Invest 2004; 114:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/37\">",
"      Weihprecht H, Lorenz JN, Schnermann J, et al. Effect of adenosine1-receptor blockade on renin release from rabbit isolated perfused juxtaglomerular apparatus. J Clin Invest 1990; 85:1622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/38\">",
"      Welch WJ, Wilcox CS. Potentiation of tubuloglomerular feedback in the rat by thromboxane mimetic. Role of macula densa. J Clin Invest 1992; 89:1857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/39\">",
"      Navar LG. Integrating multiple paracrine regulators of renal microvascular dynamics. Am J Physiol 1998; 274:F433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/40\">",
"      Thomson SC, Bachmann S, Bostanjoglo M, et al. Temporal adjustment of the juxtaglomerular apparatus during sustained inhibition of proximal reabsorption. J Clin Invest 1999; 104:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/41\">",
"      Welch WJ, Wilcox CS, Thomson SC. Nitric oxide and tubuloglomerular feedback. Semin Nephrol 1999; 19:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/42\">",
"      Wilcox CS, Welch WJ. TGF and nitric oxide: effects of salt intake and salt-sensitive hypertension. Kidney Int Suppl 1996; 55:S9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/43\">",
"      Persson BE, Sakai T, Marsh DJ. Juxtaglomerular interstitial hypertonicity in Amphiuma: tubular origin-TGF signal. Am J Physiol 1988; 254:F445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/44\">",
"      Navar LG, Inscho EW, Ibarrola M, Carmines PK. Communication between the macula densa cells and the afferent arteriole. Kidney Int Suppl 1991; 32:S78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/45\">",
"      Moore LC. Interaction of tubuloglomerular feedback and proximal nephron reabsorption in autoregulation. Kidney Int Suppl 1982; 12:S173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/46\">",
"      Thurau K, Boylan JW. Acute renal success. The unexpected logic of oliguria in acute renal failure. Am J Med 1976; 61:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/47\">",
"      Leyssac PP, Karlsen FM, Sk&oslash;tt O. Dynamics of intrarenal pressures and glomerular filtration rate after acetazolamide. Am J Physiol 1991; 261:F169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/48\">",
"      Seely JF, Dirks JH. Micropuncture study of hypertonic mannitol diuresis in the proximal and distal tubule of the dog kidney. J Clin Invest 1969; 48:2330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/49\">",
"      Dzau VJ. Renal and circulatory mechanisms in congestive heart failure. Kidney Int 1987; 31:1402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/50\">",
"      Henriksen JH, Bendtsen F, Gerbes AL, et al. Estimated central blood volume in cirrhosis: relationship to sympathetic nervous activity, beta-adrenergic blockade and atrial natriuretic factor. Hepatology 1992; 16:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/51\">",
"      Myers BD, Deen WM, Brenner BM. Effects of norepinephrine and angiotensin II on the determinants of glomerular ultrafiltration and proximal tubule fluid reabsorption in the rat. Circ Res 1975; 37:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/52\">",
"      Heyeraas KJ, Aukland K. Interlobular arterial resistance: influence of renal arterial pressure and angiotensin II. Kidney Int 1987; 31:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/53\">",
"      Tucker BJ, Mundy CA, Blantz RC. Adrenergic and angiotensin II influences on renal vascular tone in chronic sodium depletion. Am J Physiol 1987; 252:F811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/54\">",
"      Persson PB, Ehmke H, Nafz B, Kirchheim HR. Sympathetic modulation of renal autoregulation by carotid occlusion in conscious dogs. Am J Physiol 1990; 258:F364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/55\">",
"      Stahl RA, Paravicini M, Schollmeyer P. Angiotensin II stimulation of prostaglandin E2 and 6-keto-F1 alpha formation by isolated human glomeruli. Kidney Int 1984; 26:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/56\">",
"      Bonvalet JP, Pradelles P, Farman N. Segmental synthesis and actions of prostaglandins along the nephron. Am J Physiol 1987; 253:F377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/57\">",
"      Oliver JA, Pinto J, Sciacca RR, Cannon PJ. Increased renal secretion of norepinephrine and prostaglandin E2 during sodium depletion in the dog. J Clin Invest 1980; 66:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/58\">",
"      Schor N, Ichikawa I, Brenner BM. Glomerular adaptations to chronic dietary salt restriction or excess. Am J Physiol 1980; 238:F428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/59\">",
"      Johnston PA, Bernard DB, Perrin NS, et al. Control of rat renal vascular resistance during alterations in sodium balance. Circ Res 1981; 48:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/60\">",
"      Oates JA, FitzGerald GA, Branch RA, et al. Clinical implications of prostaglandin and thromboxane A2 formation (2). N Engl J Med 1988; 319:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/61\">",
"      Patrono C, Dunn MJ. The clinical significance of inhibition of renal prostaglandin synthesis. Kidney Int 1987; 32:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/62\">",
"      Kilcoyne MM, Schmidt DH, Cannon PJ. Intrarenal blood flow in congestive heart failure. Circulation 1973; 47:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/63\">",
"      Epstein M, Berk DP, Hollenberg NK, et al. Renal failure in the patient with cirrhosis. The role of active vasoconstriction. Am J Med 1970; 49:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/64\">",
"      Stein JH, Boonjarern S, Mauk RC, Ferris TF. Mechanism of the redistribution of renal cortical blood flow during hemorrhagic hypotension in the dog. J Clin Invest 1973; 52:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/65\">",
"      Bruns FJ, Alexander EA, Riley AL, Levinsky NG. Superficial and juxtamedullary nephron function during saline loading in the dog. J Clin Invest 1974; 53:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/66\">",
"      Redgrave J, Rabinowe S, Hollenberg NK, Williams GH. Correction of abnormal renal blood flow response to angiotensin II by converting enzyme inhibition in essential hypertensives. J Clin Invest 1985; 75:1285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/67\">",
"      Weidmann P, Hasler L, Gn&auml;dinger MP, et al. Blood levels and renal effects of atrial natriuretic peptide in normal man. J Clin Invest 1986; 77:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/68\">",
"      L&uuml;scher TF, Bock HA, Yang ZH, Diederich D. Endothelium-derived relaxing and contracting factors: perspectives in nephrology. Kidney Int 1991; 39:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/69\">",
"      Edwards RM, Trizna W, Ohlstein EH. Renal microvascular effects of endothelin. Am J Physiol 1990; 259:F217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/70\">",
"      Kohan DE. Endothelins in the normal and diseased kidney. Am J Kidney Dis 1997; 29:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/71\">",
"      Chou SY, Dahhan A, Porush JG. Renal actions of endothelin: interaction with prostacyclin. Am J Physiol 1990; 259:F645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/72\">",
"      Kon V, Yoshioka T, Fogo A, Ichikawa I. Glomerular actions of endothelin in vivo. J Clin Invest 1989; 83:1762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/73\">",
"      Kon V, Sugiura M, Inagami T, et al. Role of endothelin in cyclosporine-induced glomerular dysfunction. Kidney Int 1990; 37:1487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/74\">",
"      Lanese DM, Conger JD. Effects of endothelin receptor antagonist on cyclosporine-induced vasoconstriction in isolated rat renal arterioles. J Clin Invest 1993; 91:2144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/75\">",
"      Radermacher J, F&ouml;rstermann U, Fr&ouml;lich JC. Endothelium-derived relaxing factor influences renal vascular resistance. Am J Physiol 1990; 259:F9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/76\">",
"      Berthold H, Just A, Kirchheim HR, Ehmke H. Interaction between nitric oxide and endogenous vasoconstrictors in control of renal blood flow. Hypertension 1999; 34:1254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/77\">",
"      Jacobson HR, Klahr S. Chronic renal failure: Pathophysiology; Management. Lancet 1991; 338:419,423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/78\">",
"      Olson JL, Heptinstall RH. Nonimmunologic mechanisms of glomerular injury. Lab Invest 1988; 59:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/79\">",
"      Anderson S, Rennke HG, Garcia DL, Brenner BM. Short and long term effects of antihypertensive therapy in the diabetic rat. Kidney Int 1989; 36:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/80\">",
"      Zatz R, Meyer TW, Rennke HG, Brenner BM. Predominance of hemodynamic rather than metabolic factors in the pathogenesis of diabetic glomerulopathy. Proc Natl Acad Sci U S A 1985; 82:5963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/81\">",
"      Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996; 334:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/82\">",
"      Ruggenenti P, Perna A, Gherardi G, et al. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet 1998; 352:1252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/83\">",
"      Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329:1456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/84\">",
"      Wilmer WA, Hebert LA, Lewis EJ, et al. Remission of nephrotic syndrome in type 1 diabetes: long-term follow-up of patients in the Captopril Study. Am J Kidney Dis 1999; 34:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/85\">",
"      Klahr S, Levey AS, Beck GJ, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 1994; 330:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/86\">",
"      Levey AS, Greene T, Beck GJ, et al. Dietary protein restriction and the progression of chronic renal disease: what have all of the results of the MDRD study shown? Modification of Diet in Renal Disease Study group. J Am Soc Nephrol 1999; 10:2426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/87\">",
"      Kasiske BL, Lakatua JD, Ma JZ, Louis TA. A meta-analysis of the effects of dietary protein restriction on the rate of decline in renal function. Am J Kidney Dis 1998; 31:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10985/abstract/88\">",
"      Zeller K, Whittaker E, Sullivan L, et al. Effect of restricting dietary protein on the progression of renal failure in patients with insulin-dependent diabetes mellitus. N Engl J Med 1991; 324:78.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7267 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-4D580CFE0A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_46_10985=[""].join("\n");
var outline_f10_46_10985=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      AUTOREGULATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Clinical implications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Tubuloglomerular feedback",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Mediators",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Functions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      NEUROHUMORAL INFLUENCES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Clinical implications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Volume expansion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Endothelin and nitric oxide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Glomerular hemodynamics and progressive renal failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7267\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7267|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/29/33245\" title=\"figure 1\">",
"      A2 and autoregulation of GFR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/28/13773\" title=\"figure 2\">",
"      GFR and arteriolar resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/63/7165\" title=\"figure 3\">",
"      Tubuloglomerular feedback",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/9/31889\" title=\"figure 4\">",
"      Macula densa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/25/10653\" title=\"figure 5\">",
"      NSAID lowers GFR in cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/60/23503\" title=\"figure 6\">",
"      Loop of Henle segments",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/20/36163?source=related_link\">",
"      Chapter 2C: Determinants of GFR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/55/21368?source=related_link\">",
"      Chapter 2E: Clinical evaluation of the renal circulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/49/36630?source=related_link\">",
"      Chapter 4A: Cell model for loop of Henle transport",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/45/7893?source=related_link\">",
"      Chapter 8A: Effective circulating volume and the steady state",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6744?source=related_link\">",
"      Chapter 8C: Regulation of renal Na+ excretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/55/4986?source=related_link\">",
"      Clinical features and diagnosis of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/19/26938?source=related_link\">",
"      Secondary factors and progression of chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/14/14568?source=related_link\">",
"      Treatment of metabolic alkalosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_46_10986="The approach to the patient who refuses blood transfusion";
var content_f10_46_10986=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   The approach to the patient who refuses blood transfusion",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/46/10986/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/46/10986/contributors\">",
"     Kendall P Crookston, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/46/10986/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/46/10986/contributors\">",
"     Arthur J Silvergleid, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/46/10986/contributors\">",
"     Steven Kleinman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/46/10986/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/46/10986/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/46/10986/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disagreements arising between patients and their clinicians on the choice of therapy remain a challenge in the practice of modern medicine. Such conflicts can strain the critical",
"    <span class=\"nowrap\">",
"     clinician/patient",
"    </span>",
"    relationship [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Few disagreements have drawn as much attention in the medical, legal, and public spheres as the refusal of blood transfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dealing with such patients and their families takes an extraordinary amount of time and energy, which may not be available in emergency situations and may not be reimbursed. Nevertheless, clinicians are obliged to provide the best management possible, factoring in the time required to assess the specific preferences of patients and their families. A thorough understanding of these issues, combined with a precise determination of the patient&rsquo;s wishes, will enable a clinician to outline the most appropriate treatment plan or to refer the patient to an appropriate colleague when clinically possible.",
"   </p>",
"   <p>",
"    This topic review will present an overview of this subject, often called \"bloodless medicine.\" Given the paucity of specific clinical guidelines, the approach discussed here reflects prevailing concepts generalizable to all medical specialties. &nbsp;",
"   </p>",
"   <p>",
"    General discussions of the use of blood for transfusion (ie, red cells, white cells, platelets, plasma) as well as the risks of transfusion are presented in separate UpToDate reviews (see",
"    <a class=\"local\" href=\"#H4\">",
"     'Risks'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TRANSFUSION OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obtaining informed consent for blood transfusion requires an appreciation of both benefits and risks, although the patient refusing blood transfusion may be more concerned about risks than benefits. It is incumbent on the clinician to present as balanced a discussion as possible, as outlined in the following sections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Benefits",
"    </span>",
"    &nbsp;&mdash;&nbsp;The deleterious effect of severe postoperative anemia on mortality was shown in two studies of patients with a postoperative hemoglobin (Hgb) concentration &le;8",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/5\">",
"     5",
"    </a>",
"    ] or &le;6",
"    <span class=\"nowrap\">",
"     g/dl",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/6\">",
"     6",
"    </a>",
"    ], who refused blood transfusion for religious reasons. While a hemoglobin between 7 and 8",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    appeared to have no immediate adverse effect on mortality, there was a clear risk of death in the postoperative period when the hemoglobin fell much below 7",
"    <span class=\"nowrap\">",
"     g/dL.",
"    </span>",
"   </p>",
"   <p>",
"    In",
"    the retrospective cohort study of 2083 surgical patients in a postoperative setting, an increased risk of mortality was consistently noted in patients with a hemoglobin level &lt;7",
"    <span class=\"nowrap\">",
"     g/dL;",
"    </span>",
"    the risk increased 2.5-fold for every 1",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    decrease in a patient's hemoglobin concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/5\">",
"     5",
"    </a>",
"    ]. In this study, the 30-day in-hospital mortality for patients with various postoperative hemoglobin levels was:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hgb 7.1 to 8.0 (n = 99) &mdash; zero percent",
"     </li>",
"     <li>",
"      Hgb 5.1 to 7.0 (n = 110) &mdash; 9 percent",
"     </li>",
"     <li>",
"      Hgb 3.1 to 5.0 (n = 60) &mdash; 30 percent",
"     </li>",
"     <li>",
"      Hgb &le;3.0 (n = 31) &mdash; 64 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Individuals who develop a very low hemoglobin concentration often do not die quickly. This provides a time period for possible intervention by transfusion medicine specialists. A retrospective cohort study of surgical patients who refused blood for religious reasons showed that among 1958 patients, 6 percent had a post-operative hemoglobin &lt;6",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    and one-third of these 117 patients died [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/6\">",
"     6",
"    </a>",
"    ]. Individuals with hemoglobins &ge;3",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    had at least 4.5 days between the lowest hemoglobin level and the time death occurred.",
"   </p>",
"   <p>",
"    However, healthy patients frequently tolerate much greater degrees of anemia. In a study of 23 untransfused patients refusing blood transfusion who died, all but three occurred in patients with hemoglobin concentrations &le;5",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/7\">",
"     7",
"    </a>",
"    ]. At the same time, 25 other patients survived an equivalent anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Guidelines have been developed to assist clinicians in the proper use of blood products. While these recommendations may not apply to some critically ill patients (eg, underlying cardiac disease, increased metabolic demands, acute hemorrhage, trauma), guidelines have recommended that a blood hemoglobin concentration of 7",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    is adequate for many patients, and that prophylactic use of red blood cell products is unnecessary [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/52/5961?source=see_link\">",
"     \"Indications for red cell transfusion in the adult\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It has become apparent that transfusing patients who will accept blood to hematocrits higher than clinically necessary may actually harm patients. For instance, in patients with cardiac disease, transfusion to above 33 to 34 percent hematocrit may lead to a poorer outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Risks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regardless of whether a patient is willing to accept blood, transfusion carries infectious, immunologic, and other risks, which are discussed in detail elsewhere [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/11\">",
"     11",
"    </a>",
"    ]. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infectious disease transmission (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/14/10471?source=see_link\">",
"       \"Transfusion transmitted bacterial infection\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/41/40601?source=see_link\">",
"       \"Laboratory testing of donated blood\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Febrile, hemolytic, allergic, or anaphylactic reactions (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11769?source=see_link\">",
"       \"Immunologic blood transfusion reactions\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37766?source=see_link\">",
"       \"Transfusion-associated immune and non immune-mediated hemolysis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Volume overload, thermal hemolysis, hyperkalemia, hypothermia, hypocalcemia, iron overload, and air embolism (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42214?source=see_link\">",
"       \"Transfusion reactions caused by chemical and physical agents\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/25/38294?source=see_link\">",
"       \"Massive blood transfusion\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/37/21081?source=see_link&amp;anchor=H6#H6\">",
"       \"Use of red blood cells for transfusion\", section on 'Physiologic changes with storage'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Transfusion-related acute lung injury (TRALI) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/39/28282?source=see_link\">",
"       \"Transfusion-related acute lung injury (TRALI)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Graft-versus-host disease (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/35/6710?source=see_link\">",
"       \"Transfusion-associated graft-versus-host disease\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Mistransfusion of incompatible blood (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11769?source=see_link&amp;anchor=H7#H7\">",
"       \"Immunologic blood transfusion reactions\", section on 'Acute hemolytic reactions'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Bacterial contamination of transfused blood products (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/14/10471?source=see_link\">",
"       \"Transfusion transmitted bacterial infection\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Even in the absence of obvious reactions, transfusion can have adverse effects on patient outcomes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prospective study compared liberal transfusion practices (Hgb maintained at 10 to 12",
"      <span class=\"nowrap\">",
"       g/dL)",
"      </span>",
"      with a conservative approach (Hgb maintained at 7 to 9",
"      <span class=\"nowrap\">",
"       g/dL);",
"      </span>",
"      the latter was similar in terms of reducing overall patient mortality, excepting patients with significant cardiac disease [",
"      <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/8\">",
"       8",
"      </a>",
"      ]. In patients younger than 55 years and less severely ill, the restrictive approach was associated with lower mortally.",
"     </li>",
"     <li>",
"      Randomized studies currently being conducted are testing the hypothesis that giving older blood leads to increased morbidity and mortality when compared with fresher blood [",
"      <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/12\">",
"       12",
"      </a>",
"      ]. Current supply models of blood dictate that much of the blood transfused to adults may fit the definition of &ldquo;older&rdquo; blood. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/37/21081?source=see_link&amp;anchor=H12#H12\">",
"       \"Use of red blood cells for transfusion\", section on 'Clinical relevance of storage time'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATIENT BELIEFS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Jehovah's Witnesses",
"    </span>",
"    &nbsp;&mdash;&nbsp;While there are a number of situations in which a patient may refuse blood transfusion, the most well-known involve Christians known as Jehovah's Witnesses. With over one million active members in North America and six million worldwide, Witnesses are encouraged to purchase health insurance and avail themselves of modern medical care [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/13\">",
"     13",
"    </a>",
"    ], with the exception of certain forms of blood transfusion. Aversion to transfusion stems from their interpretation of Biblical scripture (eg, Genesis 9:3,4; Leviticus 7:26,27; 1 Samuel 14:32,33; and Acts 15:28,29) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Devout Witnesses generally will not accept transfusions of whole blood or any of the \"four major components\" (ie, red cells, platelets, plasma, and white blood cells) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/16\">",
"       16",
"      </a>",
"      ], and most are prepared to die rather than compromise this refusal (",
"      <a class=\"graphic graphic_table graphicRef67244 \" href=\"UTD.htm?15/2/15405\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Many Witnesses will accept blood subfractions, such as immunoglobulins, albumin, and coagulation factor concentrates, as well as recombinant coagulation factors; the choice is left up to individual discretion and religious conscience (",
"      <a class=\"graphic graphic_table graphicRef67244 \" href=\"UTD.htm?15/2/15405\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/13\">",
"       13",
"      </a>",
"      ]. The degree of acceptability of various products has been summarized in the literature [",
"      <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Devout Witnesses do",
"      <strong>",
"       NOT",
"      </strong>",
"      consider preoperative autologous blood donation as an acceptable alternative, due to a belief that blood should not be taken out of the body and stored for any length of time. However, if the blood circulates back into the patient (eg, cardiopulmonary bypass, certain intraoperative and postoperative blood salvage systems), this is acceptable to many Witnesses.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Other reasons for refusal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients may decline transfusion for reasons outside of a religious or personal context. Many patients have refused transfusion due to a fear of blood-borne disease (eg, HIV) or because of a previous experience with a life-threatening transfusion reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Risks'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The approach to such patients should differ from the approach to individuals who refuse blood for cultural or religious reasons. An understanding of the patient's psychosocial history, along with a careful explanation of the risks and benefits of transfusion particular to their situation may resolve the fear of disease. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Transfusion overview'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Investigation of previous transfusion reaction may allay patient fears and provide valuable clinical information. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the patient has had a prior anaphylactic blood transfusion reaction due to IgA deficiency, prevention of future problems consists of establishing the diagnosis and using either IgA-deficient blood products, which can be obtained through large, regional blood centers, or extra-washed (two to three times) red cell or platelet products. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11769?source=see_link&amp;anchor=H13#H13\">",
"       \"Immunologic blood transfusion reactions\", section on 'Anaphylactic reactions'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/17/30998?source=see_link\">",
"       \"Selective IgA deficiency: Management and prognosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The safety of the blood supply is an area of intense interest and the ability to detect viral contamination is continuously improving; this should put most people's fears of life-threatening infection to rest. For instance, the risk of transmitting HIV infection by transfusion in the United States is now estimated to be approximately one in two million (",
"      <a class=\"graphic graphic_table graphicRef69661 \" href=\"UTD.htm?30/59/31676\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/41/40601?source=see_link\">",
"       \"Laboratory testing of donated blood\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Maintaining patient rapport",
"    </span>",
"    &nbsp;&mdash;&nbsp;It may be tempting to engage a patient refusing blood in debate. However, this casts the clinician into an adversarial role, making it easier for the patient to discount what",
"    <span class=\"nowrap\">",
"     he/she",
"    </span>",
"    is hearing and retreat to a more global refusal of treatments that might otherwise have been acceptable.",
"   </p>",
"   <p>",
"    Discussion aimed at convincing a Witness to violate",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    own religious beliefs may cause harm by pressuring the patient to compromise",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    values. An alternate approach involves serving as the patient's advocate, with the focus on finding the best possible therapy within the boundaries of the patient's religious beliefs and comfort zone (ie, values and preferences). Except in urgent circumstances, ample time should be set aside for the discussion of transfusion issues. In most cases, this discussion should occur in private, as friends or family members may influence the patient's decision. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Shared decision making'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A Witness or a family member of a Witness who is forced to receive a transfusion unwillingly may consider such transfusion a form of battery and suffer the related emotional stress. On the other hand, to willingly accept a transfusion of blood products may result in the patient being cut off from a broad community of friends and family. In some cases, such rejection may influence the decision more than any personal belief regarding transfusion.",
"   </p>",
"   <p>",
"    In the past, the practice of \"disfellowshipping\" was applied to unrepentant Witnesses who accepted blood transfusions. However, this policy has become less stringent, since the act of accepting a transfusion itself dissociates the patient spiritually from the body of the faith [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Confidentiality",
"    </span>",
"    &nbsp;&mdash;&nbsp;A Witness who receives a transfusion secretly (ie, without the knowledge of family members, friends, or other members of the church) will not be investigated or likely to be discovered unless admitting the fact [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. As such, a patient may communicate a wish to receive transfusions privately. The clinician should take whatever steps are necessary to insure complete confidentiality concerning this point. Respect for patient confidentiality may require privacy from family and friends and hospital personnel not directly caring for the patient (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Maintaining patient rapport'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    If possible, the clinician should confirm the treatment plan with the patient in private. One exception might be another member of the healthcare team with whom the patient feels comfortable, such as the patient's nurse. Some individuals may be willing to accept transfusion in extremis and this possibility should be thoroughly explored early during the patient's hospital stay, before the patient's hemoglobin declines to the point that thinking becomes clouded. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Contingency plans'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Another exception may be in the case where the patient refuses transfusion but the family desires it. In this case, it might be well for the patient to share his convictions with family members to lessen the pressure on the clinical team to transfuse against patient wishes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SHARED DECISION MAKING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many people hold beliefs, such as refusal of blood transfusion, which they value more than their own lives. Nevertheless, clinicians should direct patients to examine their preferences in the light of possible adverse health consequences. There is increased risk of death by refusing transfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/5,20\">",
"     5,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     The patient's wishes",
"    </span>",
"    &nbsp;&mdash;&nbsp;For Witnesses, the differentiation between acceptable and unacceptable blood fractions may be complex (",
"    <a class=\"graphic graphic_table graphicRef67244 \" href=\"UTD.htm?15/2/15405\">",
"     table 1",
"    </a>",
"    ). An informed discussion with patients may relieve their concern regarding some of these products, such as certain immune globulins and albumin, which naturally cross the placenta between mother and fetus and are therefore accepted by many Witnesses [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There can be substantial variation among individual Witnesses. A chart review of obstetric patients found that among 61 self-identified Witnesses who had filled out an advanced health care directive, 39 percent would accept certain blood derivatives. An additional 10 percent indicated they would accept whole blood, suggesting that not all who identify themselves as Witnesses practice this particular belief [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/22\">",
"     22",
"    </a>",
"    ]. This emphasizes the importance of clarifying with the patient what they mean when they say that they \"do not want blood,\" in order to find out which blood fractions they are or are not willing to accept, and under what circumstances they will or will not accept them. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Contingency plans'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    It is not uncommon to find patients who are not Witnesses who initially refuse transfusion out of respect for a family member who is a Witness. Most of these will accept blood in extremis. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Family members'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     The clinician's wishes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician may not be comfortable with a patient's choices as well as the clinician&rsquo;s ability to care for the patient [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/23\">",
"     23",
"    </a>",
"    ]. The patient is also under an obligation to respect the conscience of the healthcare provider. If this is the case, the clinician may need to consider referring nonemergent patients to another competent provider willing to care for the patient.",
"   </p>",
"   <p>",
"    There is significant emotional risk to a caregiver watching a patient die from what seems to be an easily preventable death. Those responsible for the patient should consider their own reactions to this possibility and transfer care if appropriate, or prepare to seek emotional support if necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Effect on members of the treatment team'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Withdrawal from such a case does not constitute malpractice if the clinician arranges for transfer to another caregiver. The patient and family members, as well as the receiving clinician, should understand the reason for the transfer. Other caregivers that may be directly involved (eg, anesthesiologists, intensivists, nurses) should be aware of the patient's decision to refuse blood products, and should be capable of providing the alternative care necessary and willing to accept the possible consequences.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Clinical issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain interventions (eg, surgery, induction of labor, use of chemotherapy) may need to be performed sooner than expected due to the absence of a \"buffer\" of being able to transfuse red blood cells. It is important to discuss this with the patient. As an example, due to worries about uterine atony, some obstetricians might consider a cesarean section sooner in patients who have a poor \"labor curve\" or a poor response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    . In addition, the threshold for performing a hysterectomy might be lower in the presence of life-threatening postpartum hemorrhage. Patients at risk should be advised of this possibility. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Contingency plans'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Physicians from many specialties have published reports of specific clinical approaches in such areas as obstetrics [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/25-27\">",
"     25-27",
"    </a>",
"    ], anesthesia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/28\">",
"     28",
"    </a>",
"    ], orthopedics [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/29\">",
"     29",
"    </a>",
"    ], cardiothoracic surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/30\">",
"     30",
"    </a>",
"    ], and trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Legal issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;One study of physician attitudes found that only 23 percent of 564 cardiologists surveyed would be willing to commit to not performing blood transfusion under any circumstance for patients who refuse such transfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/32\">",
"     32",
"    </a>",
"    ]. Nevertheless, in most countries the right of a competent adult to refuse consent for medical treatment is well accepted, and a number of legal cases have dealt specifically with Witnesses [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/1\">",
"     1",
"    </a>",
"    ]. However, some settings deserve special attention, such as trauma, obstetrics, and pediatrics. Although many Jehovah's Witnesses carry Durable Power of Attorney cards on their person that detail their wishes [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/33\">",
"     33",
"    </a>",
"    ], these directives may be lost in the organized chaos of a trauma code.",
"   </p>",
"   <p>",
"    If there is any doubt in a clinician's mind concerning the wishes of a patient or what is legally appropriate, the prudent course in an emergency would be to treat according to the accepted standard of care, without regard to special requests of parents on behalf of their children or relatives on behalf of incapacitated adults, until reliable legal documentation is available [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Children, newborn, and unborn fetuses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conflicts can emerge between the guardians of a minor child and clinicians attempting to provide the best possible medical care. As minor children are not considered capable of informed consent, it is the duty of the clinician to seek legal intervention in cases where the child is placed at \"clear and substantial\" risk by parental decisions [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/35\">",
"     35",
"    </a>",
"    ]. Candid discussion about the clinician's obligation before the law may help parents understand that the clinician may have no alternative to transfusion in a life-threatening situation.",
"   </p>",
"   <p>",
"    Whenever possible, adolescent children should be involved in the decision-making process. Situations may arise in which the adolescent may reject a transfusion that is acceptable to his or her guardians. In the United States, individual states have differing criteria for the age of majority (independent choice), and minor patients may be emancipated by the courts through such events as marriage or enlistment in the military.",
"   </p>",
"   <p>",
"    In situations involving minors, prompt consultation with legal specialists is recommended to clarify the situation within the laws of a particular state, province, or country. Specific variations regarding pediatric transfusion and the competency of children have been published from Japan [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/36\">",
"     36",
"    </a>",
"    ], Great Britain [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/37\">",
"     37",
"    </a>",
"    ], and Canada [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the event of a life-threatening situation that requires blood transfusion, a court order is not needed in order to transfuse a minor. In some settings, a court order allowing transfusion of a minor child is obtained in anticipation of a possible need. Although transfusing the child may be legally supportable, it does not mean that a transfusion",
"    <strong>",
"     must",
"    </strong>",
"    be given. Transfusing against the will of the parents",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    child will not be without psychological consequences.",
"   </p>",
"   <p>",
"    The clinician should be straightforward with both the parents and child (if old enough) and explain the situation and intention to transfuse. Criteria that will be used to make the decision to transfuse should be clear, and guardians should feel that their objection is taken seriously and that transfusion will be a last resort. This will be helpful to the parents in understanding the legal reality faced when their conscience forbids consenting to a transfusion and a court order is sought.",
"   </p>",
"   <p>",
"    In the case of an unborn fetus, it has been accepted in courts that the mother has control over her own body. This suggests that she can legally refuse transfusion of herself. However, when a mother&rsquo;s life will likely be lost unless transfused, leaving behind a healthy newborn, the father or a designated guardian should be available to care for the child. If no parent or guardian will be available to care for the newborn after the mother&rsquo;s death, the question has been raised of whether the transfusion should be given in order to save the life of the infant&rsquo;s sole caregiver. This controversial possibility must be weighed carefully by the hospital ethics committee and in the court system, which differs greatly from state to state in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The case of a pregnant woman carrying a fetus that needs transfusion before birth to save its life is also legally and ethically charged and should be approached in the same way.",
"   </p>",
"   <p>",
"    If a court order becomes necessary, it should not be written in a way that classifies the parents as negligent and removes the child totally from parental custody. As an example, the judge can \"authorize\" the treatment requested by the clinician, avoiding the harsher term \"order\" [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/4\">",
"     4",
"    </a>",
"    ]. If such treatment is",
"    <span class=\"nowrap\">",
"     authorized/ordered",
"    </span>",
"    by a judge, then the family is not going against church teaching, since the official position of the church on this point is that \"Christians agree with laws or court actions to prevent child abuse or neglect.\" Additional information on this difficult subject is available on the Official Web Site of Jehovah's Witnesses at",
"    <a class=\"external\" href=\"file://www.watchtower.org/\">",
"     www.watchtower.org",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the courts may overrule parental decision regarding transfusion, parents still have the legal right to be informed about their child's condition and the desire to be involved in other medical decisions. The clinician should remain sensitive to the possible feelings of guilt or distress that may be present in the young patient and family, despite a court order. The healthcare team should not underestimate the child's awareness and concerns about receiving blood transfusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Family members",
"    </span>",
"    &nbsp;&mdash;&nbsp;There exists the possibility for legal entanglement from individuals other than guardians or health care decision makers. Jehovah's Witnesses are not, as a group, litigious. However, other family members who are not practicing Jehovah's Witnesses may have strong feelings about seeing a loved one die after refusing blood transfusion.",
"   </p>",
"   <p>",
"    If family members or friends strongly disagree with the patient's decision to accept or refuse blood products, the clinician may be requested to provide additional explanation. In such cases, it is wise to involve the medical center's ethics committee, legal department, and risk management group in order to balance the need between protecting confidentiality and providing effective communication of the treatment plan and its rationale.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Contingency plans",
"    </span>",
"    &nbsp;&mdash;&nbsp;There should be a clear plan concerning what will occur under the worst-case scenario, namely the potential for death or morbidity (eg, stroke, myocardial infarction, renal failure) resulting from severe anemia or hypovolemic shock. Some patients may be willing to accept blood products when the clinician determines that death is inevitable without transfusion.",
"   </p>",
"   <p>",
"    The clinician must make it clear that the patient will die if bleeding cannot be stopped in a reasonable amount of time. This may require discussing options that would not be the clinician's first choice if the patient were willing to accept blood products. As an example, a contingency plan may state that a hysterectomy or colectomy might need to be performed, rather than let a patient bleed to death if the surgeon cannot achieve sufficient hemostasis. The patient needs to understand that eliminating the option of transfusion may make a clinician proceed more rapidly toward an intervention, such as cesarean section in a difficult labor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Documentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient's wishes should be documented in an advanced health care directive, and Jehovah's Witnesses are encouraged to carry it on their person. The attending clinician(s) should review the written directive personally with the patient and make sure that a copy is placed in the medical record. Some medical centers find it helpful to flag the front of the patient's chart and the patient's arm or wrist band in cases where no blood is desired.",
"   </p>",
"   <p>",
"    The final agreement between patient and clinician may be complex and should be detailed clearly in the medical record, including any contingency plans as noted in the previous section (see above). Some hospitals provide a form specifically for this purpose to be signed by the patient. The clinician may also have the patient sign the clinical note outlining the final agreement. The patient&rsquo;s family should typically be aware of the plan unless the patient feels that his or her decisions (eg, to accept blood in extremis) should remain strictly confidential.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Effect on members of the treatment team",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians should be prepared, insofar as it is possible, for the psychological strain that may accompany a seemingly preventable death [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/24\">",
"     24",
"    </a>",
"    ]. This may involve sorrow or anger over losing a patient who they feel could have been saved. This has been seen to lead to psychological disturbance in certain cases that might have been avoided with appropriate counseling and support.",
"   </p>",
"   <p>",
"    Hospitals that establish bloodless medicine and surgery programs should be prepared to provide support to the healthcare delivery team members. Although rare, in spite of a solid legal foundation, there may also be the stress of threatened litigation from the patient",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    family members who do not share the same views about transfusion as the patient. Respecting the wishes of competent, informed patients who refuse blood requires high standards of ethics and professionalism [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     ALTERNATIVE COURSES OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bloodless medicine encompasses many situations beyond those patients who refuse transfusion. Examples include situations in which blood is simply not available, such as the wounded soldier on the battlefield, a previously transfused patient with multiple alloantibodies or an incompatible crossmatch for other reasons, and surgical procedures performed in areas of limited (or highly infectious) blood supply [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/41,42\">",
"     41,42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Overall approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bloodless medicine uses a two-pronged approach:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Blood conservation",
"     </li>",
"     <li>",
"      Use of adjunctive therapy or blood substitutes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Of critical importance for any patient unwilling or unable to receive red cell transfusions is finding out, in advance whenever possible, which of the available options for increasing the patient's oxygen-carrying capacity are acceptable. These options include breathing 100 percent oxygen, hyperbaric oxygen therapy, transfusion of the patient's own red cells either collected in advance or recycled during surgery, and the use of alternative oxygen carriers, erythropoietin, and intravenous iron [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/43-45\">",
"     43-45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/31/16890?source=see_link&amp;anchor=H9#H9\">",
"     \"Introduction to recombinant hematopoietic growth factors\", section on 'Indications for treatment with hematopoietic growth factors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/32/24073?source=see_link\">",
"     \"Oxygen carriers as alternatives to red cell transfusion\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/62/25578?source=see_link&amp;anchor=H14#H14\">",
"     \"Treatment of anemia due to iron deficiency\", section on 'Parenteral iron therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Meticulous hemostasis is necessary in patients undergoing surgery or bleeding from other causes. The clinical team and patient must realize that, in a patient who refuses transfusion,",
"    <strong>",
"     if the bleeding cannot be stopped the patient will die",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    All of these issues require close and continuing consultation among hematologists, intensivists, surgeons, anesthesiologists, and transfusion medicine specialists, as well as the patient care team and the patient",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    patient decision maker(s) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/46-49\">",
"     46-49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Examples of successful procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;The literature contains reports of many patients or groups of patients with complex medical and surgical problems who have successfully completed therapy without resorting to blood component transfusion. Cardiac surgery, in particular, has produced several studies showing favorable outcomes in Witnesses [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Organ transplantation (eg, liver, kidney, pancreas) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/46,52-54\">",
"       46,52-54",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Hematopoietic cell transplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/55-58\">",
"       55-58",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Hematological cancer treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/59-61\">",
"       59-61",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Solid organ cancer treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/62-64\">",
"       62-64",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Obstetrical emergencies (eg, placenta accreta, placenta percreta, uterine rupture) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/25,26,39,65,66\">",
"       25,26,39,65,66",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Cardiothoracic surgery with cardio-pulmonary bypass [",
"      <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/51,67\">",
"       51,67",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Hemorrhagic shock [",
"      <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/26,28,68\">",
"       26,28,68",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Severe iron deficiency anemia (hemoglobin 2.4",
"      <span class=\"nowrap\">",
"       g/dL)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/38\">",
"       38",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Severe autoimmune hemolytic anemia (hemoglobin 2.7",
"      <span class=\"nowrap\">",
"       g/dL)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/69\">",
"       69",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Trauma [",
"      <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/31,70\">",
"       31,70",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Aortic dissection, ruptured abdominal aortic aneurysm [",
"      <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/71,72\">",
"       71,72",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Thrombotic thrombocytopenic purpura [",
"      <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/73,74\">",
"       73,74",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Reducing blood loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood conservation approaches are especially applicable in the intensive care unit and the operating room. Multiple studies have found mean daily phlebotomy losses in medical-surgical ICUs of approximately 41",
"    <span class=\"nowrap\">",
"     mL/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/75\">",
"     75",
"    </a>",
"    ]. Conservation practices have been recommended, including decreased testing, small volume sampling, closed sampling circuits, and point-of-care microtesting [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other general practices include close attention to the degree of anticoagulation (if employed), minimizing use of agents with antiplatelet activity (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , nonsteroidal antiinflammatory agents,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    ), and meticulous attention to hemostasis and technical blood losses during surgery (eg, use of hemostatic surgical devices, fibrin glue and tissue adhesives, controlled hypotension) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/15,31,33,46,67,76\">",
"     15,31,33,46,67,76",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25094?source=see_link&amp;anchor=H3#H3\">",
"     \"Fibrin sealant\", section on 'Components of commercial and alternative preparations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In bleeding patients, antifibrinolytic drugs (eg",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30311?source=see_link\">",
"     aminocaproic acid",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/58/14248?source=see_link\">",
"     tranexamic acid",
"    </a>",
"    ) decrease the need for transfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/77-79\">",
"     77-79",
"    </a>",
"    ]. The safety of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/52/6982?source=see_link\">",
"     aprotinin",
"    </a>",
"    for this indication has been called into question. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35226?source=see_link&amp;anchor=H12#H12\">",
"     \"Early noncardiac complications of coronary artery bypass graft surgery\", section on 'Antifibrinolytic agents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Off-label use of recombinant factor VIIa has been effectively used to reduce hemorrhage and the need for transfusion in some Jehovah's Witness patients with gastrointestinal, surgical bleeding, or combat trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/80-82\">",
"     80-82",
"    </a>",
"    ]. In one report of 27 consecutive liver transplants in Jehovah's Witnesses,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/42/30373?source=see_link\">",
"     recombinant human factor VIIa",
"    </a>",
"    as a single-dose infusion at the beginning of the operation was used in 13 patients to augment coagulation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/46\">",
"     46",
"    </a>",
"    ]. Clinical benefits and risks of arterial thrombotic events have tempered enthusiasm for use of recombinant VIIa [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/83,84\">",
"     83,84",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31962?source=see_link&amp;anchor=H20#H20\">",
"     \"Therapeutic uses of recombinant coagulation factor VIIa\", section on 'Reduction of perioperative blood loss'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other concentrates containing multiple coagulation factors are now becoming available for similar off-label uses (eg, prothrombin complex concentrates) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Autologous transfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Devout Witnesses will not accept transfusion of stored blood, including their own, due to a belief that blood should not be taken out of the body and stored for any length of time [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/13\">",
"     13",
"    </a>",
"    ]. However, if the blood circulates back into the patient (eg, cardiopulmonary bypass, intraoperative and postoperative blood salvage systems), this is acceptable to many Witnesses. Even for non-Witnesses, the cost-effectiveness of autologous transfusion in the form of preoperative ambulatory blood donation has been called into question [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/86\">",
"     86",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/54/12134?source=see_link\">",
"     \"Preoperative autologous blood donation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/55/31605?source=see_link\">",
"     \"Controversial areas in preoperative autologous blood donation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acute normovolemic hemodilution (ANH), in which the blood is in a continuous circuit with the patient, may provide a workable alternative [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/87\">",
"     87",
"    </a>",
"    ]. The use of erythropoietin is sometimes required for this technique (along with iron, folate, and vitamin B12) to increase red cell mass in anticipation of surgery. While not always cost-effective in patients for whom allogeneic transfusion is an option, using erythropoietin in Jehovah's Witnesses to increase hematocrit and allow ANH",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    other surgical procedures has been viewed as a prudent measure [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/46,88\">",
"     46,88",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37684?source=see_link\">",
"     \"Acute normovolemic intraoperative hemodilution\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/21/10582?source=see_link\">",
"     \"Intraoperative and postoperative blood salvage\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of erythropoietin and iron is acceptable to most Jehovah's Witnesses. For patients with lower hematocrits in whom ANH is a beneficial option, several weeks are usually required to increase red cell mass. When surgery is planned, an anesthesiologist comfortable with the procedure and with the patient's transfusion restrictions should be involved in advance [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Blood substitutes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients and providers often inquire about using &ldquo;blood substitutes&rdquo;, such as hemoglobin-based oxygen carriers and perfluorocarbon emulsion. While hemoglobin-based blood substitutes are currently in development, with some in phase III trials, none has yet reached the market in the United States or Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/90\">",
"     90",
"    </a>",
"    ]. At present, the possibility of having an approved hemoglobin substitute available in the United States in the immediate future appears bleak.",
"   </p>",
"   <p>",
"    Some of these products have a history of successful use in Witnesses [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/70\">",
"     70",
"    </a>",
"    ]. The position of the faith with respect to solutions containing human or animal hemoglobin appears to leave the decision up to the individual [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/13,91\">",
"     13,91",
"    </a>",
"    ]. Unfortunately, the United States Food and Drug Administration has severely limited the availability of these products for compassionate use. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/32/24073?source=see_link\">",
"     \"Oxygen carriers as alternatives to red cell transfusion\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    After discouraging communications from the United States FDA, several manufacturers have abandoned attempts to obtain approval for their blood substitute products [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Oxygen supply and demand",
"    </span>",
"    &nbsp;&mdash;&nbsp;When a patient cannot oxygenate vital organs sufficiently, an alternative is to reduce the clinical need for oxygen through sedation, mechanical ventilation with pharmacologic paralysis, and meticulous control of body temperature [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/43,71\">",
"     43,71",
"    </a>",
"    ]. If the patient is placed intermittently in a hyperbaric chamber, plasma itself may aid in carrying dissolved oxygen [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/63,93\">",
"     63,93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The American Thoracic Society (ATS) statement on the detection, correction, and prevention of tissue hypoxia, as well as other ATS guidelines, can be accessed through the ATS web site at",
"    <a class=\"external\" href=\"file://www.thoracic.org/statements/\">",
"     www.thoracic.org/statements/",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     BLOODLESS MEDICINE RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resources exist to support the decision making process in patients refusing transfusion, including others who have had experience in similar situations. Many hospitals have an ethics committee that can provide consultation, and a risk management group can give advice for legal protection.",
"   </p>",
"   <p>",
"    Transfusion medicine specialists are available for consultation at major centers, particularly those with blood conservation programs. Sometimes patients may not understand that certain blood fractions are acceptable to many Witnesses. Many larger cities in North America and in many countries have a Hospital Liaison Committee of Jehovah's Witnesses capable of addressing patient questions, helping the clinician to obtain pertinent medical literature, as well as contacting clinicians with experience in specific situations. Such help is available by telephone (718-560-4300), e-mail (",
"    <a class=\"external\" href=\"mailto:his@jw.org\">",
"     his@jw.org",
"    </a>",
"    ), and on the Jehovah's Witness Watchtower website [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several references are available that specifically consider the approach to Witnesses [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/2,4,13,21,31,55,59,95\">",
"     2,4,13,21,31,55,59,95",
"    </a>",
"    ]. Other available resources include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Society for the Advancement of Blood Management (not affiliated with the faith), an international organization devoted to blood conservation, produces a monthly synopsis of abstracts from the field as well as locations of more than 100 hospitals in the USA with bloodless medicine and surgery programs. The organization can be reached at its website (",
"      <a class=\"external\" href=\"file://www.sabm.org/\">",
"       SABM",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Network for Advancement of Transfusion Alternatives (",
"      <a class=\"external\" href=\"file://www.nataonline.com/\">",
"       NATA online",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Institute for Patient Blood Management and Bloodless Medicine and Surgery (",
"      <a class=\"external\" href=\"file://www.englewoodhospital.com/ms_bloodless_home.asp\">",
"       Englewood Hospital and Medical Center",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26340052\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Respecting the wishes of competent, informed patients who refuse blood requires high standards of ethics and professionalism [",
"    <a class=\"abstract\" href=\"UTD.htm?10/46/10986/abstract/4\">",
"     4",
"    </a>",
"    ]. Dealing with patients (and their families) who refuse blood transfusion takes an additional amount of time and energy, which may not be reimbursed. Nevertheless, clinicians are obliged to provide the best management possible consistent with the patient&rsquo;s values and preferences.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26340149\">",
"    <span class=\"h2\">",
"     Initial steps",
"    </span>",
"    &nbsp;&mdash;&nbsp;As a minimum, the following steps should be taken as soon as possible during the hospitalization:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Discuss the benefits and risks of blood transfusion so that the patient may be fully informed (",
"      <a class=\"graphic graphic_table graphicRef69661 \" href=\"UTD.htm?30/59/31676\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Transfusion overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clarify with the patient and family what they mean when they say that they \"do not want blood,\" in order to find out which blood fractions they may or may not be willing to accept (",
"      <a class=\"graphic graphic_table graphicRef67244 \" href=\"UTD.htm?15/2/15405\">",
"       table 1",
"      </a>",
"      ). There should be a clear plan concerning what will occur under the worst-case scenario (eg, impending death or severe morbidity). Some patients may be willing to accept blood products at the point when the clinician determines that death is inevitable without transfusion. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'The patient's wishes'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Contingency plans'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The final agreement, including contingency plans, between patient and clinician should be detailed clearly in the medical record and be clearly understood by the patient and the clinical team. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Documentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Support should be available to the treatment team through Ethics Committees, legal advice, and counseling services. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Shared decision making'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'The clinician's wishes'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Effect on members of the treatment team'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26340156\">",
"    <span class=\"h2\">",
"     Therapeutic alternatives",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the patient is unwilling to be transfused under any circumstance, we suggest the use of",
"    <span class=\"nowrap\">",
"     any/all",
"    </span>",
"    of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Reduce blood loss through reducing the volume of blood used for laboratory testing",
"     </li>",
"     <li>",
"      Reduce all causes of blood loss (eg, more careful use of anticoagulants and antiplatelet agents, use of antifibrinolytic agents)",
"     </li>",
"     <li>",
"      Maximize oxygen delivery (eg, high percentage of supplemental oxygen, hyperbaric chamber)",
"     </li>",
"     <li>",
"      Reduce oxygen requirement (eg, sedation, paralysis, mechanical ventilation, control of body temperature)",
"     </li>",
"     <li>",
"      Increase the patient&rsquo;s red cell production with autologous transfusion",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      erythropoietin (if acceptable) and supplemental iron and vitamins as needed",
"     </li>",
"     <li>",
"      Use of &ldquo;blood substitutes&rdquo; if available and acceptable to the patient",
"     </li>",
"     <li>",
"      Discuss the case with experienced clinicians who have successfully cared for Witnesses in similar situations",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Henderson R, Jabbour N, Zeger G. Legal and administrative issues relate to transfusion-free medicine and surgery. In: Transfusion-free medicine and surgery, Jabbor N (Ed), Blackwell, Malden, MA 2005. p.1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/2\">",
"      Nash MJ, Cohen H. Management of Jehovah's Witness patients with haematological problems. Blood Rev 2004; 18:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/3\">",
"      Gyamfi C, Gyamfi MM, Berkowitz RL. Ethical and medicolegal considerations in the obstetric care of a Jehovah's Witness. Obstet Gynecol 2003; 102:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/4\">",
"      Rogers DM, Crookston KP. The approach to the patient who refuses blood transfusion. Transfusion 2006; 46:1471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/5\">",
"      Carson JL, Noveck H, Berlin JA, Gould SA. Mortality and morbidity in patients with very low postoperative Hb levels who decline blood transfusion. Transfusion 2002; 42:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/6\">",
"      Tobian AA, Ness PM, Noveck H, Carson JL. Time course and etiology of death in patients with severe anemia. Transfusion 2009; 49:1395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/7\">",
"      Viele MK, Weiskopf RB. What can we learn about the need for transfusion from patients who refuse blood? The experience with Jehovah's Witnesses. Transfusion 1994; 34:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/8\">",
"      H&eacute;bert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med 1999; 340:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/9\">",
"      Wang JK, Klein HG. Red blood cell transfusion in the treatment and management of anaemia: the search for the elusive transfusion trigger. Vox Sang 2010; 98:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/10\">",
"      Napolitano LM, Kurek S, Luchette FA, et al. Clinical practice guideline: red blood cell transfusion in adult trauma and critical care. Crit Care Med 2009; 37:3124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/11\">",
"      Goodnough LT. Risks of blood transfusion. Anesthesiol Clin North America 2005; 23:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/12\">",
"      Wang D, Sun J, Solomon SB, et al. Transfusion of older stored blood and risk of death: a meta-analysis. Transfusion 2012; 52:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/13\">",
"      Bodnaruk ZM, Wong CJ, Thomas MJ. Meeting the clinical challenge of care for Jehovah's Witnesses. Transfus Med Rev 2004; 18:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/14\">",
"      Bennett DR, Shulman IA. Practical issues when confronting the patient who refuses blood transfusion therapy. Am J Clin Pathol 1997; 107:S23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/15\">",
"      Berend K, Levi M. Management of adult Jehovah's Witness patients with acute bleeding. Am J Med 2009; 122:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/16\">",
"      Watch Tower Bible and Tract Society. Watchtower 2004; (June 15):14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/17\">",
"      Finucane ML, Slovic P, Mertz CK. Public perception of the risk of blood transfusion. Transfusion 2000; 40:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/18\">",
"      Muramoto O. Bioethical aspects of the recent changes in the policy of refusal of blood by Jehovah's witnesses. BMJ 2001; 322:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/19\">",
"      Malyon D. Transfusion-free treatment of Jehovah's Witnesses: respecting the autonomous patient's rights. J Med Ethics 1998; 24:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/20\">",
"      Van Wolfswinkel ME, Zwart JJ, Schutte JM, et al. Maternal mortality and serious maternal morbidity in Jehovah's witnesses in The Netherlands. BJOG 2009; 116:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/21\">",
"      Doyle DJ. Blood transfusions and the Jehovah's Witness patient. Am J Ther 2002; 9:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/22\">",
"      Gyamfi C, Berkowitz RL. Responses by pregnant Jehovah's Witnesses on health care proxies. Obstet Gynecol 2004; 104:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/23\">",
"      Campbell BH. A piece of my mind. Listening to leviticus. JAMA 2008; 299:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/24\">",
"      Meier DE, Back AL, Morrison RS. The inner life of physicians and care of the seriously ill. JAMA 2001; 286:3007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/25\">",
"      Chigbu B, Onwere S, Kamanu C, et al. Lessons learned from the outcome of bloodless emergency laparotomies on Jehovah's Witness women presenting in the extremis with ruptured uterus. Arch Gynecol Obstet 2009; 279:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/26\">",
"      Belfort M, Kofford S, Varner M. Massive obstetric hemorrhage in a Jehovah's Witness: intraoperative strategies and high-dose erythropoietin use. Am J Perinatol 2011; 28:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/27\">",
"      Arab TS, Al-Wazzan AB, Maslow K. Postpartum hemorrhage in a Jehovah's Witness patient controlled with Tisseel, tranexamic acid, and recombinant factor VIIa. J Obstet Gynaecol Can 2010; 32:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/28\">",
"      Mackenzie CF, Morrison C, Jaberi M, et al. Management of hemorrhagic shock when blood is not an option. J Clin Anesth 2008; 20:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/29\">",
"      Siddiqui FM, Slater RM, Razzaq I, et al. Tourniquet use during total knee replacement in a Jehovah's Witness with sickle cell trait: a case report. Eur J Anaesthesiol 2010; 27:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/30\">",
"      Emmert MY, Salzberg SP, Theusinger OM, et al. How good patient blood management leads to excellent outcomes in Jehovah's witness patients undergoing cardiac surgery. Interact Cardiovasc Thorac Surg 2011; 12:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/31\">",
"      Hughes DB, Ullery BW, Barie PS. The contemporary approach to the care of Jehovah's witnesses. J Trauma 2008; 65:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/32\">",
"      Grinberg M, Zlotnik GC. Attitudes in the doctor-patient relationship Jehovah's Witnesses. Arq Bras Cardiol 2011; 97:e56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/33\">",
"      Remmers PA, Speer AJ. Clinical strategies in the medical care of Jehovah's Witnesses. Am J Med 2006; 119:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/34\">",
"      Hua M, Munson R, Lucas A, et al. Medical treatment of Jehovah's witnesses. Surgery 2008; 143:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/35\">",
"      Informed consent, parental permission, and assent in pediatric practice. Committee on Bioethics, American Academy of Pediatrics. Pediatrics 1995; 95:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/36\">",
"      Ohto H, Yonemura Y, Takeda J, et al. Guidelines for managing conscientious objection to blood transfusion. Transfus Med Rev 2009; 23:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/37\">",
"      Effa-Heap G. Blood transfusion: implications of treating a Jehovah's Witness patient. Br J Nurs 2009; 18:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/38\">",
"      Kitney L, Kanani R, De Souza C. A Jehovah's Witness adolescent with pancytopenia. CMAJ 2012; 184:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/39\">",
"      Barth WH Jr, Kwolek CJ, Abrams JL, et al. Case records of the Massachusetts General Hospital. Case 23-2011. A 40-year-old pregnant woman with placenta accreta who declined blood products. N Engl J Med 2011; 365:359.",
"     </a>",
"    </li>",
"    <li>",
"     www.watchtower.org (Accessed on August 03, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/41\">",
"      Goodnough LT, Shander A, Spence R. Bloodless medicine: clinical care without allogeneic blood transfusion. Transfusion 2003; 43:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/42\">",
"      Martyn V, Farmer SL, Wren MN, et al. The theory and practice of bloodless surgery. Transfus Apher Sci 2002; 27:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/43\">",
"      Hashem B, Dillard TA. A 44-year-old Jehovah's Witness with life-threatening anemia from uterine bleeding. Chest 2004; 125:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/44\">",
"      Schwenk MH, Blaustein DA. Rapid, high-dose intravenous iron sucrose therapy in 2 Jehovah's Witness patients with severe anemia, iron deficiency and chronic kidney disease. Clin Nephrol 2004; 62:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/45\">",
"      Price S, Pepper JR, Jaggar SI. Recombinant human erythropoietin use in a critically ill Jehovah's witness after cardiac surgery. Anesth Analg 2005; 101:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/46\">",
"      Jabbour N, Gagandeep S, Mateo R, et al. Live donor liver transplantation without blood products: strategies developed for Jehovah's Witnesses offer broad application. Ann Surg 2004; 240:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/47\">",
"      Kickler TS. Why \"bloodless medicine\" and how should we do it? Transfusion 2003; 43:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/48\">",
"      Carikas DA. Bloodless surgery developments accommodate patients' choice of treatment. Med Law 1999; 18:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/49\">",
"      Savarese D, Waitkus H, Stewart FM, Callery M. Bloodless medicine and surgery. J Intensive Care Med 1999; 14:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/50\">",
"      Bhaskar B, Jack RK, Mullany D, Fraser J. Comparison of outcome in Jehovah's Witness patients in cardiac surgery: an Australian experience. Heart Lung Circ 2010; 19:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/51\">",
"      Moraca RJ, Wanamaker KM, Bailey SH, et al. Strategies and outcomes of cardiac surgery in Jehovah's Witnesses. J Card Surg 2011; 26:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/52\">",
"      Jabbour N, Gagandeep S, Mateo R, et al. Transfusion free surgery: single institution experience of 27 consecutive liver transplants in Jehovah's Witnesses. J Am Coll Surg 2005; 201:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/53\">",
"      Boggi U, Vistoli F, Del Chiaro M, et al. Kidney and pancreas transplants in Jehovah's witnesses: ethical and practical implications. Transplant Proc 2004; 36:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/54\">",
"      Darwish A. Liver transplant in Jehovah's Witnesses patients. Curr Opin Organ Transplant 2011; 16:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/55\">",
"      Ballen KK, Becker PS, Yeap BY, et al. Autologous stem-cell transplantation can be performed safely without the use of blood-product support. J Clin Oncol 2004; 22:4087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/56\">",
"      Mazza P, Prudenzano A, Amurri B, et al. Myeloablative therapy and bone marrow transplantation in Jehovah's Witnesses with malignancies: single center experience. Bone Marrow Transplant 2003; 32:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/57\">",
"      Sloan JM, Ballen K. SCT in Jehovah's Witnesses: the bloodless transplant. Bone Marrow Transplant 2008; 41:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/58\">",
"      Brown NM, Kim SY, Ford PA. Autologous stem cell transplants in Jehovah's Witnesses. Bone Marrow Transplant 2009; 44:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/59\">",
"      Laszlo D, Agazzi A, Goldhirsch A, et al. Tailored therapy of adult acute leukaemia in Jehovah's Witnesses: unjustified reluctance to treat. Eur J Haematol 2004; 72:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/60\">",
"      Bareford D, Odeh B, Narayanan S, Wiltshire S. Remission induction in a Jehovah's witness patient with acute myeloid leukaemia using gemtuzumab ozogamicin. Transfus Med 2005; 15:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/61\">",
"      Brown NM, Keck G, Ford PA. Acute myeloid leukemia in Jehovah Witnesses. Leuk Lymphoma 2008; 49:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/62\">",
"      Dhanoa A, Singh VA, Shanmugam R, Rajendram R. Major surgery in an osteosarcoma patient refusing blood transfusion: case report. World J Surg Oncol 2010; 8:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/63\">",
"      Greensmith JE. Hyperbaric oxygen reverses organ dysfunction in severe anemia. Anesthesiology 2000; 93:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/64\">",
"      Oh SY, Kim SH, Kwon HC, et al. Bloodless cancer treatment results of patients who do not want blood transfusion: single center experience of 77 cases. Support Care Cancer 2010; 18:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/65\">",
"      Weinstein A, Chandra P, Schiavello H, Fleischer A. Conservative management of placenta previa percreta in a Jehovah's Witness. Obstet Gynecol 2005; 105:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/66\">",
"      Nagy CJ, Wheeler AS, Archer TL. Acute normovolemic hemodilution, intraoperative cell salvage and PulseCO hemodynamic monitoring in a Jehovah's Witness with placenta percreta. Int J Obstet Anesth 2008; 17:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/67\">",
"      Holt RL, Martin TD, Hess PJ, et al. Jehovah's Witnesses requiring complex urgent cardiothoracic surgery. Ann Thorac Surg 2004; 78:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/68\">",
"      Haan J, Scalea T. A Jehovah's Witness with complex abdominal trauma and coagulopathy: use of factor VII and a review of the literature. Am Surg 2005; 71:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/69\">",
"      Creelan B, Thomas K, Massis K, Davis RM. Splenic arterial embolization for idiopathic warm auto-immune haemolytic anaemia. Br J Haematol 2013; 161:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/70\">",
"      Marinaro J, Smith J, Tawil I, et al. HBOC-201 use in traumatic brain injury: case report and review of literature. Transfusion 2009; 49:2054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/71\">",
"      Ballen J, Raabe M, Muirhead B. Aortic dissection and hypothermic arrest in a Jehovah's Witness patient: a case for recombinant factor VIIa? Can J Anaesth 2006; 53:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/72\">",
"      Namura O, Kanazawa H, Yoshiya K, et al. Successful surgical treatment of a ruptured abdominal aortic aneurysm without homologous blood transfusion in a Jehovah's Witness: report of a case. Surg Today 2001; 31:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/73\">",
"      Martin MG, Whitlatch NL, Shah B, Arepally GM. Thrombotic thrombocytopenic purpura induced by trimethoprim-sulfamethoxazole in a Jehovah's Witness. Am J Hematol 2007; 82:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/74\">",
"      Dabak V, Kuriakose P, Raman S. Successful management of a Jehovah's Witness with thrombotic thrombocytopenic purpura unwilling to be treated with therapeutic plasma exchange. J Clin Apher 2007; 22:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/75\">",
"      Fowler RA, Rizoli SB, Levin PD, Smith T. Blood conservation for critically ill patients. Crit Care Clin 2004; 20:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/76\">",
"      Helm RE, Rosengart TK, Gomez M, et al. Comprehensive multimodality blood conservation: 100 consecutive CABG operations without transfusion. Ann Thorac Surg 1998; 65:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/77\">",
"      Cid J, Lozano M. Tranexamic acid reduces allogeneic red cell transfusions in patients undergoing total knee arthroplasty: results of a meta-analysis of randomized controlled trials. Transfusion 2005; 45:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/78\">",
"      Mannucci PM, Levi M. Prevention and treatment of major blood loss. N Engl J Med 2007; 356:2301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/79\">",
"      Alvarez JC, Santiveri FX, Ramos I, et al. Tranexamic acid reduces blood transfusion in total knee arthroplasty even when a blood conservation program is applied. Transfusion 2008; 48:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/80\">",
"      Waddington DP, McAuley FT, Hanley JP, Summerfield GP. The use of recombinant factor viia in a jehovah's witness with auto-immune thrombocytopenia and post-splenectomy haemorrhage. Br J Haematol 2002; 119:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/81\">",
"      Veneri D, Franchini M. Successful treatment of intestinal hemorrhage in a Jehovah's Witness patient. Am J Hematol 2005; 79:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/82\">",
"      Tanaka KA, Waly AA, Cooper WA, Levy JH. Treatment of excessive bleeding in Jehovah's Witness patients after cardiac surgery with recombinant factor VIIa (NovoSeven). Anesthesiology 2003; 98:1513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/83\">",
"      Levi M, Levy JH, Andersen HF, Truloff D. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med 2010; 363:1791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/84\">",
"      Lin Y, Stanworth S, Birchall J, et al. Use of recombinant factor VIIa for the prevention and treatment of bleeding in patients without hemophilia: a systematic review and meta-analysis. CMAJ 2011; 183:E9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/85\">",
"      Robblee JA, Wilkes PR, Dickie SJ, et al. Bleeding in a Jehovah's Witness patient undergoing a redo aortic valve replacement controlled with cryoprecipitate and a prothrombin complex concentrate. Can J Anaesth 2012; 59:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/86\">",
"      Brecher ME, Goodnough LT. The rise and fall of preoperative autologous blood donation. Transfusion 2001; 41:1459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/87\">",
"      Shander A, Rijhwani TS. Acute normovolemic hemodilution. Transfusion 2004; 44:26S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/88\">",
"      Crosby E. Perioperative use of erythropoietin. Am J Ther 2002; 9:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/89\">",
"      Goodnough LT. Autologous blood donation. Anesthesiol Clin North America 2005; 23:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/90\">",
"      Inayat MS, Bernard AC, Gallicchio VS, et al. Oxygen carriers: a selected review. Transfus Apher Sci 2006; 34:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/91\">",
"      Watch Tower Bible and Tract Society. Questions from Readers: Do Jehovah's Witnesses accept any medical products derived from blood? Watchtower 2000; (June 15):29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/92\">",
"      Weiskopf RB. Hemoglobin-based oxygen carriers: compassionate use and compassionate clinical trials. Anesth Analg 2010; 110:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/93\">",
"      Van Meter KW. A systematic review of the application of hyperbaric oxygen in the treatment of severe anemia: an evidence-based approach. Undersea Hyperb Med 2005; 32:61.",
"     </a>",
"    </li>",
"    <li>",
"     Available at: &lt;www.watchtower.org&gt;. Accessed August 3, 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/46/10986/abstract/95\">",
"      Marsh JC, Bevan DH. Haematological care of the Jehovah's Witness patient. Br J Haematol 2002; 119:25.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7927 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-202.43.93.2-77D3A94D3A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_46_10986=[""].join("\n");
var outline_f10_46_10986=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26340052\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TRANSFUSION OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Benefits",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Risks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATIENT BELIEFS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Jehovah's Witnesses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Other reasons for refusal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Maintaining patient rapport",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Confidentiality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SHARED DECISION MAKING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      The patient's wishes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      The clinician's wishes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Clinical issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Legal issues",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Children, newborn, and unborn fetuses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Family members",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Contingency plans",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Documentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Effect on members of the treatment team",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      ALTERNATIVE COURSES OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Overall approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Examples of successful procedures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Reducing blood loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Autologous transfusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Blood substitutes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Oxygen supply and demand",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      BLOODLESS MEDICINE RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26340052\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26340149\">",
"      Initial steps",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26340156\">",
"      Therapeutic alternatives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7927\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7927|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/2/15405\" title=\"table 1\">",
"      Religious position medical therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/59/31676\" title=\"table 2\">",
"      Infection risk of blood products",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37684?source=related_link\">",
"      Acute normovolemic intraoperative hemodilution",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/55/31605?source=related_link\">",
"      Controversial areas in preoperative autologous blood donation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35226?source=related_link\">",
"      Early noncardiac complications of coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25094?source=related_link\">",
"      Fibrin sealant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11769?source=related_link\">",
"      Immunologic blood transfusion reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/52/5961?source=related_link\">",
"      Indications for red cell transfusion in the adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/21/10582?source=related_link\">",
"      Intraoperative and postoperative blood salvage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/31/16890?source=related_link\">",
"      Introduction to recombinant hematopoietic growth factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/41/40601?source=related_link\">",
"      Laboratory testing of donated blood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/25/38294?source=related_link\">",
"      Massive blood transfusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/32/24073?source=related_link\">",
"      Oxygen carriers as alternatives to red cell transfusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/54/12134?source=related_link\">",
"      Preoperative autologous blood donation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/17/30998?source=related_link\">",
"      Selective IgA deficiency: Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31962?source=related_link\">",
"      Therapeutic uses of recombinant coagulation factor VIIa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42214?source=related_link\">",
"      Transfusion reactions caused by chemical and physical agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/14/10471?source=related_link\">",
"      Transfusion transmitted bacterial infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/35/6710?source=related_link\">",
"      Transfusion-associated graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37766?source=related_link\">",
"      Transfusion-associated immune and non immune-mediated hemolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/39/28282?source=related_link\">",
"      Transfusion-related acute lung injury (TRALI)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/62/25578?source=related_link\">",
"      Treatment of anemia due to iron deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/37/21081?source=related_link\">",
"      Use of red blood cells for transfusion",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_46_10987="Acute knee injury diagnosis - high school sports";
var content_f10_46_10987=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F67811&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F67811&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Acute knee injury diagnosis, high school sports",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Injury",
"       </td>",
"       <td class=\"subtitle1\">",
"        Frequency (percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Complete and incomplete ligament tears",
"       </td>",
"       <td>",
"        45",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Contusions",
"       </td>",
"       <td>",
"        15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Torn cartilage",
"       </td>",
"       <td>",
"        8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fractures/dislocations",
"       </td>",
"       <td>",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Muscle tears",
"       </td>",
"       <td>",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other (stress fractures, tendinitis)",
"       </td>",
"       <td>",
"        20",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Ingram JG, Fields SK, Yard EE, Comstock RD. Epidemiology of knee injuries among boys and girls in US high school athletics. Am J Sports Med 2008; 36:1116.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_46_10987=[""].join("\n");
var outline_f10_46_10987=null;
var title_f10_46_10988="CVS support resources";
var content_f10_46_10988=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F74868&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F74868&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Family support and informational resources",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Cyclic Vomiting Syndrome Association (CVSA)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         2819 W Highland Blvd, Milwaukee, WI 53208",
"        </p>",
"        <p>",
"         Phone: 414-342-7880",
"        </p>",
"        <p>",
"         Fax: 414-342-8980",
"        </p>",
"        <p>",
"         cvsa@cvsaonline.org, www.cvsaonline.org",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        International Foundation for Functional Gastrointestinal Disorders (IFFGD)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         PO Box 170864, Milwaukee, WI 53217",
"        </p>",
"        <p>",
"         Phone: 414-964-1799",
"        </p>",
"        <p>",
"         Children: file://www.aboutkidsgi.org",
"        </p>",
"        <p>",
"         Adults: file://www.iffgd.org",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Migraine Awareness Group (MAGNUM)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         113 S Saint Asaph, Suite 300, Alexandria, VA 22314",
"        </p>",
"        <p>",
"         Phone: 703-739-9384",
"        </p>",
"        <p>",
"         www.migraines.org",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        National Organization for Rare Disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         55 Kenosia Ave, PO Box 1968, Danbury, CT 06813-1968",
"        </p>",
"        <p>",
"         Phone: 203-744-0100, 800-999-6673",
"        </p>",
"        <p>",
"         TDD number: 203-797-9590",
"        </p>",
"        <p>",
"         Fax: 203-798-2291",
"        </p>",
"        <p>",
"         www.nord-rdb.com",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        United Mitochondrial Disease Foundation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         PO Box 1151, Monroeville, PA 15146-1151",
"        </p>",
"        <p>",
"         Phone: 412-793-8077",
"        </p>",
"        <p>",
"         www.umdf.org",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Li BU, Lefevre F, Chelimsky GG, et al. North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition consensus statement on the diagnosis and management of cyclic vomiting syndrome. J Pediatr Gastroenterol Nutr 2008; 47:379. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_46_10988=[""].join("\n");
var outline_f10_46_10988=null;
var title_f10_46_10989="Proposed ATPIII LDL goals";
var content_f10_46_10989=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F67460&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F67460&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Proposed modifications of ATP III LDL-cholesterol goals and cutpoints for therapeutic lifestyle changes and drug therapy in different risk categories",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Risk category",
"       </td>",
"       <td class=\"subtitle1\">",
"        LDL goal",
"       </td>",
"       <td class=\"subtitle1\">",
"        LDL level at which to initiate therapeutic lifestyle changes",
"       </td>",
"       <td class=\"subtitle1\">",
"        LDL level at which to consider drug therapy*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         High risk:",
"        </strong>",
"        Coronary heart disease (CHD) or CHD risk equivalent (10-year risk &gt;20 percent)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        &lt;100 mg/dL (2.58 mmol/L); optional goal &lt;70 mg/dL (1.82 mmol/L) in very high risk",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        &ge;100 mg/dL (2.58 mmol/L)",
"        <sup>",
"         &loz;",
"        </sup>",
"        &ge;",
"       </td>",
"       <td>",
"        100 mg/dL (2.58 mmol/L)",
"        <sup>",
"         &sect;",
"        </sup>",
"        ; &lt;100 mg/dL (2.58 mmol/L) consider drug options",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Moderately high risk:",
"        </strong>",
"        2 or more risk factors (10-year risk 10 to 20 percent)",
"        <sup>",
"         &yen;",
"        </sup>",
"       </td>",
"       <td>",
"        &lt;130 mg/dL (3.36 mmol/L)",
"        <sup>",
"         ������",
"        </sup>",
"       </td>",
"       <td>",
"        &ge;130 mg/dL (3.36 mmol/L)",
"        <sup>",
"         &loz;",
"        </sup>",
"        &ge;",
"       </td>",
"       <td>",
"        &ge;130 mg/dL (3.36 mmol/L); 100 to 129 mg/dL consider drug options",
"        <sup>",
"         ������",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Moderate risk:",
"        </strong>",
"        2 or more risk factors (10-year risk &lt;10 percent)",
"        <sup>",
"         &yen;",
"        </sup>",
"       </td>",
"       <td>",
"        &lt;130 mg/dL (3.36 mmol/L)",
"       </td>",
"       <td>",
"        &ge;130 mg/dL (3.36 mmol/L)",
"       </td>",
"       <td>",
"        &ge;160 mg/dL (4.13 mmol/L)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Lower risk:",
"        </strong>",
"        0 to 1 risk factor**",
"       </td>",
"       <td>",
"        &lt;160 mg/dL (4.13 mmol/L)",
"       </td>",
"       <td>",
"        &ge;160 mg/dL (4.13 mmol/L)",
"       </td>",
"       <td>",
"        &ge;190 mg/dL (4.91 mmol/L); 160 to 189 mg/dL consider drug options",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * When LDL lowering drug therapy is given, it is advised that the intensity of therapy be sufficient to achieve at least a 30 to 40 percent reduction in LDL levels.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     CHD risk equivalents include noncoronary forms of atherosclerotic disease (peripheral arterial disease, abdominal aortic aneurysm, and carotid artery disease), and diabetes. Ten-year risk defined by modified Framingham risk score.",
"     <br/>",
"     &Delta; Very high risk favors the optional LDL goal of &lt;70 mg/dL (1.82 mmol/L) and, in patients with high triglycerides, non-HDL cholesterol goal of &lt;100 mg/dL.",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     &ge; Any individual at high or moderately high risk who has lifestyle-related risk factors (eg, obesity, physical inactivity, hypertriglyceridemia, low HDL-cholesterol [&lt;40 mg/dL (1.04 mmol/L)], or metabolic syndrome is a candidate for therapeutic lifestyle changes to modify these risk factors independent of LDL level.",
"     <br/>",
"     &sect; If baseline LDL is &lt;100 mg/dL (2.58 mmol/L), institution of an LDL lowering drug is an option. This can be combined with a fibrate or nicotinic acid if a high-risk person has hypertriglyceridemia or low HDL (&lt;40 mg/dL (1.04 mmol/L).",
"     <br/>",
"     &yen; Risk factors that modify LDL goals include cigarette smoking; hypertension (BP &ge;140/90 mmHg or on antihypertensive medication)s; low HDL-cholesterol (&lt;40 mg/dL [1.03 mmol/L]); family history of premature CHD (CHD in male first degree relative &lt;55 years or CHD in female first degree relative &lt;65 years); age (men &ge;45 years; women &ge;55 years). HDL-cholesterol &ge;60 mg/dL (1.55 mmol/L) counts as a negative risk factor; its presence removes one risk factor from the total count.",
"     <br/>",
"     &Dagger; Optional LDL goal &lt;100 mg/dL (2.58 mmol/L).",
"     <br/>",
"     &dagger; For moderately high risk persons with LDL of 100 to 129 mg/dL (2.58 to 3.35 mmol/L) at baseline or after lifestyle changes, initiation of an LDL lowering drug to achieve an LDL &lt;100 mg/L is an option.",
"     <br/>",
"     ** Almost all people with 0 to 1 risk factor have a 10-year risk &lt;10 percent; thus, 10-year risk assessment in people with 0 to 1 risk factor is not necessary.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Circulation 2002; 106:3143; with modifications from Grundy SM, Cleeman JI, Merz CN, et al, Circulation 2004; 110:227.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_46_10989=[""].join("\n");
var outline_f10_46_10989=null;
var title_f10_46_10990="Effects of decreased cerebral blood flow";
var content_f10_46_10990=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F77705&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F77705&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 511px\">",
"   <div class=\"ttl\">",
"    Effects of decreased cerebral blood flow on vital brain functions",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 491px; height: 338px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Mounzer Kassab.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_46_10990=[""].join("\n");
var outline_f10_46_10990=null;
var title_f10_46_10991="Nail changes docetaxel";
var content_f10_46_10991=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F63373&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F63373&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 544px\">",
"   <div class=\"ttl\">",
"    Nail changes with Docetaxel",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 524px; height: 180px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    These finger and toenail changes were noted&nbsp;eight weeks after the start of Docetaxel chemotherapy in a 40-year-old breast cancer patient. Onycholysis, where separation of the nail plate starts distally, is an unusual side effect of taxanes. Other features are nail pigmentation, subungual haematoma, sterile abscesses, Beau's lines, and acute paronychia. Prompt recognition avoids unnecessary antibiotics and antifungals. Therapy can continue and using a frozen glove reduces the incidence of this side effect. The lesions heal slowly with regrowth of the nails after the taxane is discontinued.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Elaine Sugden.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_46_10991=[""].join("\n");
var outline_f10_46_10991=null;
